0001193125-21-323812.txt : 20211109 0001193125-21-323812.hdr.sgml : 20211109 20211109075325 ACCESSION NUMBER: 0001193125-21-323812 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211109 DATE AS OF CHANGE: 20211109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 211389926 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 10-Q 1 d132524d10q.htm 10-Q 10-Q
falseQ3P1YP3M0001567514--12-31Intra-Cellular Therapies, Inc. 0001567514 2021-01-01 2021-09-30 0001567514 2021-07-01 2021-09-30 0001567514 2020-07-01 2020-09-30 0001567514 2020-01-01 2020-09-30 0001567514 2020-12-31 0001567514 2021-09-30 0001567514 2020-01-10 2020-01-10 0001567514 2020-09-15 2020-09-15 0001567514 2020-01-10 0001567514 2020-09-15 0001567514 2020-01-01 2020-12-31 0001567514 2019-01-01 2019-12-31 0001567514 2021-11-05 0001567514 2020-09-30 0001567514 2020-06-30 0001567514 2019-12-31 0001567514 2021-06-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-09-30 0001567514 us-gaap:CertificatesOfDepositMember 2021-09-30 0001567514 us-gaap:CommercialPaperMember 2021-09-30 0001567514 us-gaap:CorporateDebtSecuritiesMember 2021-09-30 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember 2021-09-30 0001567514 itci:InducementAwardPlanMember 2021-09-30 0001567514 us-gaap:ComputerEquipmentMember 2021-09-30 0001567514 us-gaap:FurnitureAndFixturesMember 2021-09-30 0001567514 us-gaap:EquipmentMember 2021-09-30 0001567514 us-gaap:LeaseholdImprovementsMember 2021-09-30 0001567514 itci:ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember 2021-09-30 0001567514 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2021-09-30 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2021-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2021-09-30 0001567514 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001567514 itci:RealEstatesLeaseMember 2021-09-30 0001567514 itci:VehicleFleetLeaseMember 2021-09-30 0001567514 us-gaap:FinancialStandbyLetterOfCreditMember itci:VehicleFleetLeaseMember 2021-09-30 0001567514 us-gaap:AccruedLiabilitiesMember 2021-09-30 0001567514 itci:MedicaidRebatesMember 2021-09-30 0001567514 itci:OtherRevenueRelatedAccrualsMember 2021-09-30 0001567514 us-gaap:PurchaseCommitmentMember 2021-09-30 0001567514 itci:SiegfriedCampaignMember us-gaap:PurchaseCommitmentMember 2021-09-30 0001567514 itci:LonzaCampaignMember us-gaap:PurchaseCommitmentMember 2021-09-30 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2020-12-31 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001567514 us-gaap:CertificatesOfDepositMember 2020-12-31 0001567514 us-gaap:CommercialPaperMember 2020-12-31 0001567514 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001567514 us-gaap:ComputerEquipmentMember 2020-12-31 0001567514 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001567514 us-gaap:EquipmentMember 2020-12-31 0001567514 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001567514 itci:ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember 2020-12-31 0001567514 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001567514 itci:VehicleFleetLeaseMember 2020-12-31 0001567514 us-gaap:AccruedLiabilitiesMember 2020-12-31 0001567514 itci:MedicaidRebatesMember 2020-12-31 0001567514 itci:OtherRevenueRelatedAccrualsMember 2020-12-31 0001567514 us-gaap:CommonStockMember 2020-12-31 0001567514 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001567514 itci:InventoriableCostsMember 2020-01-01 2020-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0001567514 itci:JanuaryTwoThousandAndTwentyInitialPublicOfferingMember us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember itci:JanuaryTwoThousandAndTwentyInitialPublicOfferingMember 2020-01-01 2020-09-30 0001567514 itci:JanuaryTwoThousandAndTwentyInitialPublicOfferingMember 2020-01-01 2020-09-30 0001567514 us-gaap:ProductMember 2020-01-01 2020-09-30 0001567514 us-gaap:GrantMember 2020-01-01 2020-09-30 0001567514 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001567514 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001567514 itci:VehicleFleetLeaseMember 2020-01-01 2020-09-30 0001567514 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember srt:MaximumMember 2020-01-01 2020-09-30 0001567514 itci:CaplytaMember 2020-01-01 2020-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2020-01-01 2020-09-30 0001567514 itci:InventoriableCostsMember 2020-07-01 2020-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0001567514 us-gaap:CommonStockMember itci:JanuaryTwoThousandAndTwentyInitialPublicOfferingMember 2020-07-01 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember itci:JanuaryTwoThousandAndTwentyInitialPublicOfferingMember 2020-07-01 2020-09-30 0001567514 itci:JanuaryTwoThousandAndTwentyInitialPublicOfferingMember 2020-07-01 2020-09-30 0001567514 us-gaap:ProductMember 2020-07-01 2020-09-30 0001567514 us-gaap:GrantMember 2020-07-01 2020-09-30 0001567514 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001567514 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001567514 itci:CaplytaMember 2020-07-01 2020-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2020-07-01 2020-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2021-01-01 2021-09-30 0001567514 itci:InventoriableCostsMember 2021-01-01 2021-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2021-01-01 2021-09-30 0001567514 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001567514 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2021-01-01 2021-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001567514 itci:InducementAwardPlanMember 2021-01-01 2021-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember srt:MinimumMember 2021-01-01 2021-09-30 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember srt:MaximumMember 2021-01-01 2021-09-30 0001567514 us-gaap:ProductMember 2021-01-01 2021-09-30 0001567514 us-gaap:GrantMember 2021-01-01 2021-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2021-01-01 2021-09-30 0001567514 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001567514 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001567514 srt:MaximumMember 2021-01-01 2021-09-30 0001567514 srt:MinimumMember 2021-01-01 2021-09-30 0001567514 itci:VehicleFleetLeaseMember 2021-01-01 2021-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0001567514 us-gaap:AccountsReceivableMember itci:CustomerOneMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001567514 us-gaap:AccountsReceivableMember itci:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001567514 us-gaap:AccountsReceivableMember itci:CustomerThreeMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001567514 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember srt:MaximumMember 2021-01-01 2021-09-30 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2021-01-01 2021-09-30 0001567514 itci:CaplytaMember 2021-01-01 2021-09-30 0001567514 itci:InventoriableCostsMember 2021-07-01 2021-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0001567514 us-gaap:ProductMember 2021-07-01 2021-09-30 0001567514 us-gaap:GrantMember 2021-07-01 2021-09-30 0001567514 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0001567514 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001567514 itci:CaplytaMember 2021-07-01 2021-09-30 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember 2021-07-01 2021-09-30 0001567514 itci:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-03-31 0001567514 us-gaap:IPOMember 2020-01-10 2020-01-10 0001567514 us-gaap:IPOMember 2020-09-15 2020-09-15 0001567514 srt:MaximumMember 2019-09-12 0001567514 srt:MaximumMember us-gaap:CommonStockMember 2019-09-12 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember itci:ITCINationalDemocraticAllianceMemberMember 2020-01-01 2020-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001567514 itci:InducementAwardPlanMember 2020-01-01 2020-12-31 0001567514 itci:AmtTaxCreditMember 2020-03-27 0001567514 itci:PerformanceBasedRestrictedStockUnitsMember 2021-01-01 2021-03-31 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2018-06-30 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2020-05-31 0001567514 itci:InducementAwardPlanMember 2019-12-31 0001567514 itci:InducementAwardPlanMember srt:MaximumMember 2019-12-31 0001567514 stpr:NY 2018-09-30 0001567514 stpr:MD 2019-02-28 0001567514 stpr:NY us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001567514 stpr:MD us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001567514 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember 2005-05-31 2005-05-31 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember 2013-12-01 2013-12-31 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember 2014-12-01 2014-12-31 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember 2019-01-31 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember itci:NationalDemocraticAllianceMember 2019-12-23 2019-12-23 0001567514 srt:MaximumMember 2019-09-12 2019-09-12 0001567514 us-gaap:CommonStockMember 2019-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001567514 us-gaap:RetainedEarningsMember 2019-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001567514 us-gaap:CommonStockMember 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001567514 us-gaap:RetainedEarningsMember 2020-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001567514 us-gaap:CommonStockMember 2020-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001567514 us-gaap:RetainedEarningsMember 2020-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2020-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001567514 us-gaap:RetainedEarningsMember 2020-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2021-09-30 0001567514 us-gaap:CommonStockMember 2021-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001567514 us-gaap:RetainedEarningsMember 2021-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001567514 itci:InducementAwardPlanMember 2020-12-31 0001567514 us-gaap:CommonStockMember 2021-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001567514 us-gaap:RetainedEarningsMember 2021-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 iso4217:USD xbrli:shares xbrli:pure utr:Month utr:Year itci:Segment iso4217:USD xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-Q
 
 
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended
 
September 30, 2021
or
 
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
    
    
    
    
to
    
    
    
    
Commission File Number:
001-36274
 
 
INTRA-CELLULAR THERAPIES, INC.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
  
36-4742850
(State or other jurisdiction of
incorporation or organization)
  
(I.R.S. Employer
Identification No.)
430 East 29th Street
New York, New York
(Address of principal executive offices)
  
10016

(Zip Code)
(646)
440-9333
(Registrant’s telephone number, including area code)
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
 
 
 
 
 
Common Stock
  
ITCI
  
The Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes 
 
 ☒    No 
 
 ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes 
 
 ☒    No 
 
 ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in
Rule 12b-2
of the Exchange Act.
 
Large accelerated filer   ☒    Accelerated filer   ☐
Non-accelerated
filer		   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act).    Yes 
 
 ☐    No 
 
 ☒
As of November 5, 2021, the registrant had 81,463,253 shares of common stock
outstanding.
 
 
 
Intra-Cellular Therapies, Inc.
Index to Form
10-Q
 
  
 
1
 
Item 1.
  
  
 
1
 
  
  
 
1
 
  
  
 
2
 
  
  
 
3
 
  
  
 
4
 
  
  
 
5
 
  
  
 
6
 
Item 2.
  
  
 
23
 
Item 3.
  
  
 
34
 
Item 4.
  
  
 
35
 
  
 
35
 
Item 1.
  
  
 
35
 
Item 1A.
  
  
 
35
 
Item 2.
  
  
 
35
 
Item 3.
  
  
 
35
 
Item 4.
  
  
 
35
 
Item 5.
  
  
 
35
 
Item 6.
  
  
 
36
 
  
 
37
 
In this Quarterly Report on Form
10-Q,
the terms “we,” “us,” “our,” and the “Company” mean Intra-Cellular Therapies, Inc. and our subsidiaries. “ITI” refers to our wholly-owned subsidiary ITI, Inc. and “ITI Limited” refers to our wholly-owned subsidiary ITI Limited.
 
 
i
PART I: FINANCIAL INFORMATION
 
Item 1.
FINANCIAL STATEMENTS
Intra-Cellular Therapies, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
 
 
  
September 30,
2021
 
 
December 31,
2020
 
 
  
(Unaudited)
 
 
 
 
Assets
                 
Current assets:
                 
Cash and cash equivalents
   
$
106,125,959
 
   $ 60,045,933  
Investment securities,
available-for-sale
   
 
371,157,974
 
     597,402,126  
Restricted cash
   
 
1,400,000
 
     1,400,000  
Accounts receivable, net
   
 
16,934,352
 
     10,764,583  
Inventory
   
 
8,166,935
 
     7,056,385  
Prepaid expenses and other current assets
   
 
29,457,445
 
     14,235,455  
    
 
 
    
 
 
  
Total current assets
   
 
533,242,665
 
     690,904,482  
Property and equipment, net
   
 
1,936,308
 
     1,998,346  
Right of use assets, net
   
 
21,710,677
 
     24,324,762  
Other assets
   
 
86,084
 
     86,084  
    
 
 
    
 
 
  
Total assets
   
$
556,975,734
 
   $ 717,313,674  
    
 
 
    
 
 
  
Liabilities and stockholders’ equity
                 
Current liabilities:
                 
Accounts payable
   
$
12,030,614
 
   $ 5,501,825  
Accrued and other current liabilities
   
 
16,928,669
 
     10,902,117  
Lease liabilities, short-term
   
 
6,082,054
 
     5,541,802  
Accrued employee benefits
   
 
14,854,226
 
     14,907,479  
    
 
 
    
 
 
  
Total current liabilitie
s
   
 
49,895,563
 
     36,853,223  
Lease liabilities
   
 
20,323,918
 
     23,600,347  
    
 
 
    
 
 
  
Total liabilities
   
 
70,219,481
 
     60,453,570  
Stockholders’ equity:
                 
Common stock, $0.0001 par value: 175,000,000 and 100,000,000 shares authorized at September 30, 2021 and December 31, 2020, respectively; 81,377,406 and 80,463,089 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively
   
 
8,138
 
     8,046  
Additional
paid-in
capital
   
 
1,622,149,674
 
     1,593,475,506  
Accumulated deficit
   
 
(1,135,495,761
) 
     (937,104,032 ) 
Accumulated comprehensive income
   
 
94,202
 
     480,584  
    
 
 
    
 
 
  
Total stockholders’ equity
   
 
486,756,253
 
     656,860,104  
    
 
 
    
 
 
  
Total liabilities and stockholders’ equity
   
$
556,975,734
 
   $ 717,313,674  
    
 
 
    
 
 
  
See accompanying notes to these condensed consolidated financial statements.
 
1
Intra-Cellular Therapies, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations (Unaudited)
 
 
  
Three Months Ended September 30,
 
 
Nine Months Ended September 30,
 
 
  
2021
 
 
2020
 
 
2021
 
 
2020
 
Revenues
                                 
Product sales, net
   
$
21,606,163
 
   $ 7,368,594    
$
56,191,848
 
   $ 10,126,999  
Grant revenue
   
 
601,038
 
     —      
 
1,940,243
 
     231,710  
    
 
 
    
 
 
    
 
 
    
 
 
  
Total revenues
   
 
22,207,201
 
     7,368,594    
 
58,132,091
 
     10,358,709  
Operating expenses:
                 
Cost of product sales
   
 
2,001,315
 
     556,107    
 
5,496,561
 
     753,957  
Research and development
   
 
27,031,825
 
     10,275,368    
 
59,386,413
 
     51,483,551  
Selling, general and administrativ
e
   
 
70,497,885
 
     52,473,573    
 
192,932,688
 
     128,015,496  
    
 
 
    
 
 
    
 
 
    
 
 
  
Total operating expenses
   
 
99,531,025
 
     63,305,048    
 
257,815,662
 
     180,253,004  
    
 
 
    
 
 
    
 
 
    
 
 
  
Loss from operations
   
 
(77,323,824
) 
     (55,936,454 )   
 
(199,683,571
) 
     (169,894,295 ) 
Interest income
   
 
392,695
 
     752,829    
 
1,297,473
 
     3,591,091  
    
 
 
    
 
 
    
 
 
    
 
 
  
Loss before provision for income taxes
   
 
(76,931,129
) 
     (55,183,625 )   
 
(198,386,098
) 
     (166,303,204 ) 
Income tax (expense) benefit
   
 
23,125
 
     —      
 
(5,631
) 
     (3,281 )
    
 
 
    
 
 
    
 
 
    
 
 
  
Net loss
   
$
(76,908,004
) 
   $ (55,183,625 )   
$
(198,391,729
) 
   $ (166,306,485 ) 
    
 
 
    
 
 
    
 
 
    
 
 
  
Net loss per common share:
                 
Basic & Diluted
   
$
(0.95
) 
   $ (0.79 )   
$
(2.44
) 
   $ (2.48 ) 
Weighted average number of common shares:
                 
Basic & Diluted
   
 
81,354,724
 
     69,530,039    
 
81,178,482
 
     67,030,991  
See accompanying notes to these condensed consolidated financial statements.
 
2
Intra-Cellular Therapies, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Loss (Unaudited)
 
    
Three Months Ended September 30,
    
Nine Months Ended September 30,
  
    
2021
     2020    
2021
     2020  
Net loss
   
$
(76,908,004
) 
   $ (55,183,625 )   
$
(198,391,729
) 
   $ (166,306,485 ) 
Other comprehensive loss:
                                 
Unrealized (loss) gain on investment securitie
s
   
 
(81,916
) 
     (399,361 )   
 
(386,382
) 
     640,421  
    
 
 
    
 
 
    
 
 
    
 
 
  
Comprehensive loss
   
$
(76,989,920
) 
   $ (55,582,986 )   
$
(198,778,111
) 
   $ (165,666,064 ) 
    
 
 
    
 
 
    
 
 
    
 
 
  
See accompanying notes to these condensed consolidated financial statements.
 
3
Intra-Cellular Therapies, Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
 
    
Common Stock
     
Additional
Paid-in

Capital
     
Accumulated
Deficit
    
Accumulated
Comprehensive
(Loss) Income
    
Total
Stockholders’
Equity
  
    
Shares
     
Amount
  
Balance at June 30, 2020
      66,777,737      $ 6,678      $ 1,199,576,320      $ (821,221,229 )    $ 1,168,099     $ 379,529,868  
Common shares issued
      13,179,458        1,318        370,137,298        —         —         370,138,616  
Common shares issued receivable collected
      —          —          5,705,186        —         —         5,705,186  
Exercise of stock options and issuances of restricted stock
      183,516        18        2,650,587        —         —         2,650,605  
Stock issued for services
      2,086        —          53,527        —         —         53,527  
Share-based compensation
      —          —          6,900,719        —         —         6,900,719  
Net loss
      —          —          —          (55,183,625 )      —         (55,183,625 ) 
Other comprehensive loss
      —          —          —          —         (399,361 )      (399,361 ) 
    
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
Balance at September 30, 2020
      80,142,797      $ 8,014      $ 1,585,023,637      $ (876,404,854 )    $ 768,738     $ 709,395,535  
    
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
           
    
Common Stock
     
Additional
Paid-in

Capital
     
Accumulated
Deficit
    
Accumulated
Comprehensive
(Loss) Income
    
Total
Stockholders’
Equity
  
    
Shares
     
Amount
  
Balance at December 31, 2019
      55,507,497      $ 5,551      $ 904,971,772      $ (710,098,369 )    $ 128,317     $ 195,007,271  
Common shares issued
      23,409,458        2,341        652,709,670        —         —         652,712,011  
Exercise of stock options and issuances of restricted stock
      1,218,188        121        7,829,463        —         —         7,829,584  
Stock issued for services
      7,654        1        160,582        —         —         160,583  
Share-based compensation
      —          —          19,352,150        —         —         19,352,150  
Net loss
      —          —          —          (166,306,485 )      —         (166,306,485 ) 
Other comprehensive gain
      —          —          —          —         640,421       640,421  
    
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
Balance at September 30, 2020
      80,142,797      $ 8,014      $ 1,585,023,637      $ (876,404,854 )    $ 768,738     $ 709,395,535  
    
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
           
    
Common Stock
     
Additional
Paid-in

Capital
     
Accumulated
Deficit
    
Accumulated
Comprehensive
(Loss) Income
    
Total
Stockholders’
Equity
  
    
Shares
     
Amount
  
Balance at June 30, 2021
   
 
81,311,878
 
   
$
8,132
 
   
$
1,611,989,381
 
   
$
(1,058,587,757
) 
  
$
176,118
 
  
$
553,585,874
 
Exercise of stock options and issuances of restricted stock
   
 
64,489
 
   
 
6
 
   
 
591,290
 
   
 
—  
 
  
 
—  
 
  
 
591,296
 
Stock issued for services
   
 
1,039
 
   
 
—  
 
   
 
38,734
 
   
 
—  
 
  
 
—  
 
  
 
38,734
 
Share-based compensation
   
 
—  
 
   
 
—  
 
   
 
9,530,269
 
   
 
—  
 
  
 
—  
 
  
 
9,530,269
 
Net loss
   
 
—  
 
   
 
—  
 
   
 
—  
 
   
 
(76,908,004
) 
  
 
—  
 
  
 
(76,908,004
) 
Other comprehensive los
s
   
 
—  
 
   
 
—  
 
   
 
—  
 
   
 
—  
 
  
 
(81,916
) 
  
 
(81,916
) 
    
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
Balance at September 30, 2021
   
 
81,377,406
 
   
$
8,138
 
   
$
1,622,149,674
 
   
$
(1,135,495,761
) 
  
$
94,202
 
  
$
486,756,253
 
    
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
           
    
Common Stock
     
Additional
Paid-in

Capital
     
Accumulated
Deficit
    
Accumulated
Comprehensive
(Loss) Income
    
Total
Stockholders’
Equity
  
    
Shares
     
Amount
  
Balance at December 31, 2020
   
 
80,463,089
 
   
$
8,046
 
   
$
1,593,475,506
 
   
$
(937,104,032
) 
  
$
480,584
 
  
$
656,860,104
 
Exercise of stock options and issuances of restricted stock
   
 
910,428
 
   
 
92
 
   
 
3,604,559
 
   
 
—  
 
  
 
—  
 
  
 
3,604,651
 
Stock issued for services
   
 
3,889
 
   
 
—  
 
   
 
144,199
 
   
 
—  
 
  
 
—  
 
  
 
144,199
 
Share-based compensation
   
 
—  
 
   
 
—  
 
   
 
24,925,410
 
   
 
—  
 
  
 
—  
 
  
 
24,925,410
 
Net loss
   
 
—  
 
   
 
—  
 
   
 
—  
 
   
 
(198,391,729
) 
  
 
—  
 
  
 
(198,391,729
) 
Other comprehensive loss
   
 
—  
 
   
 
—  
 
   
 
—  
 
   
 
—  
 
  
 
(386,382
) 
  
 
(386,382
) 
    
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
Balance at September 30, 2021
   
 
81,377,406
 
   
$
8,138
 
   
$
1,622,149,674
 
   
$
(1,135,495,761
) 
  
$
94,202
 
  
$
486,756,253
 
    
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
See accompanying notes to these condensed consolidated financial statements.
 
4
Intra-Cellular Therapies, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Unaudited)
 
 
  
Nine Months Ended September 30,
 
 
  
2021
 
 
2020
 
Cash flows used in operating activities
                 
Net loss
   
$
(198,391,729
) 
   $ (166,306,485 ) 
Adjustments to reconcile net loss to net cash used in operating activities:
                 
Depreciation
   
 
386,534
 
     402,146  
Share-based compensation
   
 
24,925,410
 
     19,352,150  
Stock issued for services
   
 
144,199
 
     160,583  
Amortization of premiums and discounts on investment securities, net
   
 
(3,301,051
) 
     (177,374 ) 
Changes in operating assets and liabilities:
                 
Accounts receivable, net
   
 
(6,169,769
) 
     (7,480,604 ) 
Inventory
   
 
(1,110,550
) 
     (2,947,138 ) 
Prepaid expenses and other assets
   
 
(15,221,990
) 
     (4,776,989 ) 
Long term deferred tax asset, net
   
 
—  
 
     264,609  
Accounts payable
   
 
6,528,789
 
     1,144,124  
Accrued liabilities and other
   
 
5,973,299
 
     (1,419,249 ) 
Lease liabilities, net
   
 
(122,092
) 
     (45,899 ) 
    
 
 
    
 
 
  
Net cash used in operating activities
   
 
(186,358,950
) 
     (161,830,126 ) 
Cash flows provided by (used in) investing activities
                 
Purchases of investments
   
 
(155,193,808
) 
     (488,524,539 ) 
Maturities of investments
   
 
384,352,629
 
     184,757,160  
Purchases of property and equipment
   
 
(324,496
) 
     (191,958 ) 
    
 
 
    
 
 
  
Net cash provided by (used in) investing activities
   
 
228,834,325
 
     (303,959,337 ) 
Cash flows provided by financing activities
                 
Proceeds from exercise of stock options
   
 
3,604,651
 
     7,829,584  
Proceeds of public offering, net
   
 
—  
 
     652,712,011  
    
 
 
    
 
 
  
Net cash provided by financing activities
   
 
3,604,651
 
     660,541,595  
    
 
 
    
 
 
  
Net increase in cash, cash equivalents, and restricted cash
   
 
46,080,026
 
     194,752,132  
Cash, cash equivalents, and restricted cash at beginning of perio
d
   
 
61,445,933
 
     107,636,849  
    
 
 
    
 
 
  
Cash, cash equivalents, and restricted cash at end of period
   
$
107,525,959
 
   $ 302,388,981  
    
 
 
    
 
 
  
Non-cash investing and financing activities
 
 
 
 
 
 
 
 
 
Right of use assets under operating leases
   
$
8,917,935
 
   $ 7,750,959  
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:
 
    
September 30,
  
    
2021
     
2020
  
Cash and cash equivalents
   
$
106,125,959
 
    $ 300,988,981  
Restricted cash
   
 
1,400,000
 
      1,400,000  
    
 
 
     
 
 
  
Total cash, cash equivalents and restricted cash
   
$
107,525,959
 
    $ 302,388,981  
    
 
 
     
 
 
  
See accompanying notes to these condensed consolidated financial statements.
 
5
Intra-Cellular Therapies, Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)
September 30, 2021
1. Organization
Intra-Cellular
 Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiaries, ITI, Inc. (“ITI”) and ITI Limited, is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (“CNS”). In
December 2019
, the Company announced that CAPLYTA
®
(lumateperone) had been approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults
(42
mg/day). The Company initiated the commercial launch of CAPLYTA in late
March 2020
. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia. Lumateperone is in Phase
3
clinical development as a novel treatment for bipolar depression and major depressive disorder.
On January 10, 2020, the Company completed a public offering o
f
 common stock in which the Company sold 10,000,000 shares of common stock at an offering price of $29.50 per share for aggregate gross proceeds of $295.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $277.0 million. On September 15, 2020, the Company completed a public offering of common stock in which the Company sold 12,666,667 shares of common stock at an offering price of $30.00 per share for aggregate gross proceeds of $380.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $357.8 million.
In order to further its commercial activities and research projects and support its collaborations, the Company will require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt or convertible debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s product candidates and technology and, to a much lesser extent, grant funding. On August 30, 2019, the Company filed a universal shelf registration statement on Form
S-3,
which was declared effective by the SEC on September 12, 2019, on which the Company registered for sale up to $350 million of any combination of its common stock, preferred stock, debt securities, warrants, rights and/or units from time to time and at prices and on terms that the Company may determine, which included up to $75 million of common stock that the Company could issue and sell from time to time, through SVB Leerink LLC acting as its sales agent, pursuant to the sale agreement that the Company entered into with SVB Leerink on August 29, 2019 for the Company’s
“at-the-market”
equity program. On September 10, 2020, the Company terminated the
“at-the-market”
equity program sales agreement with SVB Leerink LLC. During the year ended December 31, 2020, the Company issued an aggregate 742,791 shares of common stock under the Company’s
“at-the-market”
equity program which resulted in the Company receiving net proceeds of $17.9 million.
In addition, on January 6, 2020, the Company filed an automatic shelf registration statement on Form
S-3
with the SEC, which became effective upon filing, on which the Company registered for sale an unlimited amount of any combination of its common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that the Company may determine, so long as the Company continues to satisfy the requirements of a “well-known seasoned issuer” under SEC rules. These registration statements will remain in effect for up to three years from the respective dates they became effective.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders.
 
6
Recent Accounting Pronouncements
Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the condensed consolidated balance sheets.
Investment Securities
Investment securities consisted of the following (in thousands):
 
 
  
September 30, 2021
 
 
  
Amortized
Cost
 
  
Unrealized
Gains
 
  
Unrealized
(Losses)
 
  
Estimated
Fair
Value
 
 
  
(Unaudited)
 
U.S. Government Agency Securities
    $ 101,673      $ 1      $ (8 )     $ 101,666  
Certificates of Deposit
      25,500        —          —          25,500  
Commercial Paper
      66,454        5        (6 )       66,453  
Corporate Notes/Bonds
      177,437        141        (39 )       177,539  
    
 
 
     
 
 
     
 
 
     
 
 
  
     $ 371,064      $ 147      $ (53 )     $ 371,158  
    
 
 
     
 
 
     
 
 
     
 
 
  
 
    
December 31, 2020
  
    
Amortized
Cost
     
Unrealized
Gains
     
Unrealized
(Losses)
     
Estimated
Fair
Value
  
U.S. Government Agency Securities
    $ 259,304      $ 3      $ (31 )     $ 259,276  
Certificates of Deposit
      10,500        —          —          10,500  
Commercial Paper
      124,368        23        (21 )       124,370  
Corporate Notes/Bonds
      202,749        624        (117 )       203,256  
    
 
 
     
 
 
     
 
 
     
 
 
  
     $ 596,921      $ 650      $ (169 )     $ 597,402  
    
 
 
     
 
 
     
 
 
     
 
 
  
The Company has classified all of its investment securities as
available-for-sale,
including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2021 and December 31, 2020, the Company held $54.9 million and $188.5 million, respectively, of
available-for-sale
investment securities with contractual maturity dates more than one year and less than two years.
 
7
The Company monitors its investment portfolio for overall risk, specifically credit risk loss, quarterly or more frequently if circumstances warrant. The Company would estimate the expected credit loss over the lifetime of the asset and record an allowance for the portion of the amortized cost basis of the financial asset that the Company does not expect to collect.
The aggregate related fair value of investments with unrealized losses as of September 30, 2021 was $165.3 million, which consisted of $46.5 million from U.S. government agency securities, $40.0 million of commercial paper, and $78.8 million of corporate notes/bonds. The aggregate amount of unrealized losses as of September 30, 2021 was approximately $53.5 thousand, which consisted of $7.9 thousand from U.S. government agency securities, $6.2 thousand from commercial paper, and $39.4 thousand from corporate notes/bonds. The $165.3 million aggregate fair value of investments with unrealized losses as of September 30, 2021 has been held in a continuous unrealized loss position for less than 12 months. As of December 31, 2020, the aggregate related fair value of investments with unrealized losses was $372.3 million and the aggregate amount of unrealized losses was approximately $169 thousand. The $372.3 million aggregate fair value of investments with unrealized losses as of December 31, 2020 had been held in a continuous unrealized loss position for less than 12 months.
The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.
Fair Value Measurements
The Company applies the fair value method under ASC Topic 820,
Fair Value Measurements and Disclosures
. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
 
  •  
Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
 
  •  
Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
 
  •  
Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy.
The Company has no assets or liabilities that were measured using quoted prices for significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2021 or December 31, 2020. The carrying value of cash held in money market funds of approximately $88.2 million as of September 30, 2021 and $27.9 million as of December 31, 2020 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in commercial paper of approximately $7.0 million as of September 30, 2021 is included in cash and cash equivalents.
 
8
The fair value measurements of the Company’s cash equivalents and
available-for-sale
investment securities are identified in the following tables (in thousands):
 
           
Fair Value Measurements at
Reporting Date Using
  
    
September 30,
2021
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 88,250      $ 88,250      $ —        $ —    
U.S. Government Agency Securities
      101,666        —          101,666        —    
Certificates of Deposit
      25,500        —          25,500        —    
Commercial Paper
      73,452        —          73,452        —    
Corporate Notes/Bonds
      177,539        —          177,539        —    
    
 
 
     
 
 
     
 
 
     
 
 
  
 
  
$
 466,407
 
  
$
 88,250
 
  
$
 378,157
 
  
$
 —
  
 
    
 
 
     
 
 
     
 
 
     
 
 
  
     
           
Fair Value Measurements at

Reporting Date Using
  
    
December 31,
2020
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 27,917      $ 27,917      $ —        $ —    
U.S. Government Agency Securities
      259,276        —          259,276        —    
Certificates of Deposit
      10,500        —          10,500        —    
Commercial Paper
      124,370        —          124,370        —    
Corporate Notes/Bonds
      203,256        —          203,256        —    
    
 
 
     
 
 
     
 
 
     
 
 
  
 
  
$
 625,319
 
  
$
 27,917
 
  
$
 597,402
 
  
$
—  
 
    
 
 
     
 
 
     
 
 
     
 
 
  
Financial Instruments
The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, right of use asset, net, other assets, accounts payable, accrued liabilities, accrued employee benefits and lease liabilities, short-term, to approximate their fair value because of their relatively short maturities at September 30, 2021 and December 31, 2020. Management believes that the risks associated with its financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing.
Restricted Cash
Restricted cash is collateral used under the letter of credit arrangement for the vehicle lease agreement. The Company adopted ASU
No. 2016-18,
“Restricted Cash” (“ASU
2016-18”)
and presents restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows.
Accounts Receivable, Net
The Company’s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees.
The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers’ credit profiles. The Company reserves against accounts receivable for estimated losses that may arise from a customer’s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated collectability losses was not significant as of September 30, 2021 and December 31, 2020.
 
9
We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a credit loss reserve against uncollectible accounts receivable as necessary. We extend credit primarily to pharmaceutical wholesale distributors. Customer creditworthiness is monitored and collateral is not required. Historically, we have not experienced credit losses on our accounts receivable and as of September 30, 2021 and December 31, 2020, our credit loss reserve on receivables was not material.
Concentration of Credit Risk
Financial instruments which potentially subject th
e
 Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the nine-month period ended September 30, 2021, all of the Company’s accounts receivable, net arose from product sales in the United States and all customers have standard payment terms which generally require payment within 60 days. For the nine-month period ended September 30, 2021, 96% of sales were generated from three major industry wholesalers which accounted for approximately 40%, 29%, and 27% of product sales, respectively. As of September 30, 2021, the Company believes that such customers are of high credit quality. The percentage of the total net product sales by individual customers has not significantly changed since inception.
Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.
Inventory
The Company values its inventories at the lower of cost or estimated net realizable value. Inventories consist of raw materials (active pharmaceutical ingredients (“API”), drug product, and packaged product in saleable condition). The consumption of raw materials during production is classified as work in process until saleable. Once it is determined to be in saleable condition, inventory is classified as finished goods. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a
first-in,
first-out
(“FIFO”) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales.
The Company capitalizes inventory costs associated with the Company’s products after regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets when identified in the manufacturing process, and is then expensed to selling, general and administrative expenses when the sample product is distributed.
Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs.
Property and Equipment
Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred.
When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC Topic 360,
Property, Plant and Equipment
. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date.
 
10
Revenue Recognition
Effective January 1, 2018, the Company adopted ASC Topic 606,
 Revenue from Contracts with Customers
(“ASC Topic 606”). The Company did not generate any product related revenue prior to January 1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact on the Company’s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service. The reported results for the three and nine-month periods ended September 30, 2021 and 2020 reflect the application of ASC Topic 606.
To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see
Product Sales, Net
(below).
To date, the Company’s only source of product sales has been from sales of CAPLYTA in the United States, which the Company began shipping to customers in March 2020.
Product Sales, Net
The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company’s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the Customer obtains control of the Company’s product, which occurs at a point in time (upon delivery). Product revenues are recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue.
Reserves for Variable Consideration
Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company’s sales of its product.
These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include the Company’s best estimates that take into consideration a range of possible outcomes which are considered more likely in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, and forecasted customer buying and payment patterns. The Company’s estimates regarding the payer mix for CAPLYTA are based on historical industry information regarding the payer mix for comparable pharmaceutical products and product portfolios, in particular, information related to similar products in their initial launch stages and through the use of historical information experienced in CAPLYTA’s launch period.
The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined it was probable that a significant reversal of revenue would not occur in a future period for the estimates detailed below as of September 30, 2021 and 2020, and, therefore, the transaction price was not reduced further during the three and nine-month periods ended September 30, 2021 and 2020. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known.
Trade Discounts and Allowances
— The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct
 
11
from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of product sales, net within the condensed consolidated statements of operations for the three and nine-month periods ended September 30, 2021 and 2020, as well as a reduction to accounts receivable, net on the condensed consolidated balance sheets.
Product Returns
— Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product’s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any expired product returns to date.
Provider Chargebacks and Discounts
— Chargebacks fo
r
 fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who purchase the product directly from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting
period-end
that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the three and nine-month periods ended September 30, 2021 and 2020, these amounts were not significant.
Government Rebates
— The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.
Payer Rebates
— The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Other Incentives
— Other incentives which the Company offers include voluntary patient assistance programs, such as the
co-pay
assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug
co-payments
required by payers. The calculation of the accrual for
co-pay
assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company applies the claims for vouchers for product that is in the distribution channel and reduces recognized revenue accordingly.
The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.
 
12
Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the condensed consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.​​​​​​​
Cost of Product Sales
Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs).
For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The related royalties are recorded within cost of product sales on the condensed statement of operations.
Prior to FDA approval of CAPLYTA, the Company expensed all costs associated with the manufacturing of lumateperone as part of research and development expenses. From December 20, 2019, the date of approval of CAPLYTA, through December 31, 2019 there was no production of inventory and therefore, no inventory costs were incurred. Therefore, at December 31, 2019, no inventory costs had been capitalized. The cost of product sales in the three and nine-month periods ended September 30, 2021 and 2020, are lower than incurred due to the previously expensed inventory.
Research and Development, Including Clinical Trial Expenses
Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees.
Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred, among other factors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated balance sheets as prepaid or accrued research and development expense, as the case may be.
As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate clinical trial expenses in its condensed consolidated statement of operations by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period.
Advertising Expense
In connection with the FDA approval of CAPLYTA in 2019, the Company began to incur advertising costs in connection with the subsequent commercial launch of CAPLYTA in 2020. Advertising costs are expensed when services are rendered. Advertising expense for the three and nine months ended September 30, 2021 was $23.2 million and $57.4 million, respectively, as compared to $13.2 million and $18.6 million, respectively, for the three and nine months ended September 30, 2020, related to the Company’s marketed product, CAPLYTA.
 
13
Income Taxes
Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities o
f
 a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740 (previously included in FASB Interpretation No. 48,
Accounting for Uncertainty in Income Taxes—an Interpretation of FASB Statement No.
 109
). Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a
more-likely-than-not
threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.
The Company’s effective tax rate for the three and nine months ended September 30, 2021 and 2020 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit.
On March 27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (“CARES”) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (“AMT”) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, and a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the year ended December 31, 2020. The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of approximately $265,000 to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December 31, 2019 and received the refund in July 2020.
On March 11, 2021, the American Rescue Plan Act of 2021 (“ARPA 2021”) was signed into law. ARPA 2021 included various income and payroll tax provisions. The Company has analyzed the tax provisions of ARPA 2021 and determined they have no significant financial impact to the Company’s condensed consolidated financial statements.
Comprehensive Loss
All components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are incurred. Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or (losses) on its investment securities in a separate statement of comprehensive loss for each period.
Share-Based Compensation
Share-based payments for stock options are accounted for in accordance with the provisions of ASC Topic 718,
Compensation—Stock Compensation
. The fair value of share-based payments is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the “Black-Scholes model”). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.
For all awards granted with time-based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 accounts for forfeitures as they occur.
The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.
Expected volatility rates for quarterly periods prior to December 31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company’s common stock. Beginning in the fourth quarter of 2019, expected volatility rates have been based entirely on the historical volatility of the Company’s
 
14
common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the “simplified method,” which defines expected life as the midpoint between the vesting date and the end of the contractual term.
The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company’s common stock on the date of grant.
A restricted stock unit (“RSU”) is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company’s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company.
In the first quarter of 2020, the Company granted performance-based RSUs for 86,000 shares of common stock, which vest based on the achievement of certain milestones that include (i) the approval of a planned NDA by the FDA (the “2020 Milestone RSUs”) and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2020 TSR RSUs”). The 2020 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements.
In the first quarter of 2021, the Company granted performance-based RSUs for 64,518 shares of common stock, which vest based on the achievement of certain milestones that include (i) certain operational milestones (the “2021 Milestone RSUs”, and collectively with the 2020 Milestone RSUs, the “Milestone RSUs”) and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2021 TSR RSUs,” and collectively with the 2020 TSR RSUs, the “TSR RSUs”). The 2021 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements.
Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic 740,
Income Taxes
. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance.
Equity instruments issued to
non-employees
for services are accounted for under the provisions of ASC Topic 718 and ASC Topic
505-50,
Equity/Equity-Based Payments to
Non-Employees
. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the required services are completed and are marked to market during the service period.
In June 2018, the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company’s stockholders approved the Company’s 2018 Amended and Restated Equity Incentive Plan pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants.
In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement Award Plan (the “2019 Inducement Plan”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of September 30, 2021, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan.
Loss Per Share
Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants and RSUs.
 
15
The following awards were excluded in th
e
 calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2021 and 2020:
 
 
  
Three and Nine Months Ended
September 30,
 
 
  
2021
 
  
2020
 
Stock options
      5,952,252        5,964,135  
RSUs
      1,601,273        1,702,538  
TSR RSUs
      68,598        43,022  
3. Inventory
Inventory consists of the following:
 
    
September 30,
2021
      December 31,
2020		  
Raw materials
   
$
2,182,261
 
    $ 2,483,801  
Work in process
   
 
3,444,013
 
      1,781,101  
Finished goods
   
 
2,540,661
 
      2,791,483  
    
 
 
     
 
 
  
    
$
8,166,935
 
    $ 7,056,385  
    
 
 
     
 
 
  
Inventory acquired prior to receipt of the FDA approval on December 20, 2019 for CAPLYTA was expensed as research and development expense as incurred.
4. Property and Equipment
Property and equipment consist of the following:
 
    
September 30,
2021
      December 31,
2020		  
Computer equipment
   
$
408,751
 
    $ 243,532  
Furniture and fixtures
   
 
423,097
 
      423,097  
Scientific equipment
   
 
4,287,228
 
      4,127,951  
Leasehold improvement
s
   
 
1,240,315
 
      1,240,315  
    
 
 
     
 
 
  
    
 
6,359,391
 
      6,034,895  
Less accumulated depreciation
   
 
(4,423,083
) 
      (4,036,549 ) 
    
 
 
     
 
 
  
    
$
1,936,308
 
    $ 1,998,346  
    
 
 
     
 
 
  
Depreciation expense for the three and nine months ended September 30, 2021 was $133,945 and $386,534, respectively, as compared to $121,044 and $402,146 for the three and nine months ended September 30, 2020, respectively.
5. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities as of September 30, 2021 and December 31, 2020 consisted of the following:
 
    
September 30, 2021
     
December 31, 2020
  
Accrued expenses
    $ 12,144,235      $ 7,896,942  
Medicaid rebates
      3,226,394        1,998,953  
Other revenue related accruals
      1,558,040        1,006,222  
    
 
 
     
 
 
  
Total accrued expenses and other current liabilities
    $ 16,928,669      $ 10,902,117  
    
 
 
     
 
 
  
 
16
6. Right of Use Assets and Lease Liabilities
Real Estate Leases
In 2014, the Company entered into a long-term lease with a related party which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASU
2016-02
for accounting purposes. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In February 2019, the Company entered into a long-term lease for office space in Towson, Maryland beginning March 1, 2019. The lease has a term of 3.2 years ending in April 2022 and includes limited rent abatement and escalation provisions. The Company has no other significant leases. In addition, no identified leases require allocations between lease and
non-lease
components.
In adopting ASU
2016-02
as of January 1, 2019, the Company elected the package of practical expedients, which permit the Company not to reassess under the new standard the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the consolidated balance sheets. The Company also elected the lessee component election, allowing the Company to account for the lease and
non-lease
components as a single lease component. In determining whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. The Company recognized those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. The Company uses the rate implicit in the contract whenever possible when determining the applicable discount rate. As the majority of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. On the lease commencement dates, the Company estimated the lease liabilities and the right of use assets at present value using its applicable incremental borrowing rates of its two long-term leases of 7.2% for the Company’s Maryland lease of 3.2 years and 9.1% for the Company’s New York leases of 14.3 years. On January 1, 2019, upon adoption of ASU
2016-02,
the Company recorded right of use assets of approximately $20.2 million, lease liabilities of $23.4 million and eliminated deferred rent of $3.2 million. At the execution of the Maryland lease in 2019, the Company recorded a right of use asset and a lease liability of $0.2 million, which represented a
non-cash
transaction.
Maturity analysis under the lease agreements are as follows:
 
Three months ending December 31, 2021
    $ 871,321  
Year ending December 31, 2022
      3,491,166  
Year ending December 31, 2023
      3,566,466  
Year ending December 31, 2024
      3,675,196  
Year ending December 31, 2025
      3,787,248  
Thereafter
      13,839,791  
    
 
 
  
Total
      29,231,188  
Less: Present value discount
      (8,505,190 ) 
    
 
 
  
Total Lease liability
      20,725,998  
    
 
 
  
Less: Current portion
      (3,322,657 ) 
    
 
 
  
Long-term lease liabilities
    $ 17,403,341  
    
 
 
  
Lease expense for the three and nine months ended September 30, 2021 was approximately $0.8 million and $2.5 million, respectively, as compared to approximately $0.8 million and $2.5 million, respectively, for the three and nine months ended September 30, 2020.
Vehicle Fleet Lease
On May 17, 2019, the Company entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to acquire motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The Company began leasing vehicles under the Vehicle Lease in March 2020.
The contractual period of each lease is 12 months, followed by
month-to-month
renewal periods. The Company estimates the lease term for each vehicle to be 30 months based on industry standards. The lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.4 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease. The $1.4 million is recorded as restricted cash on the condensed consolidated balance sheet.
 
17
The nature of the lease is one commonly referred to as “TRAC” lease, as it contains a terminal rental adjustment clause, or “TRAC clause.” The TRAC clause limits lessee
exposure, or likelihood of having a variable lease payment
due at lease termination. This variable lease payment amount would be any difference between the vehicle stipulated (capitalized) cost and the sum of the reserve and net proceeds from disposal as described in the Vehicle Lease. Further, the Lessor guarantees that the net proceeds will not be less than 20% of the vehicle capitalized cost in the first 12 months, and 30% of the vehicle capitalized cost at the beginning of subsequent
12-month
period increments.
Right of use asset an
d
 lease liability for the vehicle fleet lease was approximately $5.7 million and $7.3 million, respectively, as of September 30, 2021 and December 31, 2020. The vehicle leases entered into since March 2020 represent
non-cash
transactions. The total operating lease cost for the three and nine months ended September 30, 2021 was $583,142 and $1.8 million, respectively. The operating cash outflows related to vehicle fleet operating lease obligations for the nine months ended September 30, 2021 and 2020 were $1.8 million and $585,490, respectively.
The following table presents the Vehicle Lease balances within the condensed consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of September 30, 2021 and December 31, 2020:
 
Lease Assets and Liabilities – Fleet
  
Classification
 
  
September 30, 2021
 
 
December 31, 2020
 
Assets
                          
Right of use assets, net
      Operating lease right of use assets      $ 5,679,974     $ 7,295,515  
             
 
 
    
 
 
  
              $ 5,679,974     $ 7,295,515  
             
 
 
    
 
 
  
Liabilities
                          
Current
                          
Lease liabilities, short-term
      Operating lease liabilities      $ 2,759,397     $ 2,257,262  
Non-Current
                          
Lease liabilities
     
Non-current operating lease liabilities
        2,920,577       5,038,253  
             
 
 
    
 
 
  
Total lease liabilities
             $ 5,679,974     $  7,295,515  
             
 
 
    
 
 
  
Weighted average remaining lease term
               1.3 years       2.0 years  
Weighted average discount rate
               1.71 %      1.74 % 
The following table presents the maturity of the Company’s fleet lease liability as of September 30, 2021:
Time Period
 
Three months ending December 31, 2021
    $ 596,241  
Year ending December 31, 2022
      3,480,355  
Year ending December 31, 2023
      1,691,462  
Thereafter
      —    
    
 
 
  
Total
      5,768,058  
Less: Present value discount
      (88,084 ) 
    
 
 
  
Total operating lease liabilities
      5,679,974  
    
 
 
  
Less: Current portion
      (2,759,397 ) 
    
 
 
  
Long-term lease liabilities
    $ 2,920,577  
    
 
 
  
Right of use assets and lease liabilities for all operating leases were approximately $21.7 million and $26.4 million, respectively, as of September 30, 2021.
 
18
7. Commitments and Contingencies
License and Royalty Commitments
On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and
know-how
of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds.
Under the agreement, the Company made an upfront payment of $1.0 million to BMS in 2005, a milestone payment of $1.25 million in December 2013, and a milestone payment of $1.5 million in December 2014 following the initiation of the Company’s first Phase 3 clinical trial for lumateperone for patients with exacerbated schizophrenia. Upon FDA acceptance of an NDA filing for lumateperone, the Company was obligated to pay BMS a $2.0 million milestone payment, which was paid in January 2019. The FDA approved the NDA filing on December 23, 2019 and as a result the Company accrued an additional milestone liability of $5.0 million in the fourth quarter of 2019 which was paid in January 2020. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of
non-royalty
payments made in consideration of any sublicense.
The agreement extends, and royalties are payable, on a
country-by-country
and
product-by-product
basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.
In September 2016, the Company transferred certain of its rights under the BMS agreement to its wholly owned subsidiary, ITI Limited. In connection with the transfer, the Company guaranteed ITI Limited’s performance of its obligations under the BMS agreement. The Company expensed approximately $1.1 million and $2.8 million, respectively, for the three and nine-month periods ended September 30, 2021, in cost of product sales to satisfy its obligation under the BMS agreement, in comparison to $0.4 million and $0.5 million, respectively, for the three and nine-month periods ended September 30, 2020.
Research and Other Commitments
As of September 30, 2021, the Company has committed to purchasing production campaigns for various raw materials and API from each of its supply vendors – Siegfried Evionnaz SA (“Siegfried”) and Lonza Ltd. (“Lonza”). The campaigns are expected to be received into inventory during 2022. The Company has a total commitment of $32.1 million related to these agreements. As of September 30, 2021, the Company had paid a deposit of $5.2 million and $4.3 million for the Siegfried and Lonza campaigns, respectively, which is recorded within prepaid expenses and other current assets. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan within the executed agreements.
8. Share-Based Compensation
On June 18, 2018, the Company’s stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan provided for the granting of share-based awards, such as stock options, restricted common stock, RSUs and stock appreciation rights to employees, directors and consultants as determined by the Board of Directors. On May 27, 2020, the Company’s stockholders approved the Amended and Restated 2018 Equity Incentive Plan (the “Amended 2018 Plan”), which amended and restated the 2018 Plan. The Amended 2018 Plan provides for the granting of up to 6,500,000 additional share-based awards, such as stock options, restricted common stock, RSUs and stock appreciation rights to employees, directors and consultants as determined by the Board of Directors. In December 2019, the Company adopted the 2019 Inducement Award Plan (the “2019 Inducement Plan”) for the grant of equity awards of up to 1,000,000 shares of common stock to newly hired employees.
As of December 31, 2020, the total number of shares reserved under all equity plans was 17,787,390 and the Company had 7,459,117 shares available for future issuance under the Amended 2018 Plan and the 2019 Inducement Plan. Stock options granted under the 2018 Plan and the 2019 Inducement Plan may be either incentive stock options (“ISOs”) as defined by the Internal Revenue Code of 1986, as amended, or
non-qualified
stock options. The Board of Directors determines who will receive options, the vesting periods (which are generally one to three years) and the exercise prices of such options. Options have a maximum term of 10 years. The exercise price of stock options granted under the Amended 2018 Plan and the 2019 Inducement Plan must be at least equal to the fair market value of the common stock on the date of grant. The Company does not intend to issue any additional equity awards under the 2019 Inducement Plan.
 
19
Total share-based compensation expense related to all of th
e
 Company’s share-based awards, including stock options and RSUs to employees, directors and consultants, recognized during the three and nine months ended September 30, 2021 and 2020, was comprised of the following:
 
 
  
Three Months Ended September 30,
 
  
Nine Months Ended September 30,
 
 
  
2021
 
  
2020
 
  
2021
 
  
2020
 
Inventoriable costs
   
$
413,103
 
    $ 345,460     
$
1,212,943
 
    $ 996,802  
Research and development
   
 
2,769,561
 
      2,402,865     
 
7,153,803
 
      6,792,498  
General and administrative
   
 
6,347,605
 
      4,152,394     
 
16,558,664
 
      11,562,850  
    
 
 
     
 
 
     
 
 
     
 
 
  
Total share-based compensation expense
   
$
9,530,269
 
    $ 6,900,719     
$
24,925,410
 
    $ 19,352,150  
    
 
 
     
 
 
     
 
 
     
 
 
  
The following table describes the weighted-average assumptions used for calculating the value of options granted during the nine months ended September 30, 2021 and 2020:
 
    
2021
  
2020
Dividend yield
   
0%
   0%
Expected volatility
   
94.5%-94.9%
  
91.6%-92.7%
Weighted-average risk-free interest rate
   
0.86%
   1.31%
Expected term (in years)
   
5.9
   6.0
Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of September 30, 2021, and changes during the three-month period then ended, are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Exercise
Price
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      39,728      $ 17.18        9.2 years  
Options granted in 2021
      —          —             
Options exercised in 2021
      (4,347 )       19.98        9.2 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      35,381      $ 16.83        9.2 years  
    
 
 
     
 
 
           
Vested and expected to vest at September 30, 2021
      35,381      $ 16.83           
    
 
 
     
 
 
           
Exercisable at September 30, 2021
      4,658      $ 19.70        9.2 years  
    
 
 
     
 
 
           
Information regarding RSU awards under the 2019 Inducement Plan during the three-month period ended September 30, 2021 are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      251,867      $ 16.03        2.2 years  
Time based RSUs vested in 2021
      (82,355 )     $ 16.03        2.0 years  
Time based RSUs cancelled in 2021
      (16,023 )     $ 15.81        2.0 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      153,489      $ 16.05        2.0 years  
    
 
 
     
 
 
           
Vested and expected to vest at September 30, 2021
      153,489      $ 16.05           
    
 
 
     
 
 
           
Exercisable at September 30, 2021
      —        $ —             
    
 
 
     
 
 
           
As of September 30, 2021, the Company granted options and time based RSUs totaling 314,138 shares under the 2019 Inducement Plan. These grants were made in the first quarter of 2020 and the Company does not intend to grant any additional equity awards under the 2019 Inducement Plan.
 
20
Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of September 30, 2021, and changes during the nine-month period then ended, are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Exercise
Price
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      5,477,894      $ 18.43        6.6 years  
Options granted 2021
      670,250      $ 30.39        9.5 years  
Options exercised 2021
      (202,124 )     $ 17.28        6.2 years  
Options canceled or expired 2021
      (29,149 )     $ 18.66        8.0 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      5,916,871      $ 20.70        6.2 years  
    
 
 
     
 
 
           
Vested and expected to vest at September 30, 2021
      5,916,871      $ 20.70           
    
 
 
     
 
 
           
Exercisable at September 30, 2021
      4,212,172      $ 18.66        5.3 years  
    
 
 
     
 
 
           
The fair value of the time based RSUs and the Milestone RSUs is based on the closing price of the Company’s common stock on the date of grant. The fair value of the TSR RSUs was determined using the Monte Carlo simulation method. Information regarding the time based RSU activity and changes during the nine-month period ended September 30, 2021 are summarized as follows:
 
    
Number of
Shares
     
Weighted-Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      1,311,877      $ 18.77        1.7 years  
Time based RSUs granted in 2021
      710,318      $ 35.69        2.4 years  
Time based RSUs vested in 2021
      (614,838 )     $ 16.58        1.0 years  
Time based RSUs cancelled in 2021
      (28,171 )     $ 29.90        2.0 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      1,379,186      $ 27.80        1.7 years  
    
 
 
     
 
 
     
 
 
  
Information related to the Company’s Milestone RSUs and TSR RSUs during the nine-month period ended September 30, 2021 are summarized as follows:
 
    
Number of
Shares
     
Weighted-Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      72,678      $ 28.25        2.1 years  
Milestone RSUs and TSR RSUs granted in 2021
      64,518      $ 44.04        2.4 years  
Milestone RSUs and TSR RSUs vested in 2021
      —        $ —          0.0 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      137,196      $ 35.67        5.2 years  
    
 
 
     
 
 
     
 
 
  
The weighted average estimated fair value per share of the 2020 TSR RSUs granted was $32.56, and the 2021 TSR RSUs granted was $51.18, which were derived from Monte Carlo simulations. Significant assumptions utilized in estimating the value of the 2020 awards granted include an expected dividend yield of 0%, a risk-free rate of 1.4%, and expected volatility of 91.3%. Significant assumptions utilized in estimating the value of the 2021 awards granted include an expected dividend yield of 0%, a risk-free rate of 0.2%, and expected volatility of 95.8%. The 2020 TSR RSUs granted will entitle the grantee to receive a number of shares of the Company’s common stock determined over a three-year performance period ending and vesting after December 31, 2022 but before February 18, 2023, provided the grantee remained in the service of the Company on the settlement date. Similarly, the 2021 TSR
RSUs
granted will entitle the grantee to receive a number of shares of the Company’s common stock determined over a three-year performance period ending and vesting after December 31, 2023 but before February 23, 2024, provided the grantee remained in the service of the Company on the settlement date. The Company is expensing the cost of these awards ratably over the requisite service period. The number of shares for which the TSR RSUs will be settled is a percentage of shares for which the award is targeted and depends on the Company’s total shareholder returns, expressed as a percentile ranking of the Company’s total shareholder return as compared to the Company’s peer group. The number of shares for which the TSR RSUs will be settled will vary depending on the level of achievement of the goal. Total shareholder return will be determined by dividing the average share value of the Company’s common stock over the 30 trading days preceding the settlement date by the average share value of the Company’s common stock over the 30 trading days beginning on January 1, 2020 and 2021, accordingly, with a deemed reinvestment of any dividends declared during the performance period. The Company’s peer group included companies that compromised the Nasdaq Biotechnology Index at December 31, 2019 and 2020, respectively.
 
21
The Company recognized
non-cash
share-based compensation expense related to time based RSUs for the three and nine months ended September 30, 2021 of approximately $4.4 million and $12.3 million, respectively, as compared to $3.2 million and $8.9 million, respectively, for the three and nine months ended September 30, 2020. Total expense for all RSUs, including the time based and performance based RSUs, was $4.3 million and $12.6 million, respectively, for the three and nine months ended September 30, 2021, as compared to $3.4 million and $9.2 million, respectively, for the three and nine months ended September 30, 2020. As of September 30, 2021, there was approximately $29.5 million of unrecognized compensation costs related to unvested time based RSUs. As of September 30, 2021, there was $2.1 million and $1.3 million of unrecognized compensation costs related to unvested Milestone RSUs and TSR RSUs, respectively.
 
22

Item 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto that appear elsewhere in this Quarterly Report on Form
10-Q
and the audited consolidated financial statements and notes thereto and under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form
10-K
filed on February 25, 2021. In addition to historical information, the following discussion and analysis includes forward-looking information that involves risks, uncertainties and assumptions. Our actual results and the timing of events could differ materially from those anticipated by these forward-looking statements as a result of many factors, including those discussed under “Risk Factors” in our Annual Report on Form
10-K
filed on February 25, 2021, as updated from time to time in our subsequent periodic and current reports filed with the SEC.
Overview
We are a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. In December 2019, CAPLYTA (lumateperone) was approved by the FDA for the treatment of schizophrenia in adults (42mg/day) and we initiated the commercial launch of CAPLYTA in late March 2020. In support of our commercialization efforts, we employ a national salesforce. As used in this report, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia.
Lumateperone is in Phase 3 clinical development as a novel treatment for bipolar depression. Our lumateperone bipolar depression clinical program consists of three monotherapy studies and one adjunctive study. In September 2020, we announced positive topline results from Study 402, conducted globally, evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. In Study 402, once daily lumateperone 42 mg met the primary endpoint for improvement in depression as measured by change from baseline versus placebo on the Montgomery-Åsberg Depression Rating Scale, or MADRS, total score (p=0.0206; effect size = 0.27). Lumateperone 42 mg also met the key secondary endpoint, the Clinical Global Impression Scale for Bipolar for Severity of Illness, or
CGI-BP-S,
Depression Score (p=0.0082; effect size = 0.31). The lower lumateperone dose, 28 mg, showed a trend for a dose-related improvement in symptoms of depression but the results did not reach statistical significance. In the first quarter of 2020, we initiated our third monotherapy Phase 3 study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. Following the positive results in Study 402, we amended Study 403 to evaluate major depressive episodes with mixed features in bipolar disorder in patients with Bipolar I or Bipolar II disorder and mixed features in patients with major depressive disorder, or MDD. We expect to complete Study 403 in the second half of 2022 and following completion we intend to discuss the results with the FDA to determine whether Study 403, as amended, will provide supportive data for a potential future regulatory filing for this indication.
In July 2019, we announced topline results from our first monotherapy study, Study 401, conducted in the United States, and our second monotherapy study, Study 404, conducted globally, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. In Study 404, lumateperone 42 mg met the primary endpoint for improvement in depression as measured by change from baseline versus placebo on the MADRS total score (p<0.0001; effect size = 0.56). These benefits were statistically significant in both Bipolar I and Bipolar II patients. Study 404 also met its key secondary endpoint, Clinical Global Impression Scale for Bipolar for Severity of Illness
(CGI-BP-S)
Total Score (p<0.001; effect size = 0.46). Study 401 tested two doses of lumateperone, 42 mg and 28mg along with placebo. In this trial, neither dose of lumateperone met the primary endpoint of statistical separation from placebo as measured by change from baseline on the MADRS total score. There was a high placebo response in this trial. Lumateperone was generally well-tolerated in all three bipolar depression studies, with a favorable safety profile.
In addition, while our Phase 3 bipolar depression trials were powered for the overall patient population and not powered for subpopulation analyses, statistically significant benefit versus placebo was seen in the subgroup of patients with Bipolar I and Bipolar II disorder in Study 404 and in patients with Bipolar I disorder in Study 402, but the Bipolar II subgroup was not statistically significant in Study 402. In February 2021, we submitted supplemental new drug applications, or sNDAs, to the FDA for potential regulatory approval of lumateperone for the treatment of bipolar depression in patients with Bipolar I or II disorder as monotherapy and adjunctive therapy. In May 2021, we announced that the FDA had accepted the sNDAs for review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 17, 2021 for these applications. In support of the potential commercial launch of lumateperone for the treatment of bipolar depression upon approval, we have substantially completed the expansion of our sales force from approximately 240 sales representatives to approximately 320 sales representatives.
 
23
We are also pursuing clinical development of lumateperone for the treatment of additional CNS diseases and disorders. At a dose of 42 mg, lumateperone has been shown effective in treating the symptoms associated with schizophrenia, and we believe lumateperone may represent a potential treatment for mood disorders including MDD, post-traumatic stress disorder and intermittent explosive disorder. Patient enrollment in Study 501 and Study 502, our global Phase 3 clinical trials evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD has commenced. We expect to file an sNDA with the FDA for approval of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD in 2024. We have also initiated a Phase 3 study evaluating lumateperone for the prevention of relapse in patients with schizophrenia. The study is being conducted in five phases consisting of a screening phase, a
6-week,
open-label
run-in
phase during which all patients will receive 42 mg of lumateperone per day, a
12-week,
open-label stabilization phase during which all patients will receive 42 mg of lumateperone per day; a double-blind treatment phase 26 weeks in duration during which patients receive either 42 mg of lumateperone per day or placebo (1:1 ratio) and a
2-week
safety
follow-up
phase. This study is being conducted in accordance with our post approval marketing commitment to the FDA in connection with the approval of CAPLTYA for the treatment of schizophrenia as is typical for antipsychotics.
Within the lumateperone portfolio, we are also developing a long-acting injectable formulation to provide more treatment options to patients suffering from mental illness. We have completed the preclinical development of a long-acting injectable formulation and in December 2020 we initiated a Phase 1 single ascending dose study of lumateperone LAI, a formulation of lumateperone designed to be administered subcutaneously and to maintain therapeutic levels of lumateperone for at least one month. This study will evaluate the pharmacokinetics, safety and tolerability of lumateperone LAI in patients with stable symptoms of schizophrenia. We anticipate we will complete this study in the second half of 2021. Results from this study will inform the dosing strategy for future studies. We are evaluating several additional formulations of the lumateperone LAI with treatment durations of one month and longer. Given the encouraging tolerability data to date with oral lumateperone, we believe that a long-acting injectable option, in particular, may lend itself to being an important formulation choice for certain patients.

We are developing
 
ITI-1284-ODT-SL
 
for the treatment of behavioral disturbances in patients with dementia, the treatment of dementia-related psychosis and for the treatment of certain depressive disorders, in the elderly.
 
ITI-1284-ODT-SL
 
is a deuterated form of lumateperone, a new molecular entity formulated as an oral disintegrating tablet for sublingual administration.
 
ITI-1284-ODT-SL
 
is formulated as an oral solid dosage form that dissolves almost instantly when placed under the tongue, allowing for ease of use in the elderly and may be particularly beneficial for patients who have difficulty swallowing conventional tablets. Phase 1 single and multiple ascending dose studies in healthy volunteers and healthy elderly volunteers (> than 65 years of age) evaluated the safety, tolerability and pharmacokinetics of
 
ITI-1284-ODT-SL.
 
In these studies, there were no reported serious adverse events in either age group. In the elderly cohort, reported adverse events were infrequent with the most common adverse event being transient dry mouth (mild). Based on these results, we have initiated our program evaluating
 
ITI-1284-ODT-SL
 
for the treatment of agitation in patients with probable Alzheimer’s disease. Clinical conduct in this program is expected to commence early in 2022. Additional studies in dementia-related psychosis, and certain depressive disorders in the elderly are planned for the first half of 2022.
We have another major program called
ITI-002
that has yielded a portfolio of compounds that selectively inhibit the enzyme phosphodiesterase type 1, or PDE1. PDE1 enzymes are highly active in multiple disease states and our PDE1 inhibitors are designed to reestablish normal function in these disease states. Abnormal PDE1 activity is associated with cellular proliferation and activation of inflammatory cells. Our PDE1 inhibitors ameliorate both of these effects in animal models. We intend to pursue the development of our phosphodiesterase, or PDE, program, for the treatment of aberrant immune system activation in several CNS and
non-CNS
conditions with a focus on diseases where excessive PDE1 activity has been demonstrated and increased inflammation is an important contributor to disease pathogenesis. Our potential disease targets include heart failure, immune system regulation, neurodegenerative diseases, cancers and other
non-CNS
disorders.
ITI-214
is our lead compound in this program. Following the favorable safety and tolerability results in our Phase 1 program, we initiated our development program for
ITI-214
for Parkinson’s disease and commenced patient enrollment in the third quarter of 2017 in a Phase 1/2 clinical trial of
ITI-214
in patients with Parkinson’s disease to evaluate safety and tolerability in this patient population, as well as motor and
non-motor
exploratory endpoints. In the fourth quarter of 2018, we announced that the Phase 1/2 clinical trial of
ITI-214
has been completed and topline results demonstrated
ITI-214
was generally well-tolerated with a favorable safety profile and clinical signs consistent with improvements in motor symptoms and dyskinesias. We have initiated our Phase 2 clinical program with
ITI-214
for Parkinson’s disease and expect to commence patient enrollment in the first half of 2022. In addition, in the second quarter of 2020, we announced topline results from Study
ITI-214-104,
a Phase 1/2 translational study of single ascending doses of
ITI-214
in patients with chronic systolic heart failure with reduced ejection fraction. In this study,
ITI-214
improved cardiac output by increasing heart contractility and decreasing vascular resistance. Agents that both increase heart contractility (inotropism) and decrease vascular resistance (vasodilation) are called inodilators. Inodilators in current clinical use are associated with the development of arrhythmias, which are abnormal heart rhythms that when serious can impair heart function and lead to mortality.
ITI-214,
which acts through a novel mechanism of action, was not associated with arrhythmias in this study and was generally well-tolerated in all patients.
 
24
We also have a development program with our
ITI-333
compound as a potential treatment for substance use disorders, pain and psychiatric comorbidities including depression and anxiety. There is a pressing need to develop new drugs to treat opioid addiction and safe, effective,
non-addictive
treatments to manage pain.
ITI-333
is a novel compound that uniquely combines activity as an antagonist at serotonin
5-HT2A
receptors and a partial agonist at µ-opioid receptors. These combined actions support the potential utility of
ITI-333
in the treatment of opioid use disorder and associated comorbidities (e.g., depression, anxiety, sleep disorders) without opioid-like safety and tolerability concerns. In December 2020, we initiated a Phase 1 single ascending dose study evaluating the safety, tolerability and pharmacokinetics of
ITI-333
in healthy volunteers and we anticipate topline results from this study will be available in the fourth quarter of 2021. We have received a grant from the National Institute on Drug Abuse under the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, that we expect will fund a significant portion of the early stage clinical development costs associated with this program.
We have assembled a management team with significant industry experience to lead the commercialization of our product and the discovery, development and potential commercialization of our product candidates. We complement our management team with a group of scientific and clinical advisors that includes recognized experts in the fields of schizophrenia and other CNS disorders.
COVID-19
In December 2019, a novel strain of
coronavirus, SARS-CoV-2,
which causes coronavirus disease 2019
(“COVID-19”),
surfaced in Wuhan, China. Since then,
SARS-CoV-2
and
COVID-19
have spread to multiple countries, including the United States. The
COVID-19
pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. In response to the spread of
SARS-CoV-2
and
COVID-19,
we have instructed the majority of our office-based employees to work from home. In connection with our commercial launch of CAPLYTA, which is approved by FDA for the treatment of schizophrenia in adults, our commercial organization and sales force and medical organization are having significantly reduced personal interactions with physicians and customers and continue to conduct many promotional activities virtually, and elected to cease
in-person
interactions with physicians and customers entirely for some period of time in the interest of employee and community safety. Even though certain of our sales force and medical organization have begun to have personal interactions with physicians and customers, we may have to cease such personal interactions depending on the
COVID-19
situation. In addition, the
COVID-19
situation has resulted in a decrease in the number of patient visits to healthcare providers. As a result of the
COVID-19
pandemic, or similar pandemics, we may experience disruptions that could severely impact our business, including our ability to successfully commercialize our only commercial product, CAPLYTA, in the United States, and these disruptions could negatively impact our sales of CAPLYTA. Business interruptions from the current or future pandemics may also adversely impact the third parties we rely on to sufficiently manufacture CAPLYTA and to produce our product candidates in quantities we require, which may impair the commercialization and our research and development activities.
We conduct clinical trials for our product candidates in many countries, including the United States, Europe and Russia and may expand to other geographies. Timely enrollment of, completion of and reporting on our clinical trials is dependent upon these global clinical trial sites which are, or in the future may be, adversely affected by
the COVID-19 pandemic
or other pandemics. Some factors from the
COVID-19
pandemic that have or may adversely affect the timing and conduct of our clinical trials and adversely impact our business generally, include but are not limited to delays or difficulties in clinical site initiation, patient enrollment, diversion of healthcare resources away from clinical trials to pandemic concerns, limitations on travel, regulatory delays and supply chain disruptions.
In response to the
COVID-19
pandemic, in March 2020, the FDA announced its intention to temporarily postpone most inspections of foreign manufacturing facilities and products, as well as routine surveillance inspections of domestic manufacturing facilities, and it also provided guidance regarding the conduct of clinical trials, which has been further updated several times since that time. In
mid-2020,
the FDA noted it was continuing to ensure timely reviews of applications for medical products during the
COVID-19
pandemic in line with its user fee performance goals and conducting mission-critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. The FDA subsequently publicized its development and use of an internal rating system called the
COVID-19
Advisory Rating system, to assist in determining when and where it is safest to conduct such inspections based on data about the virus’s trajectory in a given country, state and locality and the rules and guidelines that are put in place by foreign, state and local governments. As of October 2021, FDA is either continuing to, on a
case-by-case
basis, conduct only “mission-critical” inspections, or, where possible to do so safely, resuming prioritized domestic inspections, which generally include
pre-approval
inspections (“PAIs”). Foreign PAIs that are not deemed mission-critical remain postponed, while those deemed mission-critical will be considered for inspection on a
case-by-case
basis. FDA will use similar data to inform resumption of other prioritized operations abroad as it becomes feasible and advisable to do so.
During the global response to the
COVID-19
pandemic, moreover, there have been strategic redeployments of government resources to priority projects, including FDA and EMA resources and staff, which could have an impact on the timeline for review and approval of new marketing applications. Over the course of 2020 and to date in 2021, FDA’s new drug review programs continued to
 
25
meet key performance goals related to working with applicants and approving NDAs and NDA supplements, although the agency has also stated that the uncertainty of the
COVID-19
situation may make it difficult to sustain that level of performance indefinitely. The FDA may not be able to maintain its normal pace with respect to new drug applications and delays or setbacks are possible in the future. The FDA has told industry that it intends to be as transparent as possible about its workload and performance metrics as the situation evolves, and also that it intends to communicate proactively with applicants during the review cycle regarding the need for a
pre-approval
inspection and whether such PAI is considered “mission-critical.”
Should FDA determine that a PAI is necessary for approval of an NDA or NDA supplement and such an inspection cannot be completed during the review cycle due to restrictions on travel or other safety protocols, FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a facility, FDA may defer action on the application until an inspection can be completed. Such decisions will be based on the totality of the information available to the FDA, including considerations of whether it can obtain existing inspection reports from trusted foreign regulatory partners through mutual recognition and confidentiality agreements and/or secure additional records from the applicant, the manufacturing facility, or other inspected entities. Accordingly, FDA has encouraged applicants to effectively communicate with all their facilities and sites to ensure timely responses to any inquiries from FDA for information needed to support its assessment of pending drug applications. FDA has also stated that it is using all available tools and sources of information to support regulatory decisions on NDAs such as the historical compliance status of a manufacturing facility and other risk-benefit considerations pertaining to the proposed new drug product and its manufacturing process and facilities. In addition, whether or not FDA considers a facility inspection to be “mission-critical” involves several factors related to the public health benefits of the proposed new drug product, including but not limited to whether the candidate has been granted breakthrough therapy designation and whether the candidate is intended to treat or prevent a serious disease or medical condition for which there is no other appropriate substitute. Regulatory authorities outside the United States, including but not limited to the EMA, may adopt similar restrictions or other policy measures in response to the
COVID-19
pandemic.
The COVID-19 pandemic
continues to rapidly evolve, and the severity and duration of the pandemic remain uncertain. The extent to which the pandemic impacts our business, including our commercial results, clinical trials, and preclinical studies will depend on future developments, which are highly uncertain.
Results of Operations
The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements.
Revenues
Total revenues for the three and nine months ended September 30, 2021 were approximately $22.2 million and $58.1 million, respectively, as compared to $7.4 million and $10.4 million, respectively, for the three and nine month periods ended September 30, 2020. Net revenues from product sales consist of sales of CAPLYTA, which was approved by the FDA in December 2019. We initiated the commercial launch of CAPLYTA in late March 2020. We generated approximately $21.6 million and $56.2 million, respectively, in net revenue from product sales for the three and nine months ended September 30, 2021 as compared to approximately $7.4 million and $10.1 million, respectively, for the three and nine months ended September 30, 2020. In addition, we had $0.6 million and $1.9 million, respectively, of grant revenues for the three and nine months ended September 30, 2021 as compared to $0 and $232 thousand, respectively, of grant revenue for the three and nine months ended September 30, 2020. We have received and may continue to receive grants from U.S. government agencies and foundations.
The revenues that we may generate in the next several years may not be significant enough to fund our operations.
Expenses
The process of researching, developing and commercializing drugs for human use is lengthy, unpredictable and subject to many risks. We are unable, with certainty, to estimate either the costs or the timelines in which those costs will be incurred. The costs associated with the commercialization of CAPLYTA will be substantial and will be incurred prior to our generating sufficient revenue to offset these costs. Costs for the clinical trials of lumateperone, together with our anticipated clinical development programs for depressive disorders,
ITI-214
and
ITI-1284,
will continue to consume a large portion of our current, as well as projected, resources. We intend to pursue other disease indications that lumateperone may address, but there are significant costs associated with pursuing FDA approval for those indications, which would include the cost of additional clinical trials.
 
26
Our
ITI-002
program has a compound,
ITI-214,
in Phase 1/2 development. We intend to pursue the development of our PDE program, including
ITI-214
for the treatment of several CNS and
non-CNS
conditions, including cardiovascular disease. We have ongoing development programs for
ITI-214
for Parkinson’s disease. We also have a development program with our
ITI-333
compound as a potential treatment for substance use disorders, pain and psychiatric comorbidities including depression and anxiety, and we have initiated a Phase 1 single ascending dose study evaluating the safety, tolerability and pharmacokinetics of
ITI-333
in healthy volunteers. We are also developing
ITI-1284
for the treatment of behavioral disturbances in patients with dementia, the treatment of dementia-related psychosis and for the treatment of certain depressive disorders, in the elderly. Our other projects are still in the preclinical stages, and will require extensive funding not only to complete preclinical testing, but also to commence and complete clinical trials. Expenditures that we incur on these projects will be subject to availability of funding in addition to the funding required for the advancement of lumateperone. Any failure or delay in the advancement of lumateperone could require us to
re-allocate
resources from our other projects to the advancement of lumateperone, which could have a material adverse impact on the advancement of these other projects and on our results of operations.
Our operating expenses are comprised of (i) costs of product sales; (ii) research and development expenses; (iii) selling expenses; and (iv) general and administrative expenses.
Costs of product sales are comprised of:
 
  •  
direct costs of formulating, manufacturing and packaging drug product;
 
  •  
overhead costs consisting of labor, customs, share-based compensation, shipping, outside inventory management and other miscellaneous operating costs; and
 
  •  
royalty payments on product sales.
Research and development costs are comprised of:
 
  •  
internal recurring costs, such as costs relating to labor and fringe benefits, materials, supplies, facilities and maintenance; and
 
  •  
fees paid to external parties who provide us with contract services, such as
pre-clinical
testing, manufacturing and related testing, clinical trial activities and license milestone payments.
Selling expenses are incurred in three major categories:
 
  •  
salaries and related benefit costs of a dedicated sales force;
 
  •  
sales operation costs; and
 
  •  
marketing and promotion expenses.
General and administrative expenses are incurred in three major categories:
 
  •  
salaries and related benefit costs;
 
  •  
patent, legal, and professional costs; and
 
  •  
office and facilities overhead.
Product sold through September 30, 2021 consisted of raw materials that were previously charged to research and development expense prior to FDA approval of CAPLYTA. Because we previously expensed raw materials, the cost of drug product sold was lower than it would have been, which had a positive impact on our cost of product sales and related product gross margins for the three and nine months ended September 30, 2021 and 2020. Our reported cost of product sales as a percentage of product sales, net was 9.3% or approximately $2.0 million and 9.8% or approximately $5.5 million, respectively, for the three and nine months ended September 30, 2021, as compared to 7.5% or approximately $0.6 million and 7.4% or approximately $0.8 million, respectively, for the three and nine months ended September 30, 2020. This increase in the percentages of cost of product sales is due primarily to a higher proportion of previously expensed product costs incurred prior to drug approval associated with product sold in the prior year.
We expect to continue to have this favorable impact on cost of product sales and related product gross margins until our sales of CAPLYTA include drug product that is purchased after the FDA approval. We are currently unable to estimate when all previously expensed inventory costs will be recognized.
We expect that research and development expenses will increase moderately as we proceed with our clinical trials of lumateperone for the treatment of bipolar depression and depressive disorders, other clinical trials, and increased manufacturing of drug product for clinical trials and
pre-clinical
development activities. We also expect that our selling, general and administrative costs will increase moderately over the next several quarters as we expand our marketing and promotional activities including advertising expenses and preparing for potential FDA approval of lumateperone for the treatment of bipolar depression. In September 2018, we amended our corporate headquarters lease to acquire 15,534 square feet of additional office space. We granted options to purchase
 
27
800,200 shares of our common stock in 2020 and granted options to purchase an additional 511,932 shares of our common stock in March 2021. We also granted time based restricted stock units, or RSUs, for 1,007,402 shares of our common stock in 2020 and time based RSUs for 702,830 shares of our common stock in March 2021. We also granted 162,377 options and 6,999 RSUs to board members and new hires in June 2021. We will recognize expense associated with these RSUs and options over three years in research and development expenses, selling, general and administrative expenses, and inventoriable manufacturing expenses.
The following table sets forth our revenues, operating expenses, interest income and income tax expense for the three and nine-month periods ended September 30, 2021 and 2020 (in thousands):
 
    
For the Three Months
Ended September 30,
     
For the Nine Months
Ended September 30,
  
    
2021
     
2020
     
2021
     
2020
  
    
(Unaudited)
     
(Unaudited)
  
Revenues
                                    
Product sales, net
   
$
21,606
 
    $ 7,368     
$
56,192
 
    $ 10,127  
Grant revenue
   
 
601
 
      —       
 
1,940
 
      232  
    
 
 
     
 
 
     
 
 
     
 
 
  
Total revenues, net
   
 
22,207
 
      7,368     
 
58,132
 
      10,359  
Expenses
                                    
Cost of product sales
   
 
2,001
 
      556     
 
5,497
 
      754  
Research and development
   
 
27,032
 
      10,275     
 
59,386
 
      51,484  
Selling, general and administrative
   
 
70,498
 
      52,474     
 
192,933
 
      128,015  
    
 
 
     
 
 
     
 
 
     
 
 
  
Total costs and expenses
   
 
99,531
 
      63,305     
 
257,816
 
      180,253  
    
 
 
     
 
 
     
 
 
     
 
 
  
Loss from operations
   
 
(77,324
) 
      (55,937 )    
 
(199,684
) 
      (169,894 ) 
Interest income
   
 
393
 
      753     
 
1,298
 
      3,591  
Income tax expense (benefit)
   
 
23
 
      —       
 
(6
) 
      (3 ) 
    
 
 
     
 
 
     
 
 
     
 
 
  
Net loss
   
$
(76,908
) 
    $ (55,184 )    
$
(198,392
) 
    $ (166,306 ) 
    
 
 
     
 
 
     
 
 
     
 
 
  
Comparison of Three and Nine-Month Periods Ended September 30, 2021 and September 30, 2020
Total Revenues, Net
Revenues for the three and nine months ended September 30, 2021 were approximately $22.2 million and $58.1 million, respectively, compared to $7.4 million and $10.4 million, respectively for the three and nine months ended September 30, 2020. Net product sales were approximately $21.6 million and $56.2 million, respectively, for the three and nine months ended September 30, 2021 as compared to approximately $7.4 million and $10.1 million, respectively for the three and nine months ended September 30, 2020. Net product sales were comprised of sales of CAPYLTA, which was approved by the FDA on December 20, 2019 and became available to wholesalers in March 2020. The increase in net product sales was due to the initial launch occurring in the three months ended March 30, 2020 and the increase in prescriptions since that period. In addition, revenue from a government grant was approximately $0.6 million and $1.9 million, respectively, for the three and nine months ended September 30, 2021 as compared to $0 and $232 thousand, respectively, for the three and nine months ended September 30, 2020. The increase in grant revenue relates to the increased activity within the applicable studies during the same periods.
Cost of Product Sales
Cost of product sales was approximately $2.0 million and $5.5 million, respectively, for the three and nine months ended September 30, 2021, compared to $0.6 million and $0.8 million, respectively, for the three and nine months ended September 30, 2020. Cost of product sales consisted primarily of product royalty fees, overhead and minimal direct costs. Product sold during the nine months ended September 30, 2020 generally consisted of drug product that was previously produced and charged to research and development expense prior to FDA approval of CAPLYTA. Because the cost of drug product was charged as an expense prior to 2020, this had a positive impact on our cost of product sales and related product gross margins in 2020. In 2021, the product sold during the three and nine months ended September 30, 2021 also consisted of drug product costs and production costs that were incurred and previously charged to research and development expense prior to FDA approval of CAPLYTA. The increase in the cost of product sales in the three and nine months ended September 30, 2021 compared to the three and nine months ended September 30, 2020 is due primarily to the increase in the volume of product sales.
 
28
We will continue to have a cost of product sales that excludes the cost of the drug product that was incurred prior to FDA approval until our sales of CAPLYTA include drug product that is fully manufactured after the FDA approval. We are currently unable to estimate when all previously expensed inventory costs will be recognized.
Research and Development Expenses
The following tables set forth our research and development expenses for the three and nine-month periods ended September 30, 2021 and 2020 (in thousands):
 
    
Three Months Ended September 30,
     
Nine Months Ended September 30,
  
    
2021
      2020     
2021
      2020  
External costs
   
 
17,679
 
      2,815     
 
33,554
 
      29,897  
Internal costs
   
 
9,353
 
      7,460     
 
25,832
 
      21,587  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total research and development expenses
   
$
27,032
 
    $ 10,275     
$
59,386
 
    $ 51,484  
  
 
 
     
 
 
     
 
 
     
 
 
  
Lumateperone costs
   
 
14,750
 
      4,360     
 
32,032
 
      30,402  
Manufacturing costs
   
 
1,926
 
      160     
 
3,891
 
      3,455  
Stock based compensation
   
 
3,183
 
      2,748     
 
8,367
 
      7,789  
Other projects and overhead
   
 
7,173
 
      3,007     
 
15,096
 
      9,838  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total research and development expenses
   
$
27,032
 
    $ 10,275     
$
59,386
 
    $ 51,484  
  
 
 
     
 
 
     
 
 
     
 
 
  
Research and development expenses increased to $27.0 million for the three-month period ended September 30, 2021 as compared to $10.3 million for the three-month period ended September 30, 2020, representing an increase of approximately 163%. This increase is due primarily to an increase of approximately $8.7 million for lumateperone clinical trial costs, and an increase of $4.2 million for other projects and overhead, including the
ITI-1284,
ITI-214,
and
ITI-333
programs, among others. In addition, the remaining increase is attributable to an increase in lumateperone
non-clinical
trial and manufacturing costs. Internal costs increased by approximately $1.9 million for the period due primarily to labor related costs.
Research and development expenses increased to $59.4 million for the nine-month period ended September 30, 2021 as compared to $51.5 million for the nine-month period ended September 30, 2020, representing an increase of approximately 15%. This increase is due primarily to an increase of approximately $5.3 million for other projects and overhead, including the
ITI-1284,
ITI-214,
and
ITI-333
programs, among others, and $1.6 million for lumateperone clinical trial and other costs. Internal costs increased by approximately $4.2 million for the period due primarily to labor related costs.
As the development of lumateperone progresses, we anticipate research and development costs for lumateperone programs to increase moderately due primarily to conducting ongoing and planned Phase 3 and other clinical trials relating to our lumateperone programs in the next several years. We are also required to complete
non-clinical
testing to obtain FDA approval and manufacture material needed for clinical trial use, which includes
non-clinical
testing of the drug product and drug product in anticipation of possible additional FDA approvals of lumateperone for indications beyond schizophrenia.
We currently have several projects, in addition to lumateperone, that are in the research and development stages. We have used internal resources and incurred expenses not only in relation to the development of lumateperone, but also in connection with these additional projects as well, including our PDE program. We have not, however, reported these costs on a
project-by-project
basis, as these costs are broadly spread among these projects. The external costs for these projects have been modest and are reflected in the table above in this section “—
Research and Development Expenses
.”
The research and development process necessary to develop a pharmaceutical product for commercialization is subject to extensive regulation by numerous governmental authorities in the United States and other countries. This process typically takes years to complete and requires the expenditure of substantial resources. The steps required before a drug may be marketed in the United States generally include the following:
 
  •  
completion of extensive
pre-clinical
laboratory tests, animal studies, and formulation studies in accordance with the FDA’s Good Laboratory Practice, or GLP, regulations;
 
  •  
submission to the FDA of an Investigational New Drug application, or IND, for human clinical testing, which must become effective before human clinical trials may begin;
 
  •  
performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug for each proposed indication;
 
29
  •  
submission to the FDA of a New Drug Application, or NDA, after completion of all clinical trials;
 
  •  
satisfactory completion of an FDA
pre-approval
inspection of the manufacturing facility or facilities at which the active pharmaceutical ingredient, or API, and finished drug product are produced and tested to assess compliance with current Good Manufacturing Practices, or cGMPs;
 
  •  
satisfactory completion of FDA inspections of clinical trial sites to assure that data supporting the safety and effectiveness of product candidates has been generated in compliance with Good Clinical Practices; and
 
  •  
FDA review and approval of the NDA prior to any commercial marketing or sale of the drug in the United States.
The successful development of our product candidates and the approval process requires substantial time, effort and financial resources, and is uncertain and subject to a number of risks. We cannot be certain that any of our product candidates will prove to be safe and effective, will meet all of the applicable regulatory requirements needed to receive and maintain marketing approval, or will be granted marketing approval on a timely basis, if at all. Data from
pre-clinical
studies and clinical trials are susceptible to varying interpretations that could delay, limit or prevent regulatory approval or could result in label warnings related to or recalls of approved products. We, the FDA, or other regulatory authorities may suspend clinical trials at any time if we or they believe that the subjects participating in such trials are being exposed to unacceptable risks or if such regulatory agencies find deficiencies in the conduct of the trials or other problems with our product candidates. Other risks associated with our product candidates are described in the section entitled “Risk Factors” in our Annual Report on Form
10-K
for the year ended December 31, 2020, as updated by the section entitled “Risk Factors” in this Quarterly Report on Form
10-Q
and from time to time in our other periodic and current reports filed with the SEC.
Selling, General and Administrative Expenses
Selling, general and administrative costs for the three-month period ended September 30, 2021 were $70.5 million as compared to $52.5 million in the three-month period ended September 30, 2020, which represents an increase of 34%, which was due to an increase in selling costs and an increase in general and administrative expenses as discussed below.
Selling costs were $52.6 million for the three-month period ended September 30, 2021 as compared to selling costs of $38.3 million in the same period in 2020, which represents an increase of 37%. This increase is primarily due to increases in commercialization, marketing and advertising expenses totaling $12.5 million, approximately $941 thousand in travel and other costs, and sales related labor costs of approximately $694 thousand. Salaries, bonuses and related benefit costs for our sales and marketing functions for the three months ended September 30, 2021 and 2020 constituted approximately 32% and 43%, respectively, of our selling costs.
General and administrative expenses were $17.9 million in the three-month period ended September 30, 2021 as compared to $14.2 million for the same period in 2020, an increase of 27%. This increase is due to increases in stock-based compensation of $2.2 million, labor related costs of approximately $659 thousand, patent related expenses of approximately $353 thousand, and the remainder for insurance, professional fees, and other expenses. Salaries, bonuses and related benefit costs for our general and administrative functions for the three months ended September 30, 2021 and 2020 constituted approximately 57% and 53%, respectively of our general and administrative costs.
Selling, general and administrative costs for the nine-month period ended September 30, 2021 were $192.9 million as compared to $128.0 million in the nine-month period ended September 30, 2020, which represents an increase of 51%, which was due to an increase in selling, marketing, and advertising expenses and an increase in general and administrative expenses as discussed below.
Selling costs were $143.0 million for the nine-month period ended September 30, 2021 as compared to $87.5 million in the same period in 2020, or an increase of 63%. This increase is primarily due to an increase in commercialization costs of $45.5 million, sales related labor costs of approximately $7.0 million and approximately $2.8 million in travel and other sales related expenses. Salaries, bonuses and related benefit costs for our sales and marketing functions for the nine months ended September 30, 2021 and 2020 constituted approximately 35% and 50%, respectively, of our selling costs.
General and administrative expenses for the nine months ended September 30, 2021 were $50.0 million as compared to $40.5 million for the same period in 2020, an increase of 23%. This increase is due to increases in stock compensation expense of $5.0 million, labor and bonus expense of $2.1 million, professional fees of $1.4 million, and the remainder for insurance, lease expense, and other administrative expenses. Salaries, bonuses and related benefit costs for our general and administrative functions for the nine months ended September 30, 2021 and 2020 constituted approximately 56% and 52%, respectively of our general and administrative costs.
 
30
We expect selling, general and administrative costs to increase moderately over the next several quarters as we increase advertising costs, expand other marketing efforts, and prepare for the potential commercial launch of CAPLYTA for the treatment bipolar depression.
Liquidity and Capital Resources
Through September 30, 2021, we provided funds for our operations by obtaining a total of approximately $1.6 billion of cash primarily through public and private offerings of our common stock and other securities in prior periods, grants from government agencies and foundations and payments received under a terminated license and collaboration agreement. Through September 30, 2021, we have collected approximately $77.0 million from product sales, which we believe will increase going forward. We do not believe that grant revenue will be a significant source of funding in the future.
On January 10, 2020, we completed a public offering of 10,000,000 shares of our common stock. All of the shares in the offering were sold by the Company, with gross proceeds to the Company of $295.0 million and net proceeds of approximately $277.0 million, after deducting underwriting discounts, commissions and offering expenses.
In June 2020, we sold 230,000 shares of common stock under our
at-the-market
equity program generating $5.6 million in net proceeds, which was received in July 2020. In the third quarter of 2020, we sold an additional 512,791 shares of common stock utilizing our
at-the-market
program and received $12.3 million of net proceeds.
In September 2020 we completed a public offering of common stock in which we sold 12,666,667 shares of common stock at a public offering price of $30.00 per share for aggregate gross proceeds of $380.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $357.8 million.
As of September 30, 2021, we had a total of approximately $478.7 million in cash and cash equivalents,
available-for-sale
investment securities and restricted cash, and approximately $49.9 million of short-term liabilities consisting entirely of liabilities from operations, including approximately $6.1 million of short-term lease obligations. In the nine months ended September 30, 2021, we spent approximately $248.1 million in cash for operations and equipment. During this period, we collected $60.1 million of product sales and $1.3 million of interest income, resulting in net cash used of $186.7 million. The use of cash was primarily for selling and marketing costs in connection with our commercialization of CAPLYTA, conducting clinical trials and
non-clinical
testing, product manufacturing, and funding recurring operating expenses.
Based on our current operating plans, we expect that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the filing date of this quarterly report. During that time, we expect that our expenses will increase substantially due primarily to our commercialization activities and related infrastructure expansion in connection with the commercialization of CAPLYTA for the treatment of schizophrenia and in preparation for the potential approval of CAPLYTA for the treatment of bipolar depression; the development of lumateperone in our late-stage clinical programs; the development of our other product candidates, including
ITI-214;
the continuation of manufacturing activities for anticipated future sales of product and in connection with the development of lumateperone; and general operations.
In the fourth quarter of 2021, we expect to spend up to $100 million primarily related to the marketing and commercialization of CAPLYTA, increasing inventory and sample levels of CAPLYTA, advancing lumateperone related programs including clinical trial conduct, regulatory activities, manufacturing, expansion of our administrative infrastructure and other development activities. Our other development activities will include efforts related to our
ITI-1284,
ITI-214,
and
ITI-333
programs, among others. However, the
COVID-19
pandemic may negatively impact our commercialization of CAPLYTA, our ability to complete our ongoing or planned preclinical and clinical trials, our ability to obtain approval of any product candidates from the FDA or other regulatory authorities, and our workforce and therefore our research, development, and commercialization activities. This may ultimately have a material adverse effect on our liquidity, although we are unable to make any prediction with certainty given the rapidly changing nature of the pandemic and governmental and other responses to it.
Subject to the levels of product sales we achieve, we may require significant additional financing in the future to continue to fund our operations. We believe that we have the funding in place to commercialize CAPLYTA in patients with schizophrenia and prepare for the potential approval and initial launch of CAPLYTA for the treatment of bipolar depression. We also plan to fund additional clinical trials of lumateperone for the treatment of depressive disorders and other CNS disorders; clinical development of our
ITI-007
long acting injectable; additional clinical trials of lumateperone and
ITI-1284;
continued advancement of our PDE program, including
ITI-214;
research and preclinical development of our other product candidates; and the continuation of manufacturing activities in connection with the development of lumateperone. We anticipate requiring additional funds for further development of lumateperone in patients with depressive disorders and other indications, and for development of our other product
 
31
candidates. We have incurred losses in every year since inception with the exception of 2011, when we received an
up-front
fee and a milestone payment related to a license agreement that has been terminated. These losses have resulted in significant cash used in operations. While we have several research and development programs in progress, the lumateperone program has advanced the furthest and will continue to consume increasing amounts of cash for conducting clinical trials and the testing and manufacturing of product material. As we continue to conduct the activities necessary to pursue FDA approval of lumateperone for additional indications and our other product candidates, as well as commercialization efforts, we expect the amount of cash to be used to fund operations to increase considerably over the next several years.
We seek to balance the level of cash, cash equivalents and investments on hand with our projected needs and to allow us to withstand periods of uncertainty relative to the availability of funding on favorable terms. Until we can generate significant revenues from operations, we will need to satisfy our future cash needs through public or private sales of our equity securities, sales of debt securities, incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of our product candidates and technology and, to a lesser extent, grant funding. On August 30, 2019, we filed a universal shelf registration statement on Form
S-3,
which was declared effective by the SEC on September 12, 2019, on which we registered for sale up to $350 million of any combination of our common stock, preferred stock, debt securities, warrants, rights and/or units from time to time and at prices and on terms that we may determine, which included up to $75 million of common stock that we could issue and sell from time to time, through SVB Leerink LLC acting as our sales agent, pursuant to the sale agreement that we entered into with SVB Leerink on August 29, 2019 for our
“at-the-market”
equity program. In the quarter ended June 30, 2020, we sold 230,000 shares of common stock under our
“at-the-market”
equity program which resulted in our receiving net proceeds of $5.6 million in July 2020. In the quarter ended September 30, 2020, we issued an additional 512,791 shares of common stock under our
“at-the-market”
equity program and received approximately $12.3 million of net proceeds. On September 10, 2020, we terminated the
“at-the-market”
equity program agreement with SVB Leerink LLC.
In addition, on January 6, 2020, we filed an automatic shelf registration statement on Form
S-3
with the SEC, which became effective upon filing, on which we registered for sale an unlimited amount of any combination of its common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that we may determine, so long as we continue to satisfy the requirements of a “well-known seasoned issuer” under SEC rules. These registration statements will remain in effect for up to three years from the respective dates they became effective.
We cannot be sure that future funding will be available to us when we need it on terms that are acceptable to us, or at all. We sell securities and incur debt when the terms of such transactions are deemed favorable to us and as necessary to fund our current and projected cash needs. The amount of funding we raise through sales of our common stock or other securities depends on many factors, including, but not limited to, the magnitude of sales of CAPLYTA, the status and progress of our product development programs, projected cash needs, availability of funding from other sources, our stock price and the status of the capital markets. Due to the volatile nature of the financial markets, equity and debt financing may be difficult to obtain. Additionally, the continued spread of
COVID-19
and uncertain market conditions may limit our ability to access any financing. In addition, any unfavorable results in the commercialization of CAPLYTA and unfavorable development or delay in the progress of our lumateperone program could have a material adverse impact on our ability to raise additional capital.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.
If adequate funds are not available to us on a timely basis, we may be required to: (1) delay, limit, reduce or terminate
pre-clinical
studies, clinical trials or other clinical development activities for one or more of our product candidates, including our lead product candidate lumateperone,
ITI-214,
and our other product candidates; (2) delay, limit, reduce or terminate our discovery research or
pre-clinical
development activities; or (3) enter into licenses or other arrangements with third parties on terms that may be unfavorable to us or sell, license or relinquish rights to develop or commercialize our product candidates, technologies or intellectual property at an earlier stage of development and on less favorable terms than we would otherwise agree.
Our cash is maintained in checking accounts, money market accounts, money market mutual funds, U.S. government agency securities, certificates of deposit, commercial paper, corporate notes and corporate bonds at major financial institutions. Due to the current low interest rates available for these instruments, we are earning limited interest income. We do not expect interest income to be a significant source of funding over the next several quarters. Our investment portfolio has historically not been adversely impacted by problems in the credit markets, but there can be no assurance that our investment portfolio will not be adversely affected in the future.
 
32
In 2014, we entered into a long-term lease with a related party which, as amended, provided for a lease of 16,753 square feet of useable laboratory and office space located at 430 East 29th Street, New York, New York 10016. Concurrent with this lease, we entered into a license agreement to occupy certain vivarium related space in the same facility for the same term, rent and escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASU
2016-02
for accounting purposes. In September 2018, we further amended the lease to obtain an additional 15,534 square feet of office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In February 2019, we entered into a long-term lease for 3,164 square feet of office space in Towson, Maryland beginning March 1, 2019. The lease has a term of 3.2 years ending in April 2022. On May 17, 2019, we entered into a vehicle fleet lease with a company to acquire motor vehicles for certain employees. The vehicle fleet lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. We began leasing vehicles under the vehicle fleet lease in March 2020.
Critical Accounting Policies and Estimates
Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our condensed consolidated financial statements. We evaluate our estimates, judgments, and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form
10-K
for the year ended December 31, 2020 and Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form
10-Q.
There have been no material changes to our critical accounting policies during the nine months ended September 30, 2021.
The discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect reported amounts of assets and liabilities as of the date of the balance sheet and reported amounts of revenues and expenses for the periods presented. Judgments must also be made about the disclosure of contingent liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management makes estimates and exercises judgment in research and development, including clinical trial accruals. Actual results may differ from those estimates and under different assumptions or conditions.
Recently Issued Accounting Pronouncements
We review new accounting standards to determine the expected financial impact, if any, that the adoption of each such standard will have. For the recently issued accounting standards that we believe may have an impact on our financial statements, see “Recently Issued Accounting Standards” in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form
10-Q,
and “Recently Issued Accounting Standards” in Note 2 to our audited consolidated financial statements and “Recently Issued Accounting Pronouncements” in Part II, Item 7, in our Annual Report on
Form 10-K
for the year ended December 31, 2020 filed on February 25, 2021.
Certain Factors That May Affect Future Results of Operations
The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Quarterly Report on
Form 10-Q
contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other important factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: the accuracy of our estimates regarding expenses, revenues, uses of cash, cash equivalents and investment securities, capital requirements and the need for additional financing; our expectations regarding our commercialization of CAPLYTA, including the impact of
COVID-19
on the commercialization of CAPLYTA and our ability to adapt our approach as appropriate; the duration and severity of the
COVID-19
pandemic and its impact on our business; the supply and availability of and demand for our product; the initiation, cost, timing, progress and results of our development activities,
non-clinical
studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approval, or submit an application for regulatory approval, of lumateperone and our other existing product candidates, any product candidates that we may develop, and any related restrictions, limitations, and/or warnings in the label of any approved product candidates; our plans to research, develop and commercialize lumateperone and our other current and future product candidates; the election by any
 
33
collaborator to pursue research, development and commercialization activities; our ability to obtain future reimbursement and/or milestone payments from our collaborators; our ability to attract collaborators with development, regulatory and commercialization expertise; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to successfully commercialize lumateperone and our other product candidates; the performance of our third-party suppliers and manufacturers and our ability to obtain alternative sources of raw materials; our ability to obtain additional financing; our use of the proceeds from our securities offerings; our exposure to investment risk, interest rate risk and capital market risk; and our ability to attract and retain key scientific, management, or sales and marketing personnel.
Words such as “may,” “anticipate,” “estimate,” “expect,” “may,” “project,” “intend,” “plan,” “believe,” “potential,” “predict,” “project,” “likely,” “will,” “would,” “could,” “should,” “continue” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: whether the preclinical and clinical results of the lumateperone studies will meet the regulatory requirements for approval by the FDA for the proposed indications; whether the sNDAs for lumateperone will be approved by the FDA and whether the FDA will complete its review within its target timelines, including its target action date; whether the FDA will require additional information, whether we will be able to provide in a timely manner any additional information that the FDA requests, and whether such additional information will be satisfactory to the FDA; there are no guarantees that CAPLYTA will be commercially successful; we may encounter issues, delays or other challenges in commercializing CAPLYTA; the
COVID-19
pandemic may negatively impact our commercial plans and sales for CAPLYTA; the
COVID-19
pandemic may negatively impact the conduct of, and the timing of enrollment, completion and reporting with respect to, our clinical trials; whether CAPLYTA receives adequate reimbursement from third-party payors; the degree to which CAPLYTA receives acceptance from patients and physicians for its approved indication; challenges associated with execution of our sales activities, which in each case could limit the potential of our product; results achieved in CAPLYTA in the treatment of schizophrenia following commercialization may be different than observed in clinical trials, and may vary among patients; any other impacts on our business as a result of or related to the
COVID-19
pandemic; risks associated with our current and planned clinical trials; we may encounter unexpected safety or tolerability issues with CAPLYTA for the treatment of schizophrenia or in ongoing or future trials and other development activities; our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials or in clinical trials for other indications; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the FDA; our reliance on collaborative partners and other third parties for development, commercialization, manufacturing or supply of our product and product candidates; and the other risk factors detailed under the heading “Risk Factors” in our most recent Annual Report on Form
10-K,
as updated under the heading “Risk Factors” from time to time in our subsequent periodic and current reports filed with the SEC.
In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report on Form
10-Q
or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form
10-Q.
We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to the Company or to any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.
 
Item 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Sensitivity.
As of September 30, 2021, we had cash, cash equivalents, marketable securities, and restricted cash of approximately $478.7 million consisting of cash deposited in a highly rated financial institution in the United States, in a short-term U.S. Treasury money market fund, and in high-grade corporate bonds and commercial paper. The primary objective of our investment activities is to preserve our capital for the purpose of funding operations. We do not enter into investments for trading or speculative purposes. We believe that we do not have material exposure to high-risk investments such as mortgage-backed securities, auction rate securities or other special investment vehicles within our money-market fund investments. We believe that we do not have any material exposure to changes in fair value as a result of the recent changes in interest rates or through potential changes in the credit worthiness of the issuers of our
available-for-sale
securities. We recognized an unrealized gain of approximately $0.3 million for the nine months ended September 30, 2021, compared to an unrealized gain of approximately $0.4 million for the year
ended of December 31, 2020. We have the ability and plan to hold these investments to maturity. Declines in interest rates, however, would reduce future investment income.
 
34
Capital Market Risk.
We currently have limited product revenues and depend on funds raised through other sources. One possible source of funding is through further equity offerings. Our ability to raise funds in this manner depends upon capital market forces affecting our stock price.
 
Item 4.
CONTROLS AND PROCEDURES
(a)
 Evaluation of Disclosure Controls and Procedures
. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in
Rules 13a-15(e)
and
15d-15(e)
under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this
Form 10-Q,
have concluded that, based on such evaluation, our disclosure controls and procedures were effective at a reasonable assurance level to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
(b)
 Changes in Internal Controls
. There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control that occurred during the three months ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II: OTHER INFORMATION
 
Item 1.
LEGAL PROCEEDINGS
We are not currently a party to any material legal proceedings.
 
Item 1A.
RISK FACTORS
There have been no material changes to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form
10-K
for the year ended December 31, 2020, filed with the Securities and Exchange Commission on February 25, 2021.
 
Item 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Unregistered Sales of Equity Securities
Not applicable.
Issuer Purchases of Equity Securities
We did not repurchase any of our equity securities during the quarter ended September 30, 2021.
 
Item 3.
DEFAULTS UPON SENIOR SECURITIES
Not applicable.
 
Item 4.
MINE SAFETY DISCLOSURES
Not applicable.
 
Item 5.
OTHER INFORMATION
Not applicable.
 
35
Item 6.
EXHIBITS
 
Exhibit

Number
   
Exhibit Description
   
Filed

Herewith
   
Incorporated by
Reference herein
from Form
or Schedule
   
Filing Date
   
SEC File/
Reg. Number
  31.1    Certification of the Registrant’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.    X         
  31.2    Certification of the Registrant’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.    X         
  32    Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.    X         
  101    The following materials from the Registrant’s Quarterly Report on
Form 10-Q
for the quarter ended September 30, 2021, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020 (audited), (ii) Condensed Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2021 and 2020, (iii) Condensed Consolidated Statements of Comprehensive Loss (unaudited) for the three and nine months ended September 30, 2021 and 2020, (iv) Condensed Consolidated Statements of Stockholders’ Equity (unaudited) for the three and nine months ended September 30, 2021 and 2020, (v) Condensed Consolidated Statements of Cash Flows (unaudited) for the three and nine months ended September 30, 2021 and 2020, and (vi) Notes to Condensed Consolidated Financial Statements (unaudited).		    X         
  104    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).    X         
 
36
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
   
INTRA-CELLULAR THERAPIES, INC.
Date: November 9, 2021
    
By:
  
/s/ Sharon Mates, Ph.D.
     
Sharon Mates, Ph.D.
     
Chairman, President and Chief Executive Officer
Date: November 9, 2021
    
By:
  
/s/ Lawrence J. Hineline
     
Lawrence J. Hineline
     
Senior Vice President of Finance and Chief Financial Officer
 
 
37
EX-31.1 2 d132524dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATIONS UNDER SECTION 302

I, Sharon Mates, Ph.D., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Intra-Cellular Therapies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 9, 2021
/s/ Sharon Mates, Ph.D.
Sharon Mates, Ph.D.
Chairman, President and Chief Executive Officer
(principal executive officer)

 

 EX-31.2 3 d132524dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATIONS UNDER SECTION 302

I, Lawrence J. Hineline, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Intra-Cellular Therapies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 9, 2021

/s/ Lawrence J. Hineline

Lawrence J. Hineline

Senior Vice President of Finance and Chief Financial Officer

(principal financial officer)

 EX-32 4 d132524dex32.htm EX-32 EX-32

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Intra-Cellular Therapies, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the quarter ended September 30, 2021 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: November 9, 2021

      

/s/ Sharon Mates, Ph.D.

     

Sharon Mates, Ph.D.

     

Chairman, President and Chief Executive Officer

     

(principal executive officer)

 

Dated: November 9, 2021

      

/s/ Lawrence J. Hineline

     

Lawrence J. Hineline

     

Senior Vice President of Finance and Chief Financial Officer

     

(principal financial officer)

EX-101.SCH 5 itci-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 1008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Organization link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Inventory link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Right of Use Assets and Lease Liabilities link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Share-Based Compensation link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Inventory (Tables) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Right of Use Assets and Lease Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Organization - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Summary of Significant Accounting Policies - Schedule of Investment Securities (Detail) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Property and Equipment - Property and Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Property and Equipment - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 itci-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 itci-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 itci-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 9 itci-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 d132524d10q_htm.xml IDEA: XBRL DOCUMENT 0001567514 2021-01-01 2021-09-30 0001567514 2021-07-01 2021-09-30 0001567514 2020-07-01 2020-09-30 0001567514 2020-01-01 2020-09-30 0001567514 2020-12-31 0001567514 2021-09-30 0001567514 2020-01-10 2020-01-10 0001567514 2020-09-15 2020-09-15 0001567514 2020-01-10 0001567514 2020-09-15 0001567514 2020-01-01 2020-12-31 0001567514 2019-01-01 2019-12-31 0001567514 2021-11-05 0001567514 2020-09-30 0001567514 2020-06-30 0001567514 2019-12-31 0001567514 2021-06-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-09-30 0001567514 us-gaap:CertificatesOfDepositMember 2021-09-30 0001567514 us-gaap:CommercialPaperMember 2021-09-30 0001567514 us-gaap:CorporateDebtSecuritiesMember 2021-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2021-09-30 0001567514 itci:InducementAwardPlanMember 2021-09-30 0001567514 us-gaap:ComputerEquipmentMember 2021-09-30 0001567514 us-gaap:FurnitureAndFixturesMember 2021-09-30 0001567514 us-gaap:EquipmentMember 2021-09-30 0001567514 us-gaap:LeaseholdImprovementsMember 2021-09-30 0001567514 itci:ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember 2021-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2021-09-30 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2021-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2021-09-30 0001567514 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001567514 itci:RealEstatesLeaseMember 2021-09-30 0001567514 itci:VehicleFleetLeaseMember 2021-09-30 0001567514 us-gaap:FinancialStandbyLetterOfCreditMember itci:VehicleFleetLeaseMember 2021-09-30 0001567514 us-gaap:AccruedLiabilitiesMember 2021-09-30 0001567514 itci:MedicaidRebatesMember 2021-09-30 0001567514 itci:OtherRevenueRelatedAccrualsMember 2021-09-30 0001567514 us-gaap:PurchaseCommitmentMember 2021-09-30 0001567514 us-gaap:PurchaseCommitmentMember itci:SiegfriedCampaignMember 2021-09-30 0001567514 us-gaap:PurchaseCommitmentMember itci:LonzaCampaignMember 2021-09-30 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2020-12-31 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001567514 us-gaap:CertificatesOfDepositMember 2020-12-31 0001567514 us-gaap:CommercialPaperMember 2020-12-31 0001567514 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001567514 us-gaap:ComputerEquipmentMember 2020-12-31 0001567514 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001567514 us-gaap:EquipmentMember 2020-12-31 0001567514 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001567514 itci:ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember 2020-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001567514 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001567514 itci:VehicleFleetLeaseMember 2020-12-31 0001567514 us-gaap:AccruedLiabilitiesMember 2020-12-31 0001567514 itci:MedicaidRebatesMember 2020-12-31 0001567514 itci:OtherRevenueRelatedAccrualsMember 2020-12-31 0001567514 us-gaap:CommonStockMember 2020-12-31 0001567514 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001567514 itci:InventoriableCostsMember 2020-01-01 2020-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0001567514 us-gaap:CommonStockMember itci:JanuaryTwoThousandAndTwentyInitialPublicOfferingMember 2020-01-01 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember itci:JanuaryTwoThousandAndTwentyInitialPublicOfferingMember 2020-01-01 2020-09-30 0001567514 itci:JanuaryTwoThousandAndTwentyInitialPublicOfferingMember 2020-01-01 2020-09-30 0001567514 us-gaap:ProductMember 2020-01-01 2020-09-30 0001567514 us-gaap:GrantMember 2020-01-01 2020-09-30 0001567514 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001567514 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001567514 itci:VehicleFleetLeaseMember 2020-01-01 2020-09-30 0001567514 srt:MaximumMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001567514 itci:CaplytaMember 2020-01-01 2020-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2020-01-01 2020-09-30 0001567514 itci:InventoriableCostsMember 2020-07-01 2020-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0001567514 us-gaap:CommonStockMember itci:JanuaryTwoThousandAndTwentyInitialPublicOfferingMember 2020-07-01 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember itci:JanuaryTwoThousandAndTwentyInitialPublicOfferingMember 2020-07-01 2020-09-30 0001567514 itci:JanuaryTwoThousandAndTwentyInitialPublicOfferingMember 2020-07-01 2020-09-30 0001567514 us-gaap:ProductMember 2020-07-01 2020-09-30 0001567514 us-gaap:GrantMember 2020-07-01 2020-09-30 0001567514 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001567514 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001567514 itci:CaplytaMember 2020-07-01 2020-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2020-07-01 2020-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2021-01-01 2021-09-30 0001567514 itci:InventoriableCostsMember 2021-01-01 2021-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2021-01-01 2021-09-30 0001567514 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001567514 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2021-01-01 2021-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001567514 itci:InducementAwardPlanMember 2021-01-01 2021-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember srt:MinimumMember 2021-01-01 2021-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember srt:MaximumMember 2021-01-01 2021-09-30 0001567514 us-gaap:ProductMember 2021-01-01 2021-09-30 0001567514 us-gaap:GrantMember 2021-01-01 2021-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2021-01-01 2021-09-30 0001567514 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001567514 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001567514 srt:MaximumMember 2021-01-01 2021-09-30 0001567514 srt:MinimumMember 2021-01-01 2021-09-30 0001567514 itci:VehicleFleetLeaseMember 2021-01-01 2021-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0001567514 itci:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001567514 itci:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001567514 itci:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001567514 srt:MaximumMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2021-01-01 2021-09-30 0001567514 itci:CaplytaMember 2021-01-01 2021-09-30 0001567514 itci:InventoriableCostsMember 2021-07-01 2021-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0001567514 us-gaap:ProductMember 2021-07-01 2021-09-30 0001567514 us-gaap:GrantMember 2021-07-01 2021-09-30 0001567514 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0001567514 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001567514 itci:CaplytaMember 2021-07-01 2021-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2021-07-01 2021-09-30 0001567514 itci:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-03-31 0001567514 us-gaap:IPOMember 2020-01-10 2020-01-10 0001567514 us-gaap:IPOMember 2020-09-15 2020-09-15 0001567514 srt:MaximumMember 2019-09-12 0001567514 srt:MaximumMember us-gaap:CommonStockMember 2019-09-12 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember itci:ITCINationalDemocraticAllianceMemberMember 2020-01-01 2020-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001567514 itci:InducementAwardPlanMember 2020-01-01 2020-12-31 0001567514 itci:AmtTaxCreditMember 2020-03-27 0001567514 itci:PerformanceBasedRestrictedStockUnitsMember 2021-01-01 2021-03-31 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2018-06-30 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2020-05-31 0001567514 itci:InducementAwardPlanMember 2019-12-31 0001567514 srt:MaximumMember itci:InducementAwardPlanMember 2019-12-31 0001567514 stpr:NY 2018-09-30 0001567514 stpr:MD 2019-02-28 0001567514 stpr:NY us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001567514 stpr:MD us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001567514 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2005-05-31 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2013-12-01 2013-12-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2014-12-01 2014-12-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2019-01-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember itci:NationalDemocraticAllianceMember 2019-12-23 2019-12-23 0001567514 srt:MaximumMember 2019-09-12 2019-09-12 0001567514 us-gaap:CommonStockMember 2019-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001567514 us-gaap:RetainedEarningsMember 2019-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001567514 us-gaap:CommonStockMember 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001567514 us-gaap:RetainedEarningsMember 2020-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001567514 us-gaap:CommonStockMember 2020-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001567514 us-gaap:RetainedEarningsMember 2020-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2020-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001567514 us-gaap:RetainedEarningsMember 2020-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2021-09-30 0001567514 us-gaap:CommonStockMember 2021-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001567514 us-gaap:RetainedEarningsMember 2021-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001567514 itci:InducementAwardPlanMember 2020-12-31 0001567514 us-gaap:CommonStockMember 2021-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001567514 us-gaap:RetainedEarningsMember 2021-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 iso4217:USD shares pure utr:Month utr:Year itci:Segment iso4217:USD shares false Q3 P1Y P3M 0001567514 --12-31 Intra-Cellular Therapies, Inc. 10-Q true 2021-09-30 2021 false 001-36274 DE 36-4742850 430 East 29th Street New York NY 10016 646 440-9333 Common Stock ITCI NASDAQ Yes Yes Large Accelerated Filer false false false 81463253 106125959 60045933 371157974 597402126 1400000 1400000 16934352 10764583 8166935 7056385 29457445 14235455 533242665 690904482 1936308 1998346 21710677 24324762 86084 86084 556975734 717313674 12030614 5501825 16928669 10902117 6082054 5541802 14854226 14907479 49895563 36853223 20323918 23600347 70219481 60453570 0.0001 0.0001 175000000 100000000 81377406 81377406 80463089 80463089 8138 8046 1622149674 1593475506 -1135495761 -937104032 94202 480584 486756253 656860104 556975734 717313674 21606163 7368594 56191848 10126999 601038 0 1940243 231710 22207201 7368594 58132091 10358709 2001315 556107 5496561 753957 27031825 10275368 59386413 51483551 70497885 52473573 192932688 128015496 99531025 63305048 257815662 180253004 -77323824 -55936454 -199683571 -169894295 392695 752829 1297473 3591091 -76931129 -55183625 -198386098 -166303204 -23125 0 5631 3281 -76908004 -55183625 -198391729 -166306485 -0.95 -0.79 -2.44 -2.48 81354724 69530039 81178482 67030991 -76908004 -55183625 -198391729 -166306485 -81916 -399361 -386382 640421 -76989920 -55582986 -198778111 -165666064 66777737 6678 1199576320 -821221229 1168099 379529868 13179458 1318 370137298 370138616 5705186 5705186 183516 18 2650587 2650605 2086 53527 53527 6900719 6900719 -55183625 -55183625 -399361 -399361 80142797 8014 1585023637 -876404854 768738 709395535 55507497 5551 904971772 -710098369 128317 195007271 23409458 2341 652709670 652712011 1218188 121 7829463 7829584 7654 1 160582 160583 19352150 19352150 -166306485 -166306485 640421 640421 80142797 8014 1585023637 -876404854 768738 709395535 81311878 8132 1611989381 -1058587757 176118 553585874 64489 6 591290 591296 1039 38734 38734 9530269 9530269 -76908004 -76908004 -81916 -81916 81377406 8138 1622149674 -1135495761 94202 486756253 80463089 8046 1593475506 -937104032 480584 656860104 910428 92 3604559 3604651 3889 144199 144199 24925410 24925410 -198391729 -198391729 -386382 -386382 81377406 8138 1622149674 -1135495761 94202 486756253 -198391729 -166306485 386534 402146 24925410 19352150 144199 160583 3301051 177374 6169769 7480604 1110550 2947138 15221990 4776989 -264609 6528789 1144124 5973299 -1419249 -122092 -45899 -186358950 -161830126 155193808 488524539 384352629 184757160 324496 191958 228834325 -303959337 3604651 7829584 652712011 3604651 660541595 46080026 194752132 61445933 107636849 107525959 302388981 8917935 7750959 106125959 300988981 1400000 1400000 107525959 302388981 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intra-Cellular</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiaries, ITI, Inc. (“ITI”) and ITI Limited, is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (“CNS”). In </div>December 2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company announced that CAPLYTA</div><div style="letter-spacing: 0px; font-size: 85%; vertical-align: top; top: 0px;;display:inline;">®</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (lumateperone) had been approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults </div>(42<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">mg/day). The Company initiated the commercial launch of CAPLYTA in late </div>March 2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia. Lumateperone is in Phase </div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> clinical development as a novel treatment for bipolar depression and major depressive disorder.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January 10, 2020, the Company completed a public offering o<div style="display:inline;">f</div> common stock in which the Company sold 10,000,000 shares of common stock at an offering price of $29.50 per share for aggregate gross proceeds of $295.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $277.0 million. On September 15, 2020, the Company completed a public offering of common stock in which the Company sold 12,666,667 shares of common stock at an offering price of $30.00 per share for aggregate gross proceeds of $380.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $357.8 million. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In order to further its commercial activities and research projects and support its collaborations, the Company will require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt or convertible debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s product candidates and technology and, to a much lesser extent, grant funding. On August 30, 2019, the Company filed a universal shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3,</div> which was declared effective by the SEC on September 12, 2019, on which the Company registered for sale up to $350 million of any combination of its common stock, preferred stock, debt securities, warrants, rights and/or units from time to time and at prices and on terms that the Company may determine, which included up to $75 million of common stock that the Company could issue and sell from time to time, through SVB Leerink LLC acting as its sales agent, pursuant to the sale agreement that the Company entered into with SVB Leerink on August 29, 2019 for the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“at-the-market”</div></div> equity program. On September 10, 2020, the Company terminated the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“at-the-market”</div></div> equity program sales agreement with SVB Leerink LLC. During the year ended December 31, 2020, the Company issued an aggregate 742,791 shares of common stock under the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“at-the-market”</div></div> equity program which resulted in the Company receiving net proceeds of $17.9 million. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, on January 6, 2020, the Company filed an automatic shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> with the SEC, which became effective upon filing, on which the Company registered for sale an unlimited amount of any combination of its common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that the Company may determine, so long as the Company continues to satisfy the requirements of a “well-known seasoned issuer” under SEC rules. These registration statements will remain in effect for up to three years from the respective dates they became effective. </div> 10000000 29.50 295000000.0 277000000.0 12666667 30.00 380000000.0 357800000 350000000 75000000 75000000 742791 17900000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting Policies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the condensed consolidated balance sheets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment Securities </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investment securities consisted of the following (in thousands):<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 63%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,673</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,666</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66,454</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66,453</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,437</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">141</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,539</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">371,064</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">371,158</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="clear: both; max-height: 0px;"/> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,304</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,276</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124,368</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124,370</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">202,749</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">624</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(117</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203,256</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">596,921</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">650</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(169</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">597,402</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has classified all of its investment securities as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale,</div></div> including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2021 and December 31, 2020, the Company held $54.9 million and $188.5 million, respectively, of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities with contractual maturity dates more than one year and less than two years. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors its investment portfolio for overall risk, specifically credit risk loss, quarterly or more frequently if circumstances warrant. The Company would estimate the expected credit loss over the lifetime of the asset and record an allowance for the portion of the amortized cost basis of the financial asset that the Company does not expect to collect. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate related fair value of investments with unrealized losses as of September 30, 2021 was $165.3 million, which consisted of $46.5 million from U.S. government agency securities, $40.0 million of commercial paper, and $78.8 million of corporate notes/bonds. The aggregate amount of unrealized losses as of September 30, 2021 was approximately $53.5 thousand, which consisted of $7.9 thousand from U.S. government agency securities, $6.2 thousand from commercial paper, and $39.4 thousand from corporate notes/bonds. The $165.3 million aggregate fair value of investments with unrealized losses as of September 30, 2021 has been held in a continuous unrealized loss position for less than 12 months. As of December 31, 2020, the aggregate related fair value of investments with unrealized losses was $372.3 million and the aggregate amount of unrealized losses was approximately $169 thousand. The $372.3 million aggregate fair value of investments with unrealized losses as of December 31, 2020 had been held in a continuous unrealized loss position for less than 12 months. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company applies the fair value method under ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures</div></div>. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has no assets or liabilities that were measured using quoted prices for significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2021 or December 31, 2020. The carrying value of cash held in money market funds of approximately $88.2 million as of September 30, 2021 and $27.9 million as of December 31, 2020 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in commercial paper of approximately $7.0 million as of September 30, 2021 is included in cash and cash equivalents. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The fair value measurements of the Company’s cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities are identified in the following tables (in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements at<br/> Reporting Date Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets for<br/> Identical<br/> Assets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money Market Funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,666</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,666</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73,452</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73,452</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,539</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,539</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">466,407</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,250</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">378,157</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—<div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="12" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting Date Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets for<br/> Identical<br/> Assets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money Market Funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,917</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,917</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,276</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,276</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124,370</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124,370</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203,256</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203,256</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">625,319</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,917</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">597,402</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-weight:bold;display:inline;width:100%;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, right of use asset, net, other assets, accounts payable, accrued liabilities, accrued employee benefits and lease liabilities, short-term, to approximate their fair value because of their relatively short maturities at September 30, 2021 and December 31, 2020. Management believes that the risks associated with its financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Cash </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Restricted cash is collateral used under the letter of credit arrangement for the vehicle lease agreement. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2016-18,</div> “Restricted Cash” (“ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-18”)</div> and presents restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable, Net </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers’ credit profiles. The Company reserves against accounts receivable for estimated losses that may arise from a customer’s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated collectability losses was not significant as of September 30, 2021 and December 31, 2020. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a credit loss reserve against uncollectible accounts receivable as necessary. We extend credit primarily to pharmaceutical wholesale distributors. Customer creditworthiness is monitored and collateral is not required. Historically, we have not experienced credit losses on our accounts receivable and as of September 30, 2021 and December 31, 2020, our credit loss reserve on receivables was not material. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments which potentially subject th<div style="display:inline;">e</div> Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the nine-month period ended September 30, 2021, all of the Company’s accounts receivable, net arose from product sales in the United States and all customers have standard payment terms which generally require payment within 60 days. For the nine-month period ended September 30, 2021, 96% of sales were generated from three major industry wholesalers which accounted for approximately 40%, 29%, and 27% of product sales, respectively. As of September 30, 2021, the Company believes that such customers are of high credit quality. The percentage of the total net product sales by individual customers has not significantly changed since inception. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company values its inventories at the lower of cost or estimated net realizable value. Inventories consist of raw materials (active pharmaceutical ingredients (“API”), drug product, and packaged product in saleable condition). The consumption of raw materials during production is classified as work in process until saleable. Once it is determined to be in saleable condition, inventory is classified as finished goods. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> (“FIFO”) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company capitalizes inventory costs associated with the Company’s products after regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets when identified in the manufacturing process, and is then expensed to selling, general and administrative expenses when the sample product is distributed. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from<span style="-sec-ix-hidden:hidden28030409"> three </span>to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC Topic 360, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, Plant and Equipment</div></div>. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Effective January 1, 2018, the Company adopted ASC Topic 606,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Revenue from Contracts with Customers </div></div>(“ASC Topic 606”). The Company did not generate any product related revenue prior to January 1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact on the Company’s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service. The reported results for the three and nine-month periods ended September 30, 2021 and 2020 reflect the application of ASC Topic 606. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, Net </div></div>(below). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, the Company’s only source of product sales has been from sales of CAPLYTA in the United States, which the Company began shipping to customers in March 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, Net </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company’s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the Customer obtains control of the Company’s product, which occurs at a point in time (upon delivery). Product revenues are recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reserves for Variable Consideration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company’s sales of its product. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include the Company’s best estimates that take into consideration a range of possible outcomes which are considered more likely in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, and forecasted customer buying and payment patterns. The Company’s estimates regarding the payer mix for CAPLYTA are based on historical industry information regarding the payer mix for comparable pharmaceutical products and product portfolios, in particular, information related to similar products in their initial launch stages and through the use of historical information experienced in CAPLYTA’s launch period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined it was probable that a significant reversal of revenue would not occur in a future period for the estimates detailed below as of September 30, 2021 and 2020, and, therefore, the transaction price was not reduced further during the three and nine-month periods ended September 30, 2021 and 2020. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade Discounts and Allowances</div></div>— The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of product sales, net within the condensed consolidated statements of operations for the three and nine-month periods ended September 30, 2021 and 2020, as well as a reduction to accounts receivable, net on the condensed consolidated balance sheets. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns</div></div>— Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product’s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any expired product returns to date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Provider Chargebacks and Discounts</div></div>— Chargebacks fo<div style="display:inline;">r</div> fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who purchase the product directly from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">period-end</div> that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the three and nine-month periods ended September 30, 2021 and 2020, these amounts were not significant. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government Rebates</div></div>— The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Payer Rebates</div></div>— The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the condensed consolidated balance sheets. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Incentives</div></div>— Other incentives which the Company offers include voluntary patient assistance programs, such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> required by payers. The calculation of the accrual for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company applies the claims for vouchers for product that is in the distribution channel and reduces recognized revenue accordingly. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the condensed consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.​​​​​​​ </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of Product Sales </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The related royalties are recorded within cost of product sales on the condensed statement of operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to FDA approval of CAPLYTA, the Company expensed all costs associated with the manufacturing of lumateperone as part of research and development expenses. From December 20, 2019, the date of approval of CAPLYTA, through December 31, 2019 there was no production of inventory and therefore, no inventory costs were incurred. Therefore, at December 31, 2019, no inventory costs had been capitalized. The cost of product sales in the three and nine-month periods ended September 30, 2021 and 2020, are lower than incurred due to the previously expensed inventory. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development, Including Clinical Trial Expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred, among other factors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated balance sheets as prepaid or accrued research and development expense, as the case may be. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate clinical trial expenses in its condensed consolidated statement of operations by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising Expense </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the FDA approval of CAPLYTA in 2019, the Company began to incur advertising costs in connection with the subsequent commercial launch of CAPLYTA in 2020. Advertising costs are expensed when services are rendered. Advertising expense for the three and nine months ended September 30, 2021 was $23.2 million and $57.4 million, respectively, as compared to $13.2 million and $18.6 million, respectively, for the three and nine months ended September 30, 2020, related to the Company’s marketed product, CAPLYTA. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The effect on deferred tax assets and liabilities o<div style="letter-spacing: 0px; top: 0px;;display:inline;">f</div> a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740 (previously included in FASB Interpretation No. 48, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Uncertainty in Income Taxes—an Interpretation of FASB Statement No.</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> 109</div></div>). Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s effective tax rate for the three and nine months ended September 30, 2021 and 2020 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (“CARES”) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (“AMT”) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, and a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the year ended December 31, 2020. The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of approximately $265,000 to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December 31, 2019 and received the refund in July 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 11, 2021, the American Rescue Plan Act of 2021 (“ARPA 2021”) was signed into law. ARPA 2021 included various income and payroll tax provisions. The Company has analyzed the tax provisions of ARPA 2021 and determined they have no significant financial impact to the Company’s condensed consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive Loss </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">All components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are incurred. Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or (losses) on its investment securities in a separate statement of comprehensive loss for each period. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-Based Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Share-based payments for stock options are accounted for in accordance with the provisions of ASC Topic 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation—Stock Compensation</div></div>. The fair value of share-based payments is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the “Black-Scholes model”). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For all awards granted with time-based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 accounts for forfeitures as they occur. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility rates for quarterly periods prior to December 31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company’s common stock. Beginning in the fourth quarter of 2019, expected volatility rates have been based entirely on the historical volatility of the Company’s </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the “simplified method,” which defines expected life as the midpoint between the vesting date and the end of the contractual term. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company’s common stock on the date of grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A restricted stock unit (“RSU”) is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company’s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first quarter of 2020, the Company granted performance-based RSUs for 86,000 shares of common stock, which vest based on the achievement of certain milestones that include (i) the approval of a planned NDA by the FDA (the “2020 Milestone RSUs”) and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2020 TSR RSUs”). The 2020 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first quarter of 2021, the Company granted performance-based RSUs for 64,518 shares of common stock, which vest based on the achievement of certain milestones that include (i) certain operational milestones (the “2021 Milestone RSUs”, and collectively with the 2020 Milestone RSUs, the “Milestone RSUs”) and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2021 TSR RSUs,” and collectively with the 2020 TSR RSUs, the “TSR RSUs”). The 2021 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Equity instruments issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> for services are accounted for under the provisions of ASC Topic 718 and ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">505-50,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity/Equity-Based Payments to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employees</div></div></div>. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the required services are completed and are marked to market during the service period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2018, the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company’s stockholders approved the Company’s 2018 Amended and Restated Equity Incentive Plan pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement Award Plan (the “2019 Inducement Plan”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of September 30, 2021, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss Per Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants and RSUs. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following awards were excluded in th<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div> calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2021 and 2020: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three and Nine Months Ended</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September 30,</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,952,252</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,964,135</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,601,273</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,702,538</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TSR RSUs</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68,598</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,022</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders. </div></div> 1 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the condensed consolidated balance sheets. </div></div> P3M more than three months <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment Securities </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investment securities consisted of the following (in thousands):<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 63%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,673</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,666</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66,454</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66,453</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,437</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">141</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,539</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">371,064</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">371,158</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="clear: both; max-height: 0px;"/> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,304</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,276</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124,368</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124,370</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">202,749</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">624</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(117</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203,256</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">596,921</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">650</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(169</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">597,402</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has classified all of its investment securities as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale,</div></div> including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2021 and December 31, 2020, the Company held $54.9 million and $188.5 million, respectively, of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities with contractual maturity dates more than one year and less than two years. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors its investment portfolio for overall risk, specifically credit risk loss, quarterly or more frequently if circumstances warrant. The Company would estimate the expected credit loss over the lifetime of the asset and record an allowance for the portion of the amortized cost basis of the financial asset that the Company does not expect to collect. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate related fair value of investments with unrealized losses as of September 30, 2021 was $165.3 million, which consisted of $46.5 million from U.S. government agency securities, $40.0 million of commercial paper, and $78.8 million of corporate notes/bonds. The aggregate amount of unrealized losses as of September 30, 2021 was approximately $53.5 thousand, which consisted of $7.9 thousand from U.S. government agency securities, $6.2 thousand from commercial paper, and $39.4 thousand from corporate notes/bonds. The $165.3 million aggregate fair value of investments with unrealized losses as of September 30, 2021 has been held in a continuous unrealized loss position for less than 12 months. As of December 31, 2020, the aggregate related fair value of investments with unrealized losses was $372.3 million and the aggregate amount of unrealized losses was approximately $169 thousand. The $372.3 million aggregate fair value of investments with unrealized losses as of December 31, 2020 had been held in a continuous unrealized loss position for less than 12 months. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment Securities </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investment securities consisted of the following (in thousands):<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 63%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,673</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,666</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66,454</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66,453</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,437</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">141</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,539</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">371,064</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">371,158</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="clear: both; max-height: 0px;"/> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,304</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,276</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124,368</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124,370</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">202,749</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">624</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(117</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203,256</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">596,921</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">650</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(169</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">597,402</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 101673000 1000 8000 101666000 25500000 25500000 66454000 5000 6000 66453000 177437000 141000 39000 177539000 371064000 147000 53000 371158000 259304000 3000 31000 259276000 10500000 10500000 124368000 23000 21000 124370000 202749000 624000 117000 203256000 596921000 650000 169000 597402000 54900000 188500000 165300000 46500000 40000000.0 78800000 53500 7900 6200 39400 165300000 372300000 169000 372300000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company applies the fair value method under ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures</div></div>. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has no assets or liabilities that were measured using quoted prices for significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2021 or December 31, 2020. The carrying value of cash held in money market funds of approximately $88.2 million as of September 30, 2021 and $27.9 million as of December 31, 2020 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in commercial paper of approximately $7.0 million as of September 30, 2021 is included in cash and cash equivalents. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The fair value measurements of the Company’s cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities are identified in the following tables (in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements at<br/> Reporting Date Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets for<br/> Identical<br/> Assets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money Market Funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,666</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,666</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73,452</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73,452</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,539</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,539</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">466,407</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,250</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">378,157</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—<div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="12" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting Date Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets for<br/> Identical<br/> Assets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money Market Funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,917</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,917</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,276</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,276</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124,370</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124,370</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203,256</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203,256</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">625,319</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,917</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">597,402</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-weight:bold;display:inline;width:100%;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 0 0 0 0 88200000 27900000 7000000.0 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The fair value measurements of the Company’s cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities are identified in the following tables (in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements at<br/> Reporting Date Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets for<br/> Identical<br/> Assets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money Market Funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,666</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,666</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73,452</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73,452</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,539</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,539</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">466,407</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,250</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">378,157</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—<div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="12" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting Date Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets for<br/> Identical<br/> Assets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money Market Funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,917</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,917</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,276</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,276</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124,370</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124,370</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203,256</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203,256</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">625,319</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,917</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">597,402</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-weight:bold;display:inline;width:100%;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 88250000 88250000 101666000 101666000 25500000 25500000 73452000 73452000 177539000 177539000 466407000 88250000 378157000 0 27917000 27917000 259276000 259276000 10500000 10500000 124370000 124370000 203256000 203256000 625319000 27917000 597402000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, right of use asset, net, other assets, accounts payable, accrued liabilities, accrued employee benefits and lease liabilities, short-term, to approximate their fair value because of their relatively short maturities at September 30, 2021 and December 31, 2020. Management believes that the risks associated with its financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Cash </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Restricted cash is collateral used under the letter of credit arrangement for the vehicle lease agreement. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2016-18,</div> “Restricted Cash” (“ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-18”)</div> and presents restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable, Net </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers’ credit profiles. The Company reserves against accounts receivable for estimated losses that may arise from a customer’s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated collectability losses was not significant as of September 30, 2021 and December 31, 2020. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a credit loss reserve against uncollectible accounts receivable as necessary. We extend credit primarily to pharmaceutical wholesale distributors. Customer creditworthiness is monitored and collateral is not required. Historically, we have not experienced credit losses on our accounts receivable and as of September 30, 2021 and December 31, 2020, our credit loss reserve on receivables was not material. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments which potentially subject th<div style="display:inline;">e</div> Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the nine-month period ended September 30, 2021, all of the Company’s accounts receivable, net arose from product sales in the United States and all customers have standard payment terms which generally require payment within 60 days. For the nine-month period ended September 30, 2021, 96% of sales were generated from three major industry wholesalers which accounted for approximately 40%, 29%, and 27% of product sales, respectively. As of September 30, 2021, the Company believes that such customers are of high credit quality. The percentage of the total net product sales by individual customers has not significantly changed since inception. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. </div></div> 0.96 0.96 0.40 0.29 0.27 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company values its inventories at the lower of cost or estimated net realizable value. Inventories consist of raw materials (active pharmaceutical ingredients (“API”), drug product, and packaged product in saleable condition). The consumption of raw materials during production is classified as work in process until saleable. Once it is determined to be in saleable condition, inventory is classified as finished goods. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> (“FIFO”) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company capitalizes inventory costs associated with the Company’s products after regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets when identified in the manufacturing process, and is then expensed to selling, general and administrative expenses when the sample product is distributed. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from<span style="-sec-ix-hidden:hidden28030409"> three </span>to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC Topic 360, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, Plant and Equipment</div></div>. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date. </div> P5Y 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Effective January 1, 2018, the Company adopted ASC Topic 606,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Revenue from Contracts with Customers </div></div>(“ASC Topic 606”). The Company did not generate any product related revenue prior to January 1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact on the Company’s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service. The reported results for the three and nine-month periods ended September 30, 2021 and 2020 reflect the application of ASC Topic 606. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, Net </div></div>(below). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, the Company’s only source of product sales has been from sales of CAPLYTA in the United States, which the Company began shipping to customers in March 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, Net </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company’s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the Customer obtains control of the Company’s product, which occurs at a point in time (upon delivery). Product revenues are recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reserves for Variable Consideration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company’s sales of its product. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include the Company’s best estimates that take into consideration a range of possible outcomes which are considered more likely in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, and forecasted customer buying and payment patterns. The Company’s estimates regarding the payer mix for CAPLYTA are based on historical industry information regarding the payer mix for comparable pharmaceutical products and product portfolios, in particular, information related to similar products in their initial launch stages and through the use of historical information experienced in CAPLYTA’s launch period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined it was probable that a significant reversal of revenue would not occur in a future period for the estimates detailed below as of September 30, 2021 and 2020, and, therefore, the transaction price was not reduced further during the three and nine-month periods ended September 30, 2021 and 2020. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade Discounts and Allowances</div></div>— The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of product sales, net within the condensed consolidated statements of operations for the three and nine-month periods ended September 30, 2021 and 2020, as well as a reduction to accounts receivable, net on the condensed consolidated balance sheets. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns</div></div>— Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product’s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any expired product returns to date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Provider Chargebacks and Discounts</div></div>— Chargebacks fo<div style="display:inline;">r</div> fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who purchase the product directly from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">period-end</div> that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the three and nine-month periods ended September 30, 2021 and 2020, these amounts were not significant. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government Rebates</div></div>— The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Payer Rebates</div></div>— The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the condensed consolidated balance sheets. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Incentives</div></div>— Other incentives which the Company offers include voluntary patient assistance programs, such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> required by payers. The calculation of the accrual for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company applies the claims for vouchers for product that is in the distribution channel and reduces recognized revenue accordingly. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the condensed consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.​​​​​​​ </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of Product Sales </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The related royalties are recorded within cost of product sales on the condensed statement of operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to FDA approval of CAPLYTA, the Company expensed all costs associated with the manufacturing of lumateperone as part of research and development expenses. From December 20, 2019, the date of approval of CAPLYTA, through December 31, 2019 there was no production of inventory and therefore, no inventory costs were incurred. Therefore, at December 31, 2019, no inventory costs had been capitalized. The cost of product sales in the three and nine-month periods ended September 30, 2021 and 2020, are lower than incurred due to the previously expensed inventory. </div></div> 0.05 0.09 0 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development, Including Clinical Trial Expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred, among other factors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated balance sheets as prepaid or accrued research and development expense, as the case may be. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate clinical trial expenses in its condensed consolidated statement of operations by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising Expense </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the FDA approval of CAPLYTA in 2019, the Company began to incur advertising costs in connection with the subsequent commercial launch of CAPLYTA in 2020. Advertising costs are expensed when services are rendered. Advertising expense for the three and nine months ended September 30, 2021 was $23.2 million and $57.4 million, respectively, as compared to $13.2 million and $18.6 million, respectively, for the three and nine months ended September 30, 2020, related to the Company’s marketed product, CAPLYTA. </div></div> 23200000 57400000 13200000 18600000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The effect on deferred tax assets and liabilities o<div style="letter-spacing: 0px; top: 0px;;display:inline;">f</div> a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740 (previously included in FASB Interpretation No. 48, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Uncertainty in Income Taxes—an Interpretation of FASB Statement No.</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> 109</div></div>). Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s effective tax rate for the three and nine months ended September 30, 2021 and 2020 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (“CARES”) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (“AMT”) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, and a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the year ended December 31, 2020. The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of approximately $265,000 to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December 31, 2019 and received the refund in July 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 11, 2021, the American Rescue Plan Act of 2021 (“ARPA 2021”) was signed into law. ARPA 2021 included various income and payroll tax provisions. The Company has analyzed the tax provisions of ARPA 2021 and determined they have no significant financial impact to the Company’s condensed consolidated financial statements. </div></div> 0 0 0 0 0.21 265000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive Loss </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">All components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are incurred. Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or (losses) on its investment securities in a separate statement of comprehensive loss for each period. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-Based Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Share-based payments for stock options are accounted for in accordance with the provisions of ASC Topic 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation—Stock Compensation</div></div>. The fair value of share-based payments is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the “Black-Scholes model”). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For all awards granted with time-based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 accounts for forfeitures as they occur. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility rates for quarterly periods prior to December 31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company’s common stock. Beginning in the fourth quarter of 2019, expected volatility rates have been based entirely on the historical volatility of the Company’s </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the “simplified method,” which defines expected life as the midpoint between the vesting date and the end of the contractual term. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company’s common stock on the date of grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A restricted stock unit (“RSU”) is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company’s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first quarter of 2020, the Company granted performance-based RSUs for 86,000 shares of common stock, which vest based on the achievement of certain milestones that include (i) the approval of a planned NDA by the FDA (the “2020 Milestone RSUs”) and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2020 TSR RSUs”). The 2020 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first quarter of 2021, the Company granted performance-based RSUs for 64,518 shares of common stock, which vest based on the achievement of certain milestones that include (i) certain operational milestones (the “2021 Milestone RSUs”, and collectively with the 2020 Milestone RSUs, the “Milestone RSUs”) and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2021 TSR RSUs,” and collectively with the 2020 TSR RSUs, the “TSR RSUs”). The 2021 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Equity instruments issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> for services are accounted for under the provisions of ASC Topic 718 and ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">505-50,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity/Equity-Based Payments to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employees</div></div></div>. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the required services are completed and are marked to market during the service period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2018, the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company’s stockholders approved the Company’s 2018 Amended and Restated Equity Incentive Plan pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement Award Plan (the “2019 Inducement Plan”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of September 30, 2021, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan. </div></div> 0 86000 64518 4750000 6500000 1000000 314138 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss Per Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants and RSUs. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following awards were excluded in th<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div> calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2021 and 2020: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three and Nine Months Ended</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September 30,</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,952,252</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,964,135</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,601,273</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,702,538</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TSR RSUs</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68,598</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,022</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following awards were excluded in th<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div> calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2021 and 2020: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three and Nine Months Ended</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September 30,</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,952,252</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,964,135</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,601,273</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,702,538</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TSR RSUs</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68,598</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,022</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> 5952252 5964135 1601273 1702538 68598 43022 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Inventory </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory consists of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 74%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">December 31,<br/> 2020</td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">2,182,261</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2,483,801</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Work in process</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,444,013</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,781,101</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,540,661</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,791,483</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,166,935</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7,056,385</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory acquired prior to receipt of the FDA approval on December 20, 2019 for CAPLYTA was expensed as research and development expense as incurred. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory consists of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 74%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">December 31,<br/> 2020</td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">2,182,261</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2,483,801</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Work in process</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,444,013</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,781,101</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,540,661</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,791,483</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,166,935</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7,056,385</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 2182261 2483801 3444013 1781101 2540661 2791483 8166935 7056385 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Property and Equipment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 73%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">December 31,<br/> 2020</td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">408,751</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">243,532</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">423,097</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">423,097</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scientific equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,287,228</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,127,951</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvement<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,240,315</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,240,315</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,359,391</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,034,895</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,423,083</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,036,549</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,936,308</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,998,346</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense for the three and nine months ended September 30, 2021 was $133,945 and $386,534, respectively, as compared to $121,044 and $402,146 for the three and nine months ended September 30, 2020, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 73%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">December 31,<br/> 2020</td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">408,751</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">243,532</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">423,097</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">423,097</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scientific equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,287,228</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,127,951</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvement<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,240,315</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,240,315</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,359,391</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,034,895</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,423,083</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,036,549</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,936,308</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,998,346</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 408751 243532 423097 423097 4287228 4127951 1240315 1240315 6359391 6034895 4423083 4036549 1936308 1998346 133945 386534 121044 402146 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Accrued Expenses and Other Current Liabilities </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other current liabilities as of September 30, 2021 and December 31, 2020 consisted of the following: </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,144,235</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,896,942</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid rebates</div></div></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,226,394</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,998,953</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue related accruals</div></div></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,558,040</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,006,222</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses and other current liabilities</div></div></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,928,669</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,902,117</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other current liabilities as of September 30, 2021 and December 31, 2020 consisted of the following: </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,144,235</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,896,942</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid rebates</div></div></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,226,394</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,998,953</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue related accruals</div></div></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,558,040</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,006,222</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses and other current liabilities</div></div></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,928,669</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,902,117</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 12144235 7896942 3226394 1998953 1558040 1006222 16928669 10902117 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Right of Use Assets and Lease Liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Real Estate Leases </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In 2014, the Company entered into a long-term lease with a related party which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02</div> for accounting purposes. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In February 2019, the Company entered into a long-term lease for office space in Towson, Maryland beginning March 1, 2019. The lease has a term of 3.2 years ending in April 2022 and includes limited rent abatement and escalation provisions. The Company has no other significant leases. In addition, no identified leases require allocations between lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In adopting ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02</div> as of January 1, 2019, the Company elected the package of practical expedients, which permit the Company not to reassess under the new standard the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the consolidated balance sheets. The Company also elected the lessee component election, allowing the Company to account for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components as a single lease component. In determining whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. The Company recognized those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. The Company uses the rate implicit in the contract whenever possible when determining the applicable discount rate. As the majority of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. On the lease commencement dates, the Company estimated the lease liabilities and the right of use assets at present value using its applicable incremental borrowing rates of its two long-term leases of 7.2% for the Company’s Maryland lease of 3.2 years and 9.1% for the Company’s New York leases of 14.3 years. On January 1, 2019, upon adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> the Company recorded right of use assets of approximately $20.2 million, lease liabilities of $23.4 million and eliminated deferred rent of $3.2 million. At the execution of the Maryland lease in 2019, the Company recorded a right of use asset and a lease liability of $0.2 million, which represented a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> transaction. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturity analysis under the lease agreements are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three months ending December 31, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">871,321</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2022</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,491,166</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,566,466</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2024</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,675,196</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2025</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,787,248</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,839,791</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,231,188</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Present value discount</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,505,190</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Lease liability</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,725,998</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current portion</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,322,657</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term lease liabilities</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,403,341</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease expense for the three and nine months ended September 30, 2021 was approximately $0.8 million and $2.5 million, respectively, as compared to approximately $0.8 million and $2.5 million, respectively, for the three and nine months ended September 30, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Vehicle Fleet Lease </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May 17, 2019, the Company entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to acquire motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The Company began leasing vehicles under the Vehicle Lease in March 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The contractual period of each lease is 12 months, followed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">month-to-month</div></div> renewal periods. The Company estimates the lease term for each vehicle to be 30 months based on industry standards. The lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.4 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease. The $1.4 million is recorded as restricted cash on the condensed consolidated balance sheet. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The nature of the lease is one commonly referred to as “TRAC” lease, as it contains a terminal rental adjustment clause, or “TRAC clause.” The TRAC clause limits lessee<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>exposure, or likelihood of having a variable lease payment<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>due at lease termination. This variable lease payment amount would be any difference between the vehicle stipulated (capitalized) cost and the sum of the reserve and net proceeds from disposal as described in the Vehicle Lease. Further, the Lessor guarantees that the net proceeds will not be less than 20% of the vehicle capitalized cost in the first 12 months, and 30% of the vehicle capitalized cost at the beginning of subsequent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> period increments. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Right of use asset an<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div> lease liability for the vehicle fleet lease was approximately $5.7 million and $7.3 million, respectively, as of September 30, 2021 and December 31, 2020. The vehicle leases entered into since March 2020 represent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> transactions. The total operating lease cost for the three and nine months ended September 30, 2021 was $583,142 and $1.8 million, respectively. The operating cash outflows related to vehicle fleet operating lease obligations for the nine months ended September 30, 2021 and 2020 were $1.8 million and $585,490, respectively. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Vehicle Lease balances within the condensed consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of September 30, 2021 and December 31, 2020: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 37%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lease Assets and Liabilities – Fleet</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2021</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets, net</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">Operating lease right of use assets</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">5,679,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7,295,515</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 37%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 37%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,679,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,295,515</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 37%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 37%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Lease liabilities, short-term</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap; text-align: right;">Operating lease liabilities</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,759,397</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,257,262</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current operating lease liabilities</div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,920,577</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,038,253</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 37%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 37%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Total lease liabilities</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,679,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"> 7,295,515</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 37%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 37%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Weighted average remaining lease term</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.3 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.71</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.74</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the maturity of the Company’s fleet lease liability as of September 30, 2021: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time Period </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three months ending December 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">596,241</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,480,355</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2023</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,691,462</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,768,058</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Present value discount</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(88,084</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,679,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current portion</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,759,397</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term lease liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,920,577</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets and lease liabilities for all operating leases were approximately $21.7 million and $26.4 million, respectively, as of September 30, 2021. </div></div> P14Y3M18D P3Y2M12D 0.072 P3Y2M12D 0.091 P14Y3M18D 20200000 23400000 3200000 200000 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturity analysis under the lease agreements are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three months ending December 31, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">871,321</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2022</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,491,166</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,566,466</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2024</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,675,196</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2025</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,787,248</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,839,791</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,231,188</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Present value discount</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,505,190</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Lease liability</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,725,998</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current portion</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,322,657</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term lease liabilities</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,403,341</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 871321 3491166 3566466 3675196 3787248 13839791 29231188 8505190 20725998 3322657 17403341 800000 2500000 800000 2500000 P12Y 1400000 1400000 0.20 0.30 5700000 7300000 583142 1800000 1800000 585490 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Vehicle Lease balances within the condensed consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of September 30, 2021 and December 31, 2020: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 37%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lease Assets and Liabilities – Fleet</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2021</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets, net</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">Operating lease right of use assets</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">5,679,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7,295,515</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 37%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 37%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,679,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,295,515</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 37%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 37%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Lease liabilities, short-term</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap; text-align: right;">Operating lease liabilities</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,759,397</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,257,262</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current operating lease liabilities</div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,920,577</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,038,253</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 37%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 37%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Total lease liabilities</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,679,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"> 7,295,515</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 37%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 37%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Weighted average remaining lease term</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.3 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 37%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.71</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom; width: 5%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.74</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> 5679974 7295515 5679974 7295515 2759397 2257262 2920577 5038253 5679974 7295515 P1Y3M18D P2Y 0.0171 0.0174 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the maturity of the Company’s fleet lease liability as of September 30, 2021: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time Period </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three months ending December 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">596,241</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,480,355</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2023</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,691,462</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,768,058</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Present value discount</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(88,084</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,679,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current portion</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,759,397</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term lease liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,920,577</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 596241 3480355 1691462 0 5768058 88084 5679974 2759397 2920577 21700000 26400000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Commitments and Contingencies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License and Royalty Commitments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the agreement, the Company made an upfront payment of $1.0 million to BMS in 2005, a milestone payment of $1.25 million in December 2013, and a milestone payment of $1.5 million in December 2014 following the initiation of the Company’s first Phase 3 clinical trial for lumateperone for patients with exacerbated schizophrenia. Upon FDA acceptance of an NDA filing for lumateperone, the Company was obligated to pay BMS a $2.0 million milestone payment, which was paid in January 2019. The FDA approved the NDA filing on December 23, 2019 and as a result the Company accrued an additional milestone liability of $5.0 million in the fourth quarter of 2019 which was paid in January 2020. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-royalty</div> payments made in consideration of any sublicense. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The agreement extends, and royalties are payable, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2016, the Company transferred certain of its rights under the BMS agreement to its wholly owned subsidiary, ITI Limited. In connection with the transfer, the Company guaranteed ITI Limited’s performance of its obligations under the BMS agreement. The Company expensed approximately $1.1 million and $2.8 million, respectively, for the three and nine-month periods ended September 30, 2021, in cost of product sales to satisfy its obligation under the BMS agreement, in comparison to $0.4 million and $0.5 million, respectively, for the three and nine-month periods ended September 30, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Other Commitments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2021, the Company has committed to purchasing production campaigns for various raw materials and API from each of its supply vendors – Siegfried Evionnaz SA (“Siegfried”) and Lonza Ltd. (“Lonza”). The campaigns are expected to be received into inventory during 2022. The Company has a total commitment of $32.1 million related to these agreements. As of September 30, 2021, the Company had paid a deposit of $5.2 million and $4.3 million for the Siegfried and Lonza campaigns, respectively, which is recorded within prepaid expenses and other current assets. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan within the executed agreements. </div></div> 1000000.0 1250000 1500000 2000000.0 5000000.0 5000000.0 14750000 0.05 0.09 through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product 1100000 2800000 400000 500000 32100000 5200000 4300000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Share-Based Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June 18, 2018, the Company’s stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan provided for the granting of share-based awards, such as stock options, restricted common stock, RSUs and stock appreciation rights to employees, directors and consultants as determined by the Board of Directors. On May 27, 2020, the Company’s stockholders approved the Amended and Restated 2018 Equity Incentive Plan (the “Amended 2018 Plan”), which amended and restated the 2018 Plan. The Amended 2018 Plan provides for the granting of up to 6,500,000 additional share-based awards, such as stock options, restricted common stock, RSUs and stock appreciation rights to employees, directors and consultants as determined by the Board of Directors. In December 2019, the Company adopted the 2019 Inducement Award Plan (the “2019 Inducement Plan”) for the grant of equity awards of up to 1,000,000 shares of common stock to newly hired employees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December 31, 2020, the total number of shares reserved under all equity plans was 17,787,390 and the Company had 7,459,117 shares available for future issuance under the Amended 2018 Plan and the 2019 Inducement Plan. Stock options granted under the 2018 Plan and the 2019 Inducement Plan may be either incentive stock options (“ISOs”) as defined by the Internal Revenue Code of 1986, as amended, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options. The Board of Directors determines who will receive options, the vesting periods (which are generally <span style="-sec-ix-hidden:hidden28670497">one</span> to three years) and the exercise prices of such options. Options have a maximum term of 10 years. The exercise price of stock options granted under the Amended 2018 Plan and the 2019 Inducement Plan must be at least equal to the fair market value of the common stock on the date of grant. The Company does not intend to issue any additional equity awards under the 2019 Inducement Plan. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expense related to all of th<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div> Company’s share-based awards, including stock options and RSUs to employees, directors and consultants, recognized during the three and nine months ended September 30, 2021 and 2020, was comprised of the following: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 54%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended September 30,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended September 30,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventoriable costs</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">413,103</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">345,460</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,212,943</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">996,802</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,769,561</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,402,865</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,153,803</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,792,498</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,347,605</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,152,394</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,558,664</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,562,850</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expense</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,530,269</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">6,900,719</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24,925,410</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">19,352,150</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table describes the weighted-average assumptions used for calculating the value of options granted during the nine months ended September 30, 2021 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 87%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0%</div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:center;">0%</td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">94.5%-94.9%</div></div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">91.6%-92.7%</div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average risk-free interest rate</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.86%</div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:center;">1.31%</td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.9</div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:center;">6.0</td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of September 30, 2021, and changes during the three-month period then ended, are summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 70%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2020</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,728</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.18</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercised in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,347</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.98</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,381</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.83</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,381</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.83</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,658</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.70</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding RSU awards under the 2019 Inducement Plan during the three-month period ended September 30, 2021 are summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Grant Date<br/> Fair Value Per Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2020</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">251,867</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.03</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs vested in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(82,355</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.03</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs cancelled in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,023</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.81</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">153,489</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.05</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">153,489</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.05</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2021, the Company granted options and time based RSUs totaling 314,138 shares under the 2019 Inducement Plan. These grants were made in the first quarter of 2020 and the Company does not intend to grant any additional equity awards under the 2019 Inducement Plan. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of September 30, 2021, and changes during the nine-month period then ended, are summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 67%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2020</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,477,894</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.43</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.6 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">670,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30.39</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.5 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercised 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(202,124</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.28</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options canceled or expired 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,149</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.66</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,916,871</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.70</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,916,871</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.70</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,212,172</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.66</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the time based RSUs and the Milestone RSUs is based on the closing price of the Company’s common stock on the date of grant. The fair value of the TSR RSUs was determined using the Monte Carlo simulation method. Information regarding the time based RSU activity and changes during the nine-month period ended September 30, 2021 are summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 61%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant Date<br/> Fair Value Per Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2020</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,311,877</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.77</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.7 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs granted in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">710,318</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35.69</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.4 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs vested in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(614,838</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.58</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs cancelled in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,171</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29.90</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,379,186</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.80</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.7 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information related to the Company’s Milestone RSUs and TSR RSUs during the nine-month period ended September 30, 2021 are summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant Date<br/> Fair Value Per Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2020</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,678</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28.25</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.1 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone RSUs and TSR RSUs granted in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,518</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44.04</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.4 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone RSUs and TSR RSUs vested in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137,196</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35.67</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average estimated fair value per share of the 2020 TSR RSUs granted was $32.56, and the 2021 TSR RSUs granted was $51.18, which were derived from Monte Carlo simulations. Significant assumptions utilized in estimating the value of the 2020 awards granted include an expected dividend yield of 0%, a risk-free rate of 1.4%, and expected volatility of 91.3%. Significant assumptions utilized in estimating the value of the 2021 awards granted include an expected dividend yield of 0%, a risk-free rate of 0.2%, and expected volatility of 95.8%. The 2020 TSR RSUs granted will entitle the grantee to receive a number of shares of the Company’s common stock determined over a three-year performance period ending and vesting after December 31, 2022 but before February 18, 2023, provided the grantee remained in the service of the Company on the settlement date. Similarly, the 2021 TSR <div style="letter-spacing: 0px; top: 0px;;display:inline;">RSUs </div>granted will entitle the grantee to receive a number of shares of the Company’s common stock determined over a three-year performance period ending and vesting after December 31, 2023 but before February 23, 2024, provided the grantee remained in the service of the Company on the settlement date. The Company is expensing the cost of these awards ratably over the requisite service period. The number of shares for which the TSR RSUs will be settled is a percentage of shares for which the award is targeted and depends on the Company’s total shareholder returns, expressed as a percentile ranking of the Company’s total shareholder return as compared to the Company’s peer group. The number of shares for which the TSR RSUs will be settled will vary depending on the level of achievement of the goal. Total shareholder return will be determined by dividing the average share value of the Company’s common stock over the 30 trading days preceding the settlement date by the average share value of the Company’s common stock over the 30 trading days beginning on January 1, 2020 and 2021, accordingly, with a deemed reinvestment of any dividends declared during the performance period. The Company’s peer group included companies that compromised the Nasdaq Biotechnology Index at December 31, 2019 and 2020, respectively. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;">The Company recognized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> share-based compensation expense related to time based RSUs for the three and nine months ended September 30, 2021 of approximately $4.4 million and $12.3 million, respectively, as compared to $3.2 million and $8.9 million, respectively, for the three and nine months ended September 30, 2020. Total expense for all RSUs, including the time based and performance based RSUs, was $4.3 million and $12.6 million, respectively, for the three and nine months ended September 30, 2021, as compared to $3.4 million and $9.2 million, respectively, for the three and nine months ended September 30, 2020. As of September 30, 2021, there was approximately $29.5 million of unrecognized compensation costs related to unvested time based RSUs. As of September 30, 2021, there was $2.1 million and $1.3 million of unrecognized compensation costs related to unvested Milestone RSUs and TSR RSUs, respectively. </div> 6500000 1000000 17787390 7459117 P3Y P10Y <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expense related to all of th<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div> Company’s share-based awards, including stock options and RSUs to employees, directors and consultants, recognized during the three and nine months ended September 30, 2021 and 2020, was comprised of the following: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 54%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended September 30,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended September 30,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventoriable costs</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">413,103</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">345,460</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,212,943</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">996,802</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,769,561</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,402,865</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,153,803</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,792,498</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,347,605</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,152,394</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,558,664</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,562,850</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expense</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,530,269</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">6,900,719</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24,925,410</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">19,352,150</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 413103 345460 1212943 996802 2769561 2402865 7153803 6792498 6347605 4152394 16558664 11562850 9530269 6900719 24925410 19352150 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table describes the weighted-average assumptions used for calculating the value of options granted during the nine months ended September 30, 2021 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 87%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0%</div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:center;">0%</td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">94.5%-94.9%</div></div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">91.6%-92.7%</div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average risk-free interest rate</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.86%</div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:center;">1.31%</td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.9</div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:center;">6.0</td></tr></table> 0 0 0.945 0.949 0.916 0.927 0.0086 0.0131 P5Y10M24D P6Y <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of September 30, 2021, and changes during the three-month period then ended, are summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 70%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2020</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,728</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.18</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercised in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,347</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.98</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,381</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.83</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,381</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.83</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,658</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.70</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr></table> 39728 17.18 P9Y2M12D 0 0 4347 19.98 P9Y2M12D 35381 16.83 P9Y2M12D 35381 16.83 4658 19.70 P9Y2M12D <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding RSU awards under the 2019 Inducement Plan during the three-month period ended September 30, 2021 are summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Grant Date<br/> Fair Value Per Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2020</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">251,867</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.03</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs vested in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(82,355</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.03</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs cancelled in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,023</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.81</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">153,489</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.05</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">153,489</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.05</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr></table> 251867 16.03 P2Y2M12D 82355 16.03 P2Y 16023 15.81 P2Y 153489 16.05 P2Y 153489 16.05 0 0 314138 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of September 30, 2021, and changes during the nine-month period then ended, are summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 67%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2020</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,477,894</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.43</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.6 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">670,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30.39</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.5 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercised 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(202,124</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.28</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options canceled or expired 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,149</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.66</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,916,871</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.70</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,916,871</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.70</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,212,172</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.66</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr></table> 5477894 18.43 P6Y7M6D 670250 30.39 P9Y6M 202124 17.28 P6Y2M12D 29149 18.66 P8Y 5916871 20.70 P6Y2M12D 5916871 20.70 4212172 18.66 P5Y3M18D Information regarding the time based RSU activity and changes during the nine-month period ended September 30, 2021 are summarized as follows: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 61%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant Date<br/> Fair Value Per Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2020</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,311,877</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.77</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.7 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs granted in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">710,318</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35.69</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.4 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs vested in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(614,838</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.58</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs cancelled in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,171</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29.90</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,379,186</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.80</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.7 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 1311877 18.77 P1Y8M12D 710318 35.69 P2Y4M24D 614838 16.58 P1Y 28171 29.90 P2Y 1379186 27.80 P1Y8M12D <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information related to the Company’s Milestone RSUs and TSR RSUs during the nine-month period ended September 30, 2021 are summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant Date<br/> Fair Value Per Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2020</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,678</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28.25</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.1 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone RSUs and TSR RSUs granted in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,518</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44.04</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.4 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone RSUs and TSR RSUs vested in 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2021</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137,196</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35.67</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.2 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 72678 28.25 P2Y1M6D 64518 44.04 P2Y4M24D 0 0 P0Y 137196 35.67 P5Y2M12D 32.56 51.18 0 0.014 0.913 0 0.002 0.958 P3Y Total shareholder return will be determined by dividing the average share value of the Company’s common stock over the 30 trading days preceding the settlement date by the average share value of the Company’s common stock over the 30 trading days beginning on January 1, 2020 and 2021, accordingly, with a deemed reinvestment of any dividends declared during the performance period 4400000 12300000 3200000 8900000 4300000 12600000 3400000 9200000 29500000 2100000 1300000 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2021
Nov. 05, 2021
Cover [Abstract]    
Amendment Flag false  
Document Type 10-Q  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Document Quarterly Report true  
Entity Central Index Key 0001567514  
Document Transition Report false  
Current Fiscal Year End Date --12-31  
Document Period End Date Sep. 30, 2021  
Entity Registrant Name Intra-Cellular Therapies, Inc.  
Trading Symbol ITCI  
Entity Filer Category Large Accelerated Filer  
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Interactive Data Current Yes  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity File Number 001-36274  
Entity Tax Identification Number 36-4742850  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 430 East 29th Street  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10016  
City Area Code 646  
Local Phone Number 440-9333  
Title of 12(b) Security Common Stock  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   81,463,253
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 106,125,959 $ 60,045,933
Investment securities, available-for-sale 371,157,974 597,402,126
Restricted cash 1,400,000 1,400,000
Accounts receivable, net 16,934,352 10,764,583
Inventory 8,166,935 7,056,385
Prepaid expenses and other current assets 29,457,445 14,235,455
Total current assets 533,242,665 690,904,482
Property and equipment, net 1,936,308 1,998,346
Right of use assets, net 21,710,677 24,324,762
Other assets 86,084 86,084
Total assets 556,975,734 717,313,674
Current liabilities:    
Accounts payable 12,030,614 5,501,825
Accrued and other current liabilities 16,928,669 10,902,117
Lease liabilities, short-term 6,082,054 5,541,802
Accrued employee benefits 14,854,226 14,907,479
Total current liabilities 49,895,563 36,853,223
Lease liabilities 20,323,918 23,600,347
Total liabilities 70,219,481 60,453,570
Stockholders' equity:    
Common stock, $0.0001 par value: 175,000,000 and 100,000,000 shares authorized at September 30, 2021 and December 31, 2020, respectively; 81,377,406 and 80,463,089 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively 8,138 8,046
Additional paid-in capital 1,622,149,674 1,593,475,506
Accumulated deficit (1,135,495,761) (937,104,032)
Accumulated comprehensive income 94,202 480,584
Total stockholders' equity 486,756,253 656,860,104
Total liabilities and stockholders' equity $ 556,975,734 $ 717,313,674
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 175,000,000 100,000,000
Common stock, shares issued 81,377,406 80,463,089
Common stock, shares outstanding 81,377,406 80,463,089
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue $ 22,207,201 $ 7,368,594 $ 58,132,091 $ 10,358,709
Operating expenses:        
Cost of product sales 2,001,315 556,107 5,496,561 753,957
Research and development 27,031,825 10,275,368 59,386,413 51,483,551
Selling, general and administrative 70,497,885 52,473,573 192,932,688 128,015,496
Total operating expenses 99,531,025 63,305,048 257,815,662 180,253,004
Loss from operations (77,323,824) (55,936,454) (199,683,571) (169,894,295)
Interest income 392,695 752,829 1,297,473 3,591,091
Loss before provision for income taxes (76,931,129) (55,183,625) (198,386,098) (166,303,204)
Income tax (expense) benefit 23,125 0 (5,631) (3,281)
Net loss $ (76,908,004) $ (55,183,625) $ (198,391,729) $ (166,306,485)
Net loss per common share:        
Basic & Diluted $ (0.95) $ (0.79) $ (2.44) $ (2.48)
Weighted average number of common shares:        
Basic & Diluted 81,354,724 69,530,039 81,178,482 67,030,991
Product sales, net [Member]        
Revenue $ 21,606,163 $ 7,368,594 $ 56,191,848 $ 10,126,999
Grant revenue [Member]        
Revenue $ 601,038 $ 0 $ 1,940,243 $ 231,710
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]        
Net loss $ (76,908,004) $ (55,183,625) $ (198,391,729) $ (166,306,485)
Other comprehensive loss:        
Unrealized (loss) gain on investment securities (81,916) (399,361) (386,382) 640,421
Comprehensive loss $ (76,989,920) $ (55,582,986) $ (198,778,111) $ (165,666,064)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
Total
January 2020 [Member]
Common Stock [Member]
Common Stock [Member]
January 2020 [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
January 2020 [Member]
Accumulated Deficit [Member]
Accumulated Comprehensive (Loss) Income [Member]
Balance at Dec. 31, 2019 $ 195,007,271   $ 5,551   $ 904,971,772   $ (710,098,369) $ 128,317
Balance, shares at Dec. 31, 2019     55,507,497          
Common shares issued   $ 652,712,011   $ 2,341   $ 652,709,670    
Common shares issued, shares       23,409,458        
Exercise of stock options and issuances of restricted stock (Value) 7,829,584   $ 121   7,829,463      
Exercise of stock options and issuances of restricted stock (Shares)     1,218,188          
Stock issued for services 160,583   $ 1   160,582      
Stock issued for services, shares     7,654          
Share-based compensation 19,352,150       19,352,150      
Net loss (166,306,485)           (166,306,485)  
Other comprehensive gain (loss) 640,421             640,421
Balance at Sep. 30, 2020 709,395,535   $ 8,014   1,585,023,637   (876,404,854) 768,738
Balance, shares at Sep. 30, 2020     80,142,797          
Balance at Jun. 30, 2020 379,529,868   $ 6,678   1,199,576,320   (821,221,229) 1,168,099
Balance, shares at Jun. 30, 2020     66,777,737          
Common shares issued   370,138,616   $ 1,318   370,137,298    
Common shares issued, shares       13,179,458        
Common shares issued receivable collected   $ 5,705,186       $ 5,705,186    
Exercise of stock options and issuances of restricted stock (Value) 2,650,605   $ 18   2,650,587      
Exercise of stock options and issuances of restricted stock (Shares)     183,516          
Stock issued for services 53,527       53,527      
Stock issued for services, shares     2,086          
Share-based compensation 6,900,719       6,900,719      
Net loss (55,183,625)           (55,183,625)  
Other comprehensive gain (loss) (399,361)             (399,361)
Balance at Sep. 30, 2020 709,395,535   $ 8,014   1,585,023,637   (876,404,854) 768,738
Balance, shares at Sep. 30, 2020     80,142,797          
Balance at Dec. 31, 2020 656,860,104   $ 8,046   1,593,475,506   (937,104,032) 480,584
Balance, shares at Dec. 31, 2020     80,463,089          
Exercise of stock options and issuances of restricted stock (Value) 3,604,651   $ 92   3,604,559      
Exercise of stock options and issuances of restricted stock (Shares)     910,428          
Stock issued for services 144,199       144,199      
Stock issued for services, shares     3,889          
Share-based compensation 24,925,410       24,925,410      
Net loss (198,391,729)           (198,391,729)  
Other comprehensive gain (loss) (386,382)             (386,382)
Balance at Sep. 30, 2021 486,756,253   $ 8,138   1,622,149,674   (1,135,495,761) 94,202
Balance, shares at Sep. 30, 2021     81,377,406          
Balance at Jun. 30, 2021 553,585,874   $ 8,132   1,611,989,381   (1,058,587,757) 176,118
Balance, shares at Jun. 30, 2021     81,311,878          
Exercise of stock options and issuances of restricted stock (Value) 591,296   $ 6   591,290      
Exercise of stock options and issuances of restricted stock (Shares)     64,489          
Stock issued for services 38,734       38,734      
Stock issued for services, shares     1,039          
Share-based compensation 9,530,269       9,530,269      
Net loss (76,908,004)           (76,908,004)  
Other comprehensive gain (loss) (81,916)             (81,916)
Balance at Sep. 30, 2021 $ 486,756,253   $ 8,138   $ 1,622,149,674   $ (1,135,495,761) $ 94,202
Balance, shares at Sep. 30, 2021     81,377,406          
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows used in operating activities    
Net loss $ (198,391,729) $ (166,306,485)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 386,534 402,146
Share-based compensation 24,925,410 19,352,150
Stock issued for services 144,199 160,583
Amortization of premiums and discounts on investment securities, net (3,301,051) (177,374)
Changes in operating assets and liabilities:    
Accounts receivable, net (6,169,769) (7,480,604)
Inventory (1,110,550) (2,947,138)
Prepaid expenses and other assets (15,221,990) (4,776,989)
Long term deferred tax asset, net   264,609
Accounts payable 6,528,789 1,144,124
Accrued liabilities and other 5,973,299 (1,419,249)
Lease liabilities, net (122,092) (45,899)
Net cash used in operating activities (186,358,950) (161,830,126)
Cash flows provided by (used in) investing activities    
Purchases of investments (155,193,808) (488,524,539)
Maturities of investments 384,352,629 184,757,160
Purchases of property and equipment (324,496) (191,958)
Net cash provided by (used) in investing activities 228,834,325 (303,959,337)
Cash flows provided by financing activities    
Proceeds from exercise of stock options 3,604,651 7,829,584
Proceeds of public offering, net   652,712,011
Net cash provided by financing activities 3,604,651 660,541,595
Net increase in cash, cash equivalents, and restricted cash 46,080,026 194,752,132
Cash, cash equivalents, and restricted cash at beginning of period 61,445,933 107,636,849
Cash, cash equivalents, and restricted cash at end of period 107,525,959 302,388,981
Non-cash investing and financing activities    
Right of use assets under operating leases $ 8,917,935 $ 7,750,959
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Sep. 30, 2020
Dec. 31, 2019
Statement of Cash Flows [Abstract]        
Cash and cash equivalents $ 106,125,959 $ 60,045,933 $ 300,988,981  
Restricted cash 1,400,000 1,400,000 1,400,000  
Total cash, cash equivalents and restricted cash $ 107,525,959 $ 61,445,933 $ 302,388,981 $ 107,636,849
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Organization
 9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization
1. Organization
Intra-Cellular
 Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiaries, ITI, Inc. (“ITI”) and ITI Limited, is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (“CNS”). In
December 2019
, the Company announced that CAPLYTA
®
(lumateperone) had been approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults
(42
mg/day). The Company initiated the commercial launch of CAPLYTA in late
March 2020
. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia. Lumateperone is in Phase
3
clinical development as a novel treatment for bipolar depression and major depressive disorder.
On January 10, 2020, the Company completed a public offering o
f
 common stock in which the Company sold 10,000,000 shares of common stock at an offering price of $29.50 per share for aggregate gross proceeds of $295.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $277.0 million. On September 15, 2020, the Company completed a public offering of common stock in which the Company sold 12,666,667 shares of common stock at an offering price of $30.00 per share for aggregate gross proceeds of $380.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $357.8 million.
In order to further its commercial activities and research projects and support its collaborations, the Company will require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt or convertible debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s product candidates and technology and, to a much lesser extent, grant funding. On August 30, 2019, the Company filed a universal shelf registration statement on Form
S-3,
which was declared effective by the SEC on September 12, 2019, on which the Company registered for sale up to $350 million of any combination of its common stock, preferred stock, debt securities, warrants, rights and/or units from time to time and at prices and on terms that the Company may determine, which included up to $75 million of common stock that the Company could issue and sell from time to time, through SVB Leerink LLC acting as its sales agent, pursuant to the sale agreement that the Company entered into with SVB Leerink on August 29, 2019 for the Company’s
“at-the-market”
equity program. On September 10, 2020, the Company terminated the
“at-the-market”
equity program sales agreement with SVB Leerink LLC. During the year ended December 31, 2020, the Company issued an aggregate 742,791 shares of common stock under the Company’s
“at-the-market”
equity program which resulted in the Company receiving net proceeds of $17.9 million.
In addition, on January 6, 2020, the Company filed an automatic shelf registration statement on Form
S-3
with the SEC, which became effective upon filing, on which the Company registered for sale an unlimited amount of any combination of its common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that the Company may determine, so long as the Company continues to satisfy the requirements of a “well-known seasoned issuer” under SEC rules. These registration statements will remain in effect for up to three years from the respective dates they became effective.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders.
 
Recent Accounting Pronouncements
Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the condensed consolidated balance sheets.
Investment Securities
Investment securities consisted of the following (in thousands):
 
 
  
September 30, 2021
 
 
  
Amortized
Cost
 
  
Unrealized
Gains
 
  
Unrealized
(Losses)
 
  
Estimated
Fair
Value
 
 
  
(Unaudited)
 
U.S. Government Agency Securities
    $ 101,673      $ 1      $ (8 )     $ 101,666  
Certificates of Deposit
      25,500        —          —          25,500  
Commercial Paper
      66,454        5        (6 )       66,453  
Corporate Notes/Bonds
      177,437        141        (39 )       177,539  
    
 
 
     
 
 
     
 
 
     
 
 
  
     $ 371,064      $ 147      $ (53 )     $ 371,158  
    
 
 
     
 
 
     
 
 
     
 
 
  
 
    
December 31, 2020
  
    
Amortized
Cost
     
Unrealized
Gains
     
Unrealized
(Losses)
     
Estimated
Fair
Value
  
U.S. Government Agency Securities
    $ 259,304      $ 3      $ (31 )     $ 259,276  
Certificates of Deposit
      10,500        —          —          10,500  
Commercial Paper
      124,368        23        (21 )       124,370  
Corporate Notes/Bonds
      202,749        624        (117 )       203,256  
    
 
 
     
 
 
     
 
 
     
 
 
  
     $ 596,921      $ 650      $ (169 )     $ 597,402  
    
 
 
     
 
 
     
 
 
     
 
 
  
The Company has classified all of its investment securities as
available-for-sale,
including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2021 and December 31, 2020, the Company held $54.9 million and $188.5 million, respectively, of
available-for-sale
investment securities with contractual maturity dates more than one year and less than two years.
 
The Company monitors its investment portfolio for overall risk, specifically credit risk loss, quarterly or more frequently if circumstances warrant. The Company would estimate the expected credit loss over the lifetime of the asset and record an allowance for the portion of the amortized cost basis of the financial asset that the Company does not expect to collect.
The aggregate related fair value of investments with unrealized losses as of September 30, 2021 was $165.3 million, which consisted of $46.5 million from U.S. government agency securities, $40.0 million of commercial paper, and $78.8 million of corporate notes/bonds. The aggregate amount of unrealized losses as of September 30, 2021 was approximately $53.5 thousand, which consisted of $7.9 thousand from U.S. government agency securities, $6.2 thousand from commercial paper, and $39.4 thousand from corporate notes/bonds. The $165.3 million aggregate fair value of investments with unrealized losses as of September 30, 2021 has been held in a continuous unrealized loss position for less than 12 months. As of December 31, 2020, the aggregate related fair value of investments with unrealized losses was $372.3 million and the aggregate amount of unrealized losses was approximately $169 thousand. The $372.3 million aggregate fair value of investments with unrealized losses as of December 31, 2020 had been held in a continuous unrealized loss position for less than 12 months.
The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.
Fair Value Measurements
The Company applies the fair value method under ASC Topic 820,
Fair Value Measurements and Disclosures
. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
 
  •  
Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
 
  •  
Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
 
  •  
Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy.
The Company has no assets or liabilities that were measured using quoted prices for significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2021 or December 31, 2020. The carrying value of cash held in money market funds of approximately $88.2 million as of September 30, 2021 and $27.9 million as of December 31, 2020 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in commercial paper of approximately $7.0 million as of September 30, 2021 is included in cash and cash equivalents.
 
The fair value measurements of the Company’s cash equivalents and
available-for-sale
investment securities are identified in the following tables (in thousands):
 
           
Fair Value Measurements at
Reporting Date Using
  
    
September 30,
2021
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 88,250      $ 88,250      $ —        $ —    
U.S. Government Agency Securities
      101,666        —          101,666        —    
Certificates of Deposit
      25,500        —          25,500        —    
Commercial Paper
      73,452        —          73,452        —    
Corporate Notes/Bonds
      177,539        —          177,539        —    
    
 
 
     
 
 
     
 
 
     
 
 
  
 
  
$
 466,407
 
  
$
 88,250
 
  
$
 378,157
 
  
$
 —
  
 
    
 
 
     
 
 
     
 
 
     
 
 
  
     
           
Fair Value Measurements at

Reporting Date Using
  
    
December 31,
2020
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 27,917      $ 27,917      $ —        $ —    
U.S. Government Agency Securities
      259,276        —          259,276        —    
Certificates of Deposit
      10,500        —          10,500        —    
Commercial Paper
      124,370        —          124,370        —    
Corporate Notes/Bonds
      203,256        —          203,256        —    
    
 
 
     
 
 
     
 
 
     
 
 
  
 
  
$
 625,319
 
  
$
 27,917
 
  
$
 597,402
 
  
$
—  
 
    
 
 
     
 
 
     
 
 
     
 
 
  
Financial Instruments
The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, right of use asset, net, other assets, accounts payable, accrued liabilities, accrued employee benefits and lease liabilities, short-term, to approximate their fair value because of their relatively short maturities at September 30, 2021 and December 31, 2020. Management believes that the risks associated with its financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing.
Restricted Cash
Restricted cash is collateral used under the letter of credit arrangement for the vehicle lease agreement. The Company adopted ASU
No. 2016-18,
“Restricted Cash” (“ASU
2016-18”)
and presents restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows.
Accounts Receivable, Net
The Company’s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees.
The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers’ credit profiles. The Company reserves against accounts receivable for estimated losses that may arise from a customer’s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated collectability losses was not significant as of September 30, 2021 and December 31, 2020.
 
We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a credit loss reserve against uncollectible accounts receivable as necessary. We extend credit primarily to pharmaceutical wholesale distributors. Customer creditworthiness is monitored and collateral is not required. Historically, we have not experienced credit losses on our accounts receivable and as of September 30, 2021 and December 31, 2020, our credit loss reserve on receivables was not material.
Concentration of Credit Risk
Financial instruments which potentially subject th
e
 Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the nine-month period ended September 30, 2021, all of the Company’s accounts receivable, net arose from product sales in the United States and all customers have standard payment terms which generally require payment within 60 days. For the nine-month period ended September 30, 2021, 96% of sales were generated from three major industry wholesalers which accounted for approximately 40%, 29%, and 27% of product sales, respectively. As of September 30, 2021, the Company believes that such customers are of high credit quality. The percentage of the total net product sales by individual customers has not significantly changed since inception.
Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.
Inventory
The Company values its inventories at the lower of cost or estimated net realizable value. Inventories consist of raw materials (active pharmaceutical ingredients (“API”), drug product, and packaged product in saleable condition). The consumption of raw materials during production is classified as work in process until saleable. Once it is determined to be in saleable condition, inventory is classified as finished goods. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a
first-in,
first-out
(“FIFO”) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales.
The Company capitalizes inventory costs associated with the Company’s products after regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets when identified in the manufacturing process, and is then expensed to selling, general and administrative expenses when the sample product is distributed.
Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs.
Property and Equipment
Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred.
When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC Topic 360,
Property, Plant and Equipment
. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date.
 
Revenue Recognition
Effective January 1, 2018, the Company adopted ASC Topic 606,
 Revenue from Contracts with Customers
(“ASC Topic 606”). The Company did not generate any product related revenue prior to January 1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact on the Company’s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service. The reported results for the three and nine-month periods ended September 30, 2021 and 2020 reflect the application of ASC Topic 606.
To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see
Product Sales, Net
(below).
To date, the Company’s only source of product sales has been from sales of CAPLYTA in the United States, which the Company began shipping to customers in March 2020.
Product Sales, Net
The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company’s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the Customer obtains control of the Company’s product, which occurs at a point in time (upon delivery). Product revenues are recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue.
Reserves for Variable Consideration
Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company’s sales of its product.
These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include the Company’s best estimates that take into consideration a range of possible outcomes which are considered more likely in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, and forecasted customer buying and payment patterns. The Company’s estimates regarding the payer mix for CAPLYTA are based on historical industry information regarding the payer mix for comparable pharmaceutical products and product portfolios, in particular, information related to similar products in their initial launch stages and through the use of historical information experienced in CAPLYTA’s launch period.
The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined it was probable that a significant reversal of revenue would not occur in a future period for the estimates detailed below as of September 30, 2021 and 2020, and, therefore, the transaction price was not reduced further during the three and nine-month periods ended September 30, 2021 and 2020. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known.
Trade Discounts and Allowances
— The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct
 
from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of product sales, net within the condensed consolidated statements of operations for the three and nine-month periods ended September 30, 2021 and 2020, as well as a reduction to accounts receivable, net on the condensed consolidated balance sheets.
Product Returns
— Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product’s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any expired product returns to date.
Provider Chargebacks and Discounts
— Chargebacks fo
r
 fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who purchase the product directly from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting
period-end
that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the three and nine-month periods ended September 30, 2021 and 2020, these amounts were not significant.
Government Rebates
— The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.
Payer Rebates
— The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Other Incentives
— Other incentives which the Company offers include voluntary patient assistance programs, such as the
co-pay
assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug
co-payments
required by payers. The calculation of the accrual for
co-pay
assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company applies the claims for vouchers for product that is in the distribution channel and reduces recognized revenue accordingly.
The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.
 
Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the condensed consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.​​​​​​​
Cost of Product Sales
Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs).
For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The related royalties are recorded within cost of product sales on the condensed statement of operations.
Prior to FDA approval of CAPLYTA, the Company expensed all costs associated with the manufacturing of lumateperone as part of research and development expenses. From December 20, 2019, the date of approval of CAPLYTA, through December 31, 2019 there was no production of inventory and therefore, no inventory costs were incurred. Therefore, at December 31, 2019, no inventory costs had been capitalized. The cost of product sales in the three and nine-month periods ended September 30, 2021 and 2020, are lower than incurred due to the previously expensed inventory.
Research and Development, Including Clinical Trial Expenses
Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees.
Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred, among other factors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated balance sheets as prepaid or accrued research and development expense, as the case may be.
As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate clinical trial expenses in its condensed consolidated statement of operations by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period.
Advertising Expense
In connection with the FDA approval of CAPLYTA in 2019, the Company began to incur advertising costs in connection with the subsequent commercial launch of CAPLYTA in 2020. Advertising costs are expensed when services are rendered. Advertising expense for the three and nine months ended September 30, 2021 was $23.2 million and $57.4 million, respectively, as compared to $13.2 million and $18.6 million, respectively, for the three and nine months ended September 30, 2020, related to the Company’s marketed product, CAPLYTA.
 
Income Taxes
Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities o
f
 a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740 (previously included in FASB Interpretation No. 48,
Accounting for Uncertainty in Income Taxes—an Interpretation of FASB Statement No.
 109
). Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a
more-likely-than-not
threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.
The Company’s effective tax rate for the three and nine months ended September 30, 2021 and 2020 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit.
On March 27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (“CARES”) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (“AMT”) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, and a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the year ended December 31, 2020. The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of approximately $265,000 to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December 31, 2019 and received the refund in July 2020.
On March 11, 2021, the American Rescue Plan Act of 2021 (“ARPA 2021”) was signed into law. ARPA 2021 included various income and payroll tax provisions. The Company has analyzed the tax provisions of ARPA 2021 and determined they have no significant financial impact to the Company’s condensed consolidated financial statements.
Comprehensive Loss
All components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are incurred. Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or (losses) on its investment securities in a separate statement of comprehensive loss for each period.
Share-Based Compensation
Share-based payments for stock options are accounted for in accordance with the provisions of ASC Topic 718,
Compensation—Stock Compensation
. The fair value of share-based payments is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the “Black-Scholes model”). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.
For all awards granted with time-based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 accounts for forfeitures as they occur.
The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.
Expected volatility rates for quarterly periods prior to December 31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company’s common stock. Beginning in the fourth quarter of 2019, expected volatility rates have been based entirely on the historical volatility of the Company’s
 
common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the “simplified method,” which defines expected life as the midpoint between the vesting date and the end of the contractual term.
The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company’s common stock on the date of grant.
A restricted stock unit (“RSU”) is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company’s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company.
In the first quarter of 2020, the Company granted performance-based RSUs for 86,000 shares of common stock, which vest based on the achievement of certain milestones that include (i) the approval of a planned NDA by the FDA (the “2020 Milestone RSUs”) and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2020 TSR RSUs”). The 2020 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements.
In the first quarter of 2021, the Company granted performance-based RSUs for 64,518 shares of common stock, which vest based on the achievement of certain milestones that include (i) certain operational milestones (the “2021 Milestone RSUs”, and collectively with the 2020 Milestone RSUs, the “Milestone RSUs”) and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2021 TSR RSUs,” and collectively with the 2020 TSR RSUs, the “TSR RSUs”). The 2021 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements.
Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic 740,
Income Taxes
. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance.
Equity instruments issued to
non-employees
for services are accounted for under the provisions of ASC Topic 718 and ASC Topic
505-50,
Equity/Equity-Based Payments to
Non-Employees
. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the required services are completed and are marked to market during the service period.
In June 2018, the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company’s stockholders approved the Company’s 2018 Amended and Restated Equity Incentive Plan pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants.
In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement Award Plan (the “2019 Inducement Plan”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of September 30, 2021, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan.
Loss Per Share
Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants and RSUs.
 
The following awards were excluded in th
e
 calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2021 and 2020:
 
 
  
Three and Nine Months Ended
September 30,
 
 
  
2021
 
  
2020
 
Stock options
      5,952,252        5,964,135  
RSUs
      1,601,273        1,702,538  
TSR RSUs
      68,598        43,022  
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Inventory
 9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Inventory
3. Inventory
Inventory consists of the following:
 
    
September 30,
2021
      December 31,
2020		  
Raw materials
   
$
2,182,261
 
    $ 2,483,801  
Work in process
   
 
3,444,013
 
      1,781,101  
Finished goods
   
 
2,540,661
 
      2,791,483  
    
 
 
     
 
 
  
    
$
8,166,935
 
    $ 7,056,385  
    
 
 
     
 
 
  
Inventory acquired prior to receipt of the FDA approval on December 20, 2019 for CAPLYTA was expensed as research and development expense as incurred.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment
 9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment
4. Property and Equipment
Property and equipment consist of the following:
 
    
September 30,
2021
      December 31,
2020		  
Computer equipment
   
$
408,751
 
    $ 243,532  
Furniture and fixtures
   
 
423,097
 
      423,097  
Scientific equipment
   
 
4,287,228
 
      4,127,951  
Leasehold improvement
s
   
 
1,240,315
 
      1,240,315  
    
 
 
     
 
 
  
    
 
6,359,391
 
      6,034,895  
Less accumulated depreciation
   
 
(4,423,083
) 
      (4,036,549 ) 
    
 
 
     
 
 
  
    
$
1,936,308
 
    $ 1,998,346  
    
 
 
     
 
 
  
Depreciation expense for the three and nine months ended September 30, 2021 was $133,945 and $386,534, respectively, as compared to $121,044 and $402,146 for the three and nine months ended September 30, 2020, respectively.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses and Other Current Liabilities
 9 Months Ended
Sep. 30, 2021
Accrued Liabilities and Other Liabilities [Abstract]  
Accrued Expenses and Other Current Liabilities
5. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities as of September 30, 2021 and December 31, 2020 consisted of the following:
 
    
September 30, 2021
     
December 31, 2020
  
Accrued expenses
    $ 12,144,235      $ 7,896,942  
Medicaid rebates
      3,226,394        1,998,953  
Other revenue related accruals
      1,558,040        1,006,222  
    
 
 
     
 
 
  
Total accrued expenses and other current liabilities
    $ 16,928,669      $ 10,902,117  
    
 
 
     
 
 
  
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Right of Use Assets and Lease Liabilities
 9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Right of Use Assets and Lease Liabilities
6. Right of Use Assets and Lease Liabilities
Real Estate Leases
In 2014, the Company entered into a long-term lease with a related party which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASU
2016-02
for accounting purposes. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In February 2019, the Company entered into a long-term lease for office space in Towson, Maryland beginning March 1, 2019. The lease has a term of 3.2 years ending in April 2022 and includes limited rent abatement and escalation provisions. The Company has no other significant leases. In addition, no identified leases require allocations between lease and
non-lease
components.
In adopting ASU
2016-02
as of January 1, 2019, the Company elected the package of practical expedients, which permit the Company not to reassess under the new standard the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the consolidated balance sheets. The Company also elected the lessee component election, allowing the Company to account for the lease and
non-lease
components as a single lease component. In determining whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. The Company recognized those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. The Company uses the rate implicit in the contract whenever possible when determining the applicable discount rate. As the majority of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. On the lease commencement dates, the Company estimated the lease liabilities and the right of use assets at present value using its applicable incremental borrowing rates of its two long-term leases of 7.2% for the Company’s Maryland lease of 3.2 years and 9.1% for the Company’s New York leases of 14.3 years. On January 1, 2019, upon adoption of ASU
2016-02,
the Company recorded right of use assets of approximately $20.2 million, lease liabilities of $23.4 million and eliminated deferred rent of $3.2 million. At the execution of the Maryland lease in 2019, the Company recorded a right of use asset and a lease liability of $0.2 million, which represented a
non-cash
transaction.
Maturity analysis under the lease agreements are as follows:
 
Three months ending December 31, 2021
    $ 871,321  
Year ending December 31, 2022
      3,491,166  
Year ending December 31, 2023
      3,566,466  
Year ending December 31, 2024
      3,675,196  
Year ending December 31, 2025
      3,787,248  
Thereafter
      13,839,791  
    
 
 
  
Total
      29,231,188  
Less: Present value discount
      (8,505,190 ) 
    
 
 
  
Total Lease liability
      20,725,998  
    
 
 
  
Less: Current portion
      (3,322,657 ) 
    
 
 
  
Long-term lease liabilities
    $ 17,403,341  
    
 
 
  
Lease expense for the three and nine months ended September 30, 2021 was approximately $0.8 million and $2.5 million, respectively, as compared to approximately $0.8 million and $2.5 million, respectively, for the three and nine months ended September 30, 2020.
Vehicle Fleet Lease
On May 17, 2019, the Company entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to acquire motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The Company began leasing vehicles under the Vehicle Lease in March 2020.
The contractual period of each lease is 12 months, followed by
month-to-month
renewal periods. The Company estimates the lease term for each vehicle to be 30 months based on industry standards. The lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.4 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease. The $1.4 million is recorded as restricted cash on the condensed consolidated balance sheet.
The nature of the lease is one commonly referred to as “TRAC” lease, as it contains a terminal rental adjustment clause, or “TRAC clause.” The TRAC clause limits lessee
exposure, or likelihood of having a variable lease payment
due at lease termination. This variable lease payment amount would be any difference between the vehicle stipulated (capitalized) cost and the sum of the reserve and net proceeds from disposal as described in the Vehicle Lease. Further, the Lessor guarantees that the net proceeds will not be less than 20% of the vehicle capitalized cost in the first 12 months, and 30% of the vehicle capitalized cost at the beginning of subsequent
12-month
period increments.
Right of use asset an
d
 lease liability for the vehicle fleet lease was approximately $5.7 million and $7.3 million, respectively, as of September 30, 2021 and December 31, 2020. The vehicle leases entered into since March 2020 represent
non-cash
transactions. The total operating lease cost for the three and nine months ended September 30, 2021 was $583,142 and $1.8 million, respectively. The operating cash outflows related to vehicle fleet operating lease obligations for the nine months ended September 30, 2021 and 2020 were $1.8 million and $585,490, respectively.
The following table presents the Vehicle Lease balances within the condensed consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of September 30, 2021 and December 31, 2020:
 
Lease Assets and Liabilities – Fleet
  
Classification
 
  
September 30, 2021
 
 
December 31, 2020
 
Assets
                          
Right of use assets, net
      Operating lease right of use assets      $ 5,679,974     $ 7,295,515  
             
 
 
    
 
 
  
              $ 5,679,974     $ 7,295,515  
             
 
 
    
 
 
  
Liabilities
                          
Current
                          
Lease liabilities, short-term
      Operating lease liabilities      $ 2,759,397     $ 2,257,262  
Non-Current
                          
Lease liabilities
     
Non-current operating lease liabilities
        2,920,577       5,038,253  
             
 
 
    
 
 
  
Total lease liabilities
             $ 5,679,974     $  7,295,515  
             
 
 
    
 
 
  
Weighted average remaining lease term
               1.3 years       2.0 years  
Weighted average discount rate
               1.71 %      1.74 % 
The following table presents the maturity of the Company’s fleet lease liability as of September 30, 2021:
Time Period
 
Three months ending December 31, 2021
    $ 596,241  
Year ending December 31, 2022
      3,480,355  
Year ending December 31, 2023
      1,691,462  
Thereafter
      —    
    
 
 
  
Total
      5,768,058  
Less: Present value discount
      (88,084 ) 
    
 
 
  
Total operating lease liabilities
      5,679,974  
    
 
 
  
Less: Current portion
      (2,759,397 ) 
    
 
 
  
Long-term lease liabilities
    $ 2,920,577  
    
 
 
  
Right of use assets and lease liabilities for all operating leases were approximately $21.7 million and $26.4 million, respectively, as of September 30, 2021.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
7. Commitments and Contingencies
License and Royalty Commitments
On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and
know-how
of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds.
Under the agreement, the Company made an upfront payment of $1.0 million to BMS in 2005, a milestone payment of $1.25 million in December 2013, and a milestone payment of $1.5 million in December 2014 following the initiation of the Company’s first Phase 3 clinical trial for lumateperone for patients with exacerbated schizophrenia. Upon FDA acceptance of an NDA filing for lumateperone, the Company was obligated to pay BMS a $2.0 million milestone payment, which was paid in January 2019. The FDA approved the NDA filing on December 23, 2019 and as a result the Company accrued an additional milestone liability of $5.0 million in the fourth quarter of 2019 which was paid in January 2020. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of
non-royalty
payments made in consideration of any sublicense.
The agreement extends, and royalties are payable, on a
country-by-country
and
product-by-product
basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.
In September 2016, the Company transferred certain of its rights under the BMS agreement to its wholly owned subsidiary, ITI Limited. In connection with the transfer, the Company guaranteed ITI Limited’s performance of its obligations under the BMS agreement. The Company expensed approximately $1.1 million and $2.8 million, respectively, for the three and nine-month periods ended September 30, 2021, in cost of product sales to satisfy its obligation under the BMS agreement, in comparison to $0.4 million and $0.5 million, respectively, for the three and nine-month periods ended September 30, 2020.
Research and Other Commitments
As of September 30, 2021, the Company has committed to purchasing production campaigns for various raw materials and API from each of its supply vendors – Siegfried Evionnaz SA (“Siegfried”) and Lonza Ltd. (“Lonza”). The campaigns are expected to be received into inventory during 2022. The Company has a total commitment of $32.1 million related to these agreements. As of September 30, 2021, the Company had paid a deposit of $5.2 million and $4.3 million for the Siegfried and Lonza campaigns, respectively, which is recorded within prepaid expenses and other current assets. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan within the executed agreements.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation
 9 Months Ended
Sep. 30, 2021
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation
8. Share-Based Compensation
On June 18, 2018, the Company’s stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan provided for the granting of share-based awards, such as stock options, restricted common stock, RSUs and stock appreciation rights to employees, directors and consultants as determined by the Board of Directors. On May 27, 2020, the Company’s stockholders approved the Amended and Restated 2018 Equity Incentive Plan (the “Amended 2018 Plan”), which amended and restated the 2018 Plan. The Amended 2018 Plan provides for the granting of up to 6,500,000 additional share-based awards, such as stock options, restricted common stock, RSUs and stock appreciation rights to employees, directors and consultants as determined by the Board of Directors. In December 2019, the Company adopted the 2019 Inducement Award Plan (the “2019 Inducement Plan”) for the grant of equity awards of up to 1,000,000 shares of common stock to newly hired employees.
As of December 31, 2020, the total number of shares reserved under all equity plans was 17,787,390 and the Company had 7,459,117 shares available for future issuance under the Amended 2018 Plan and the 2019 Inducement Plan. Stock options granted under the 2018 Plan and the 2019 Inducement Plan may be either incentive stock options (“ISOs”) as defined by the Internal Revenue Code of 1986, as amended, or
non-qualified
stock options. The Board of Directors determines who will receive options, the vesting periods (which are generally one to three years) and the exercise prices of such options. Options have a maximum term of 10 years. The exercise price of stock options granted under the Amended 2018 Plan and the 2019 Inducement Plan must be at least equal to the fair market value of the common stock on the date of grant. The Company does not intend to issue any additional equity awards under the 2019 Inducement Plan.
 
Total share-based compensation expense related to all of th
e
 Company’s share-based awards, including stock options and RSUs to employees, directors and consultants, recognized during the three and nine months ended September 30, 2021 and 2020, was comprised of the following:
 
 
  
Three Months Ended September 30,
 
  
Nine Months Ended September 30,
 
 
  
2021
 
  
2020
 
  
2021
 
  
2020
 
Inventoriable costs
   
$
413,103
 
    $ 345,460     
$
1,212,943
 
    $ 996,802  
Research and development
   
 
2,769,561
 
      2,402,865     
 
7,153,803
 
      6,792,498  
General and administrative
   
 
6,347,605
 
      4,152,394     
 
16,558,664
 
      11,562,850  
    
 
 
     
 
 
     
 
 
     
 
 
  
Total share-based compensation expense
   
$
9,530,269
 
    $ 6,900,719     
$
24,925,410
 
    $ 19,352,150  
    
 
 
     
 
 
     
 
 
     
 
 
  
The following table describes the weighted-average assumptions used for calculating the value of options granted during the nine months ended September 30, 2021 and 2020:
 
    
2021
  
2020
Dividend yield
   
0%
   0%
Expected volatility
   
94.5%-94.9%
  
91.6%-92.7%
Weighted-average risk-free interest rate
   
0.86%
   1.31%
Expected term (in years)
   
5.9
   6.0
Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of September 30, 2021, and changes during the three-month period then ended, are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Exercise
Price
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      39,728      $ 17.18        9.2 years  
Options granted in 2021
      —          —             
Options exercised in 2021
      (4,347 )       19.98        9.2 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      35,381      $ 16.83        9.2 years  
    
 
 
     
 
 
           
Vested and expected to vest at September 30, 2021
      35,381      $ 16.83           
    
 
 
     
 
 
           
Exercisable at September 30, 2021
      4,658      $ 19.70        9.2 years  
    
 
 
     
 
 
           
Information regarding RSU awards under the 2019 Inducement Plan during the three-month period ended September 30, 2021 are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      251,867      $ 16.03        2.2 years  
Time based RSUs vested in 2021
      (82,355 )     $ 16.03        2.0 years  
Time based RSUs cancelled in 2021
      (16,023 )     $ 15.81        2.0 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      153,489      $ 16.05        2.0 years  
    
 
 
     
 
 
           
Vested and expected to vest at September 30, 2021
      153,489      $ 16.05           
    
 
 
     
 
 
           
Exercisable at September 30, 2021
      —        $ —             
    
 
 
     
 
 
           
As of September 30, 2021, the Company granted options and time based RSUs totaling 314,138 shares under the 2019 Inducement Plan. These grants were made in the first quarter of 2020 and the Company does not intend to grant any additional equity awards under the 2019 Inducement Plan.
 
Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of September 30, 2021, and changes during the nine-month period then ended, are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Exercise
Price
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      5,477,894      $ 18.43        6.6 years  
Options granted 2021
      670,250      $ 30.39        9.5 years  
Options exercised 2021
      (202,124 )     $ 17.28        6.2 years  
Options canceled or expired 2021
      (29,149 )     $ 18.66        8.0 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      5,916,871      $ 20.70        6.2 years  
    
 
 
     
 
 
           
Vested and expected to vest at September 30, 2021
      5,916,871      $ 20.70           
    
 
 
     
 
 
           
Exercisable at September 30, 2021
      4,212,172      $ 18.66        5.3 years  
    
 
 
     
 
 
           
The fair value of the time based RSUs and the Milestone RSUs is based on the closing price of the Company’s common stock on the date of grant. The fair value of the TSR RSUs was determined using the Monte Carlo simulation method. Information regarding the time based RSU activity and changes during the nine-month period ended September 30, 2021 are summarized as follows:
 
    
Number of
Shares
     
Weighted-Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      1,311,877      $ 18.77        1.7 years  
Time based RSUs granted in 2021
      710,318      $ 35.69        2.4 years  
Time based RSUs vested in 2021
      (614,838 )     $ 16.58        1.0 years  
Time based RSUs cancelled in 2021
      (28,171 )     $ 29.90        2.0 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      1,379,186      $ 27.80        1.7 years  
    
 
 
     
 
 
     
 
 
  
Information related to the Company’s Milestone RSUs and TSR RSUs during the nine-month period ended September 30, 2021 are summarized as follows:
 
    
Number of
Shares
     
Weighted-Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      72,678      $ 28.25        2.1 years  
Milestone RSUs and TSR RSUs granted in 2021
      64,518      $ 44.04        2.4 years  
Milestone RSUs and TSR RSUs vested in 2021
      —        $ —          0.0 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      137,196      $ 35.67        5.2 years  
    
 
 
     
 
 
     
 
 
  
The weighted average estimated fair value per share of the 2020 TSR RSUs granted was $32.56, and the 2021 TSR RSUs granted was $51.18, which were derived from Monte Carlo simulations. Significant assumptions utilized in estimating the value of the 2020 awards granted include an expected dividend yield of 0%, a risk-free rate of 1.4%, and expected volatility of 91.3%. Significant assumptions utilized in estimating the value of the 2021 awards granted include an expected dividend yield of 0%, a risk-free rate of 0.2%, and expected volatility of 95.8%. The 2020 TSR RSUs granted will entitle the grantee to receive a number of shares of the Company’s common stock determined over a three-year performance period ending and vesting after December 31, 2022 but before February 18, 2023, provided the grantee remained in the service of the Company on the settlement date. Similarly, the 2021 TSR
RSUs
granted will entitle the grantee to receive a number of shares of the Company’s common stock determined over a three-year performance period ending and vesting after December 31, 2023 but before February 23, 2024, provided the grantee remained in the service of the Company on the settlement date. The Company is expensing the cost of these awards ratably over the requisite service period. The number of shares for which the TSR RSUs will be settled is a percentage of shares for which the award is targeted and depends on the Company’s total shareholder returns, expressed as a percentile ranking of the Company’s total shareholder return as compared to the Company’s peer group. The number of shares for which the TSR RSUs will be settled will vary depending on the level of achievement of the goal. Total shareholder return will be determined by dividing the average share value of the Company’s common stock over the 30 trading days preceding the settlement date by the average share value of the Company’s common stock over the 30 trading days beginning on January 1, 2020 and 2021, accordingly, with a deemed reinvestment of any dividends declared during the performance period. The Company’s peer group included companies that compromised the Nasdaq Biotechnology Index at December 31, 2019 and 2020, respectively.
 
The Company recognized
non-cash
share-based compensation expense related to time based RSUs for the three and nine months ended September 30, 2021 of approximately $4.4 million and $12.3 million, respectively, as compared to $3.2 million and $8.9 million, respectively, for the three and nine months ended September 30, 2020. Total expense for all RSUs, including the time based and performance based RSUs, was $4.3 million and $12.6 million, respectively, for the three and nine months ended September 30, 2021, as compared to $3.4 million and $9.2 million, respectively, for the three and nine months ended September 30, 2020. As of September 30, 2021, there was approximately $29.5 million of unrecognized compensation costs related to unvested time based RSUs. As of September 30, 2021, there was $2.1 million and $1.3 million of unrecognized compensation costs related to unvested Milestone RSUs and TSR RSUs, respectively.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the condensed consolidated balance sheets.
Investment Securities
Investment Securities
Investment securities consisted of the following (in thousands):
 
 
  
September 30, 2021
 
 
  
Amortized
Cost
 
  
Unrealized
Gains
 
  
Unrealized
(Losses)
 
  
Estimated
Fair
Value
 
 
  
(Unaudited)
 
U.S. Government Agency Securities
    $ 101,673      $ 1      $ (8 )     $ 101,666  
Certificates of Deposit
      25,500        —          —          25,500  
Commercial Paper
      66,454        5        (6 )       66,453  
Corporate Notes/Bonds
      177,437        141        (39 )       177,539  
    
 
 
     
 
 
     
 
 
     
 
 
  
     $ 371,064      $ 147      $ (53 )     $ 371,158  
    
 
 
     
 
 
     
 
 
     
 
 
  
 
    
December 31, 2020
  
    
Amortized
Cost
     
Unrealized
Gains
     
Unrealized
(Losses)
     
Estimated
Fair
Value
  
U.S. Government Agency Securities
    $ 259,304      $ 3      $ (31 )     $ 259,276  
Certificates of Deposit
      10,500        —          —          10,500  
Commercial Paper
      124,368        23        (21 )       124,370  
Corporate Notes/Bonds
      202,749        624        (117 )       203,256  
    
 
 
     
 
 
     
 
 
     
 
 
  
     $ 596,921      $ 650      $ (169 )     $ 597,402  
    
 
 
     
 
 
     
 
 
     
 
 
  
The Company has classified all of its investment securities as
available-for-sale,
including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2021 and December 31, 2020, the Company held $54.9 million and $188.5 million, respectively, of
available-for-sale
investment securities with contractual maturity dates more than one year and less than two years.
 
The Company monitors its investment portfolio for overall risk, specifically credit risk loss, quarterly or more frequently if circumstances warrant. The Company would estimate the expected credit loss over the lifetime of the asset and record an allowance for the portion of the amortized cost basis of the financial asset that the Company does not expect to collect.
The aggregate related fair value of investments with unrealized losses as of September 30, 2021 was $165.3 million, which consisted of $46.5 million from U.S. government agency securities, $40.0 million of commercial paper, and $78.8 million of corporate notes/bonds. The aggregate amount of unrealized losses as of September 30, 2021 was approximately $53.5 thousand, which consisted of $7.9 thousand from U.S. government agency securities, $6.2 thousand from commercial paper, and $39.4 thousand from corporate notes/bonds. The $165.3 million aggregate fair value of investments with unrealized losses as of September 30, 2021 has been held in a continuous unrealized loss position for less than 12 months. As of December 31, 2020, the aggregate related fair value of investments with unrealized losses was $372.3 million and the aggregate amount of unrealized losses was approximately $169 thousand. The $372.3 million aggregate fair value of investments with unrealized losses as of December 31, 2020 had been held in a continuous unrealized loss position for less than 12 months.
The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.
Fair Value Measurements
Fair Value Measurements
The Company applies the fair value method under ASC Topic 820,
Fair Value Measurements and Disclosures
. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
 
  •  
Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
 
  •  
Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
 
  •  
Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy.
The Company has no assets or liabilities that were measured using quoted prices for significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2021 or December 31, 2020. The carrying value of cash held in money market funds of approximately $88.2 million as of September 30, 2021 and $27.9 million as of December 31, 2020 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in commercial paper of approximately $7.0 million as of September 30, 2021 is included in cash and cash equivalents.
 
The fair value measurements of the Company’s cash equivalents and
available-for-sale
investment securities are identified in the following tables (in thousands):
 
           
Fair Value Measurements at
Reporting Date Using
  
    
September 30,
2021
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 88,250      $ 88,250      $ —        $ —    
U.S. Government Agency Securities
      101,666        —          101,666        —    
Certificates of Deposit
      25,500        —          25,500        —    
Commercial Paper
      73,452        —          73,452        —    
Corporate Notes/Bonds
      177,539        —          177,539        —    
    
 
 
     
 
 
     
 
 
     
 
 
  
 
  
$
 466,407
 
  
$
 88,250
 
  
$
 378,157
 
  
$
 —
  
 
    
 
 
     
 
 
     
 
 
     
 
 
  
     
           
Fair Value Measurements at

Reporting Date Using
  
    
December 31,
2020
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 27,917      $ 27,917      $ —        $ —    
U.S. Government Agency Securities
      259,276        —          259,276        —    
Certificates of Deposit
      10,500        —          10,500        —    
Commercial Paper
      124,370        —          124,370        —    
Corporate Notes/Bonds
      203,256        —          203,256        —    
    
 
 
     
 
 
     
 
 
     
 
 
  
 
  
$
 625,319
 
  
$
 27,917
 
  
$
 597,402
 
  
$
—  
 
    
 
 
     
 
 
     
 
 
     
 
 
  
Financial Instruments
Financial Instruments
The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, right of use asset, net, other assets, accounts payable, accrued liabilities, accrued employee benefits and lease liabilities, short-term, to approximate their fair value because of their relatively short maturities at September 30, 2021 and December 31, 2020. Management believes that the risks associated with its financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing.
Restricted Cash
Restricted Cash
Restricted cash is collateral used under the letter of credit arrangement for the vehicle lease agreement. The Company adopted ASU
No. 2016-18,
“Restricted Cash” (“ASU
2016-18”)
and presents restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows.
Accounts Receivable, net
Accounts Receivable, Net
The Company’s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees.
The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers’ credit profiles. The Company reserves against accounts receivable for estimated losses that may arise from a customer’s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated collectability losses was not significant as of September 30, 2021 and December 31, 2020.
 
We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a credit loss reserve against uncollectible accounts receivable as necessary. We extend credit primarily to pharmaceutical wholesale distributors. Customer creditworthiness is monitored and collateral is not required. Historically, we have not experienced credit losses on our accounts receivable and as of September 30, 2021 and December 31, 2020, our credit loss reserve on receivables was not material.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments which potentially subject th
e
 Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the nine-month period ended September 30, 2021, all of the Company’s accounts receivable, net arose from product sales in the United States and all customers have standard payment terms which generally require payment within 60 days. For the nine-month period ended September 30, 2021, 96% of sales were generated from three major industry wholesalers which accounted for approximately 40%, 29%, and 27% of product sales, respectively. As of September 30, 2021, the Company believes that such customers are of high credit quality. The percentage of the total net product sales by individual customers has not significantly changed since inception.
Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.
Inventory
Inventory
The Company values its inventories at the lower of cost or estimated net realizable value. Inventories consist of raw materials (active pharmaceutical ingredients (“API”), drug product, and packaged product in saleable condition). The consumption of raw materials during production is classified as work in process until saleable. Once it is determined to be in saleable condition, inventory is classified as finished goods. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a
first-in,
first-out
(“FIFO”) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales.
The Company capitalizes inventory costs associated with the Company’s products after regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets when identified in the manufacturing process, and is then expensed to selling, general and administrative expenses when the sample product is distributed.
Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs.
Property and Equipment
Property and Equipment
Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred.
When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC Topic 360,
Property, Plant and Equipment
. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date.
Revenue Recognition
Revenue Recognition
Effective January 1, 2018, the Company adopted ASC Topic 606,
 Revenue from Contracts with Customers
(“ASC Topic 606”). The Company did not generate any product related revenue prior to January 1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact on the Company’s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service. The reported results for the three and nine-month periods ended September 30, 2021 and 2020 reflect the application of ASC Topic 606.
To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see
Product Sales, Net
(below).
To date, the Company’s only source of product sales has been from sales of CAPLYTA in the United States, which the Company began shipping to customers in March 2020.
Product Sales, Net
The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company’s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the Customer obtains control of the Company’s product, which occurs at a point in time (upon delivery). Product revenues are recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue.
Reserves for Variable Consideration
Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company’s sales of its product.
These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include the Company’s best estimates that take into consideration a range of possible outcomes which are considered more likely in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, and forecasted customer buying and payment patterns. The Company’s estimates regarding the payer mix for CAPLYTA are based on historical industry information regarding the payer mix for comparable pharmaceutical products and product portfolios, in particular, information related to similar products in their initial launch stages and through the use of historical information experienced in CAPLYTA’s launch period.
The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined it was probable that a significant reversal of revenue would not occur in a future period for the estimates detailed below as of September 30, 2021 and 2020, and, therefore, the transaction price was not reduced further during the three and nine-month periods ended September 30, 2021 and 2020. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known.
Trade Discounts and Allowances
— The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct
 
from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of product sales, net within the condensed consolidated statements of operations for the three and nine-month periods ended September 30, 2021 and 2020, as well as a reduction to accounts receivable, net on the condensed consolidated balance sheets.
Product Returns
— Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product’s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any expired product returns to date.
Provider Chargebacks and Discounts
— Chargebacks fo
r
 fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who purchase the product directly from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting
period-end
that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the three and nine-month periods ended September 30, 2021 and 2020, these amounts were not significant.
Government Rebates
— The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.
Payer Rebates
— The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Other Incentives
— Other incentives which the Company offers include voluntary patient assistance programs, such as the
co-pay
assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug
co-payments
required by payers. The calculation of the accrual for
co-pay
assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company applies the claims for vouchers for product that is in the distribution channel and reduces recognized revenue accordingly.
The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the condensed consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.​​​​​​​
Cost of Product Sales
Cost of Product Sales
Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs).
For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The related royalties are recorded within cost of product sales on the condensed statement of operations.
Prior to FDA approval of CAPLYTA, the Company expensed all costs associated with the manufacturing of lumateperone as part of research and development expenses. From December 20, 2019, the date of approval of CAPLYTA, through December 31, 2019 there was no production of inventory and therefore, no inventory costs were incurred. Therefore, at December 31, 2019, no inventory costs had been capitalized. The cost of product sales in the three and nine-month periods ended September 30, 2021 and 2020, are lower than incurred due to the previously expensed inventory.
Research and Development, including Clinical trial expenses
Research and Development, Including Clinical Trial Expenses
Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees.
Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred, among other factors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated balance sheets as prepaid or accrued research and development expense, as the case may be.
As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate clinical trial expenses in its condensed consolidated statement of operations by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period.
Advertising Expense
Advertising Expense
In connection with the FDA approval of CAPLYTA in 2019, the Company began to incur advertising costs in connection with the subsequent commercial launch of CAPLYTA in 2020. Advertising costs are expensed when services are rendered. Advertising expense for the three and nine months ended September 30, 2021 was $23.2 million and $57.4 million, respectively, as compared to $13.2 million and $18.6 million, respectively, for the three and nine months ended September 30, 2020, related to the Company’s marketed product, CAPLYTA.
Income Taxes
Income Taxes
Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities o
f
 a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740 (previously included in FASB Interpretation No. 48,
Accounting for Uncertainty in Income Taxes—an Interpretation of FASB Statement No.
 109
). Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a
more-likely-than-not
threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.
The Company’s effective tax rate for the three and nine months ended September 30, 2021 and 2020 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit.
On March 27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (“CARES”) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (“AMT”) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, and a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the year ended December 31, 2020. The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of approximately $265,000 to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December 31, 2019 and received the refund in July 2020.
On March 11, 2021, the American Rescue Plan Act of 2021 (“ARPA 2021”) was signed into law. ARPA 2021 included various income and payroll tax provisions. The Company has analyzed the tax provisions of ARPA 2021 and determined they have no significant financial impact to the Company’s condensed consolidated financial statements.
Comprehensive Loss
Comprehensive Loss
All components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are incurred. Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or (losses) on its investment securities in a separate statement of comprehensive loss for each period.
Share-Based Compensation
Share-Based Compensation
Share-based payments for stock options are accounted for in accordance with the provisions of ASC Topic 718,
Compensation—Stock Compensation
. The fair value of share-based payments is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the “Black-Scholes model”). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.
For all awards granted with time-based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 accounts for forfeitures as they occur.
The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.
Expected volatility rates for quarterly periods prior to December 31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company’s common stock. Beginning in the fourth quarter of 2019, expected volatility rates have been based entirely on the historical volatility of the Company’s
 
common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the “simplified method,” which defines expected life as the midpoint between the vesting date and the end of the contractual term.
The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company’s common stock on the date of grant.
A restricted stock unit (“RSU”) is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company’s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company.
In the first quarter of 2020, the Company granted performance-based RSUs for 86,000 shares of common stock, which vest based on the achievement of certain milestones that include (i) the approval of a planned NDA by the FDA (the “2020 Milestone RSUs”) and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2020 TSR RSUs”). The 2020 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements.
In the first quarter of 2021, the Company granted performance-based RSUs for 64,518 shares of common stock, which vest based on the achievement of certain milestones that include (i) certain operational milestones (the “2021 Milestone RSUs”, and collectively with the 2020 Milestone RSUs, the “Milestone RSUs”) and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2021 TSR RSUs,” and collectively with the 2020 TSR RSUs, the “TSR RSUs”). The 2021 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements.
Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic 740,
Income Taxes
. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance.
Equity instruments issued to
non-employees
for services are accounted for under the provisions of ASC Topic 718 and ASC Topic
505-50,
Equity/Equity-Based Payments to
Non-Employees
. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the required services are completed and are marked to market during the service period.
In June 2018, the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company’s stockholders approved the Company’s 2018 Amended and Restated Equity Incentive Plan pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants.
In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement Award Plan (the “2019 Inducement Plan”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of September 30, 2021, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan.
Loss Per Share
Loss Per Share
Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants and RSUs.
 
The following awards were excluded in th
e
 calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2021 and 2020:
 
 
  
Three and Nine Months Ended
September 30,
 
 
  
2021
 
  
2020
 
Stock options
      5,952,252        5,964,135  
RSUs
      1,601,273        1,702,538  
TSR RSUs
      68,598        43,022  
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Schedule of Investment Securities
Investment Securities
Investment securities consisted of the following (in thousands):
 
 
  
September 30, 2021
 
 
  
Amortized
Cost
 
  
Unrealized
Gains
 
  
Unrealized
(Losses)
 
  
Estimated
Fair
Value
 
 
  
(Unaudited)
 
U.S. Government Agency Securities
    $ 101,673      $ 1      $ (8 )     $ 101,666  
Certificates of Deposit
      25,500        —          —          25,500  
Commercial Paper
      66,454        5        (6 )       66,453  
Corporate Notes/Bonds
      177,437        141        (39 )       177,539  
    
 
 
     
 
 
     
 
 
     
 
 
  
     $ 371,064      $ 147      $ (53 )     $ 371,158  
    
 
 
     
 
 
     
 
 
     
 
 
  
 
    
December 31, 2020
  
    
Amortized
Cost
     
Unrealized
Gains
     
Unrealized
(Losses)
     
Estimated
Fair
Value
  
U.S. Government Agency Securities
    $ 259,304      $ 3      $ (31 )     $ 259,276  
Certificates of Deposit
      10,500        —          —          10,500  
Commercial Paper
      124,368        23        (21 )       124,370  
Corporate Notes/Bonds
      202,749        624        (117 )       203,256  
    
 
 
     
 
 
     
 
 
     
 
 
  
     $ 596,921      $ 650      $ (169 )     $ 597,402  
    
 
 
     
 
 
     
 
 
     
 
 
  
Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities
The fair value measurements of the Company’s cash equivalents and
available-for-sale
investment securities are identified in the following tables (in thousands):
 
           
Fair Value Measurements at
Reporting Date Using
  
    
September 30,
2021
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 88,250      $ 88,250      $ —        $ —    
U.S. Government Agency Securities
      101,666        —          101,666        —    
Certificates of Deposit
      25,500        —          25,500        —    
Commercial Paper
      73,452        —          73,452        —    
Corporate Notes/Bonds
      177,539        —          177,539        —    
    
 
 
     
 
 
     
 
 
     
 
 
  
 
  
$
 466,407
 
  
$
 88,250
 
  
$
 378,157
 
  
$
 —
  
 
    
 
 
     
 
 
     
 
 
     
 
 
  
     
           
Fair Value Measurements at

Reporting Date Using
  
    
December 31,
2020
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 27,917      $ 27,917      $ —        $ —    
U.S. Government Agency Securities
      259,276        —          259,276        —    
Certificates of Deposit
      10,500        —          10,500        —    
Commercial Paper
      124,370        —          124,370        —    
Corporate Notes/Bonds
      203,256        —          203,256        —    
    
 
 
     
 
 
     
 
 
     
 
 
  
 
  
$
 625,319
 
  
$
 27,917
 
  
$
 597,402
 
  
$
—  
 
    
 
 
     
 
 
     
 
 
     
 
 
  
Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share
The following awards were excluded in th
e
 calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2021 and 2020:
 
 
  
Three and Nine Months Ended
September 30,
 
 
  
2021
 
  
2020
 
Stock options
      5,952,252        5,964,135  
RSUs
      1,601,273        1,702,538  
TSR RSUs
      68,598        43,022  
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Inventory (Tables)
 9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current
Inventory consists of the following:
 
    
September 30,
2021
      December 31,
2020		  
Raw materials
   
$
2,182,261
 
    $ 2,483,801  
Work in process
   
 
3,444,013
 
      1,781,101  
Finished goods
   
 
2,540,661
 
      2,791,483  
    
 
 
     
 
 
  
    
$
8,166,935
 
    $ 7,056,385  
    
 
 
     
 
 
  
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment (Tables)
 9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and equipment consist of the following:
 
    
September 30,
2021
      December 31,
2020		  
Computer equipment
   
$
408,751
 
    $ 243,532  
Furniture and fixtures
   
 
423,097
 
      423,097  
Scientific equipment
   
 
4,287,228
 
      4,127,951  
Leasehold improvement
s
   
 
1,240,315
 
      1,240,315  
    
 
 
     
 
 
  
    
 
6,359,391
 
      6,034,895  
Less accumulated depreciation
   
 
(4,423,083
) 
      (4,036,549 ) 
    
 
 
     
 
 
  
    
$
1,936,308
 
    $ 1,998,346  
    
 
 
     
 
 
  
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses and Other Current Liabilities (Tables)
 9 Months Ended
Sep. 30, 2021
Accrued Liabilities and Other Liabilities [Abstract]  
Schedule of Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities as of September 30, 2021 and December 31, 2020 consisted of the following:
 
    
September 30, 2021
     
December 31, 2020
  
Accrued expenses
    $ 12,144,235      $ 7,896,942  
Medicaid rebates
      3,226,394        1,998,953  
Other revenue related accruals
      1,558,040        1,006,222  
    
 
 
     
 
 
  
Total accrued expenses and other current liabilities
    $ 16,928,669      $ 10,902,117  
    
 
 
     
 
 
  
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Right of Use Assets and Lease Liabilities (Tables)
 9 Months Ended
Sep. 30, 2021
Schedule Of Maturity Analysis Under Lease Agreements
Maturity analysis under the lease agreements are as follows:
 
Three months ending December 31, 2021
    $ 871,321  
Year ending December 31, 2022
      3,491,166  
Year ending December 31, 2023
      3,566,466  
Year ending December 31, 2024
      3,675,196  
Year ending December 31, 2025
      3,787,248  
Thereafter
      13,839,791  
    
 
 
  
Total
      29,231,188  
Less: Present value discount
      (8,505,190 ) 
    
 
 
  
Total Lease liability
      20,725,998  
    
 
 
  
Less: Current portion
      (3,322,657 ) 
    
 
 
  
Long-term lease liabilities
    $ 17,403,341  
    
 
 
  
Vehicle Fleet Lease [Member]  
Schedule Of Quantitative Information About Operating Leases
The following table presents the Vehicle Lease balances within the condensed consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of September 30, 2021 and December 31, 2020:
 
Lease Assets and Liabilities – Fleet
  
Classification
 
  
September 30, 2021
 
 
December 31, 2020
 
Assets
                          
Right of use assets, net
      Operating lease right of use assets      $ 5,679,974     $ 7,295,515  
             
 
 
    
 
 
  
              $ 5,679,974     $ 7,295,515  
             
 
 
    
 
 
  
Liabilities
                          
Current
                          
Lease liabilities, short-term
      Operating lease liabilities      $ 2,759,397     $ 2,257,262  
Non-Current
                          
Lease liabilities
     
Non-current operating lease liabilities
        2,920,577       5,038,253  
             
 
 
    
 
 
  
Total lease liabilities
             $ 5,679,974     $  7,295,515  
             
 
 
    
 
 
  
Weighted average remaining lease term
               1.3 years       2.0 years  
Weighted average discount rate
               1.71 %      1.74 % 
Schedule Of Maturity Analysis Under Lease Agreements
The following table presents the maturity of the Company’s fleet lease liability as of September 30, 2021:
Time Period
 
Three months ending December 31, 2021
    $ 596,241  
Year ending December 31, 2022
      3,480,355  
Year ending December 31, 2023
      1,691,462  
Thereafter
      —    
    
 
 
  
Total
      5,768,058  
Less: Present value discount
      (88,084 ) 
    
 
 
  
Total operating lease liabilities
      5,679,974  
    
 
 
  
Less: Current portion
      (2,759,397 ) 
    
 
 
  
Long-term lease liabilities
    $ 2,920,577  
    
 
 
  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2021
Total Stock-Based Compensation Expense
Total share-based compensation expense related to all of th
e
 Company’s share-based awards, including stock options and RSUs to employees, directors and consultants, recognized during the three and nine months ended September 30, 2021 and 2020, was comprised of the following:
 
 
  
Three Months Ended September 30,
 
  
Nine Months Ended September 30,
 
 
  
2021
 
  
2020
 
  
2021
 
  
2020
 
Inventoriable costs
   
$
413,103
 
    $ 345,460     
$
1,212,943
 
    $ 996,802  
Research and development
   
 
2,769,561
 
      2,402,865     
 
7,153,803
 
      6,792,498  
General and administrative
   
 
6,347,605
 
      4,152,394     
 
16,558,664
 
      11,562,850  
    
 
 
     
 
 
     
 
 
     
 
 
  
Total share-based compensation expense
   
$
9,530,269
 
    $ 6,900,719     
$
24,925,410
 
    $ 19,352,150  
    
 
 
     
 
 
     
 
 
     
 
 
  
Assumptions Used for Calculating Value of Options Granted
The following table describes the weighted-average assumptions used for calculating the value of options granted during the nine months ended September 30, 2021 and 2020:
 
    
2021
  
2020
Dividend yield
   
0%
   0%
Expected volatility
   
94.5%-94.9%
  
91.6%-92.7%
Weighted-average risk-free interest rate
   
0.86%
   1.31%
Expected term (in years)
   
5.9
   6.0
Stock Option Activity
Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of September 30, 2021, and changes during the nine-month period then ended, are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Exercise
Price
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      5,477,894      $ 18.43        6.6 years  
Options granted 2021
      670,250      $ 30.39        9.5 years  
Options exercised 2021
      (202,124 )     $ 17.28        6.2 years  
Options canceled or expired 2021
      (29,149 )     $ 18.66        8.0 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      5,916,871      $ 20.70        6.2 years  
    
 
 
     
 
 
           
Vested and expected to vest at September 30, 2021
      5,916,871      $ 20.70           
    
 
 
     
 
 
           
Exercisable at September 30, 2021
      4,212,172      $ 18.66        5.3 years  
    
 
 
     
 
 
           
Time Based Restricted Stock Units [Member]  
Summary of Information Regarding RSU Activity Information regarding the time based RSU activity and changes during the nine-month period ended September 30, 2021 are summarized as follows:
 
    
Number of
Shares
     
Weighted-Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      1,311,877      $ 18.77        1.7 years  
Time based RSUs granted in 2021
      710,318      $ 35.69        2.4 years  
Time based RSUs vested in 2021
      (614,838 )     $ 16.58        1.0 years  
Time based RSUs cancelled in 2021
      (28,171 )     $ 29.90        2.0 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      1,379,186      $ 27.80        1.7 years  
    
 
 
     
 
 
     
 
 
  
Milestone and Total Shareholder Return Restricted Stock Units [Member]  
Summary of Information Regarding RSU Activity
Information related to the Company’s Milestone RSUs and TSR RSUs during the nine-month period ended September 30, 2021 are summarized as follows:
 
    
Number of
Shares
     
Weighted-Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      72,678      $ 28.25        2.1 years  
Milestone RSUs and TSR RSUs granted in 2021
      64,518      $ 44.04        2.4 years  
Milestone RSUs and TSR RSUs vested in 2021
      —        $ —          0.0 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      137,196      $ 35.67        5.2 years  
    
 
 
     
 
 
     
 
 
  
Inducement Award Plan [Member]  
Stock Option Activity
Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of September 30, 2021, and changes during the three-month period then ended, are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Exercise
Price
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      39,728      $ 17.18        9.2 years  
Options granted in 2021
      —          —             
Options exercised in 2021
      (4,347 )       19.98        9.2 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      35,381      $ 16.83        9.2 years  
    
 
 
     
 
 
           
Vested and expected to vest at September 30, 2021
      35,381      $ 16.83           
    
 
 
     
 
 
           
Exercisable at September 30, 2021
      4,658      $ 19.70        9.2 years  
    
 
 
     
 
 
           
Summary of Information Regarding RSU Activity
Information regarding RSU awards under the 2019 Inducement Plan during the three-month period ended September 30, 2021 are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2020
      251,867      $ 16.03        2.2 years  
Time based RSUs vested in 2021
      (82,355 )     $ 16.03        2.0 years  
Time based RSUs cancelled in 2021
      (16,023 )     $ 15.81        2.0 years  
    
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2021
      153,489      $ 16.05        2.0 years  
    
 
 
     
 
 
           
Vested and expected to vest at September 30, 2021
      153,489      $ 16.05           
    
 
 
     
 
 
           
Exercisable at September 30, 2021
      —        $ —             
    
 
 
     
 
 
           
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Organization - Additional Information (Detail) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 15, 2020
Jan. 10, 2020
Sep. 12, 2019
Sep. 30, 2020
Dec. 31, 2020
Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]            
Initial public offering, Number of shares 12,666,667 10,000,000        
Initial public offering, Price per share $ 30.00 $ 29.50        
Common stock, shares issued         80,463,089 81,377,406
Net proceeds from the sale of common stock       $ 652,712,011 $ 17,900,000  
Common Stock [Member]            
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]            
Common stock, shares issued         742,791  
IPO [Member]            
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]            
Initial public offering, Gross proceeds $ 380,000,000.0 $ 295,000,000.0        
Initial public offering, Net proceeds $ 357,800,000 $ 277,000,000.0        
Maximum [Member]            
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]            
Universal shelf registration statement, effective date value     $ 350,000,000      
Net proceeds from the sale of common stock     75,000,000      
Maximum [Member] | Common Stock [Member]            
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]            
Universal shelf registration statement, effective date value     $ 75,000,000      
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Additional Information (Detail)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
USD ($)
shares
Mar. 31, 2021
shares
Sep. 30, 2020
USD ($)
Mar. 31, 2020
shares
Sep. 30, 2021
USD ($)
Segment
shares
Sep. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
shares
Dec. 31, 2020
USD ($)
May 31, 2020
shares
Mar. 27, 2020
USD ($)
Jun. 30, 2018
shares
Significant Accounting Policies [Line Items]                      
Number of operating segments | Segment         1            
Maturity of highly liquid investments         3 months            
Maturity of certificates of deposit, commercial paper, corporate notes and corporate bonds         more than three months            
Investment securities, available-for-sale $ 371,157,974       $ 371,157,974     $ 597,402,126      
Aggregate related fair value of investments with unrealized losses 165,300,000       165,300,000     372,300,000      
Investment securities aggregate amount of unrealized loss 53,500       53,500     169,000      
Investment securities, held in continuous unrealized loss position for less than 12 months               372,300,000      
Carrying value of cash held in money market funds $ 88,200,000       88,200,000     27,900,000      
Impairment losses recognized         $ 0            
Manufacturing Costs             $ 0        
Inventory Costs             $ 0        
Effective tax rate 0.00%   0.00%   0.00% 0.00%          
US statutory rate         21.00%            
Assumed expected dividend rate         0.00% 0.00%          
Commercial Paper, at Carrying Value $ 7,000,000.0       $ 7,000,000.0            
AMT Tax Credit [Member]                      
Significant Accounting Policies [Line Items]                      
Deferred Tax Assets, Gross                   $ 265,000  
CAPLYTA [Member]                      
Significant Accounting Policies [Line Items]                      
Advertising costs 23,200,000   $ 13,200,000   $ 57,400,000 $ 18,600,000          
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer one [Member]                      
Significant Accounting Policies [Line Items]                      
Concentration Risk, Percentage         40.00%            
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer two [Member]                      
Significant Accounting Policies [Line Items]                      
Concentration Risk, Percentage         29.00%            
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer three [Member]                      
Significant Accounting Policies [Line Items]                      
Concentration Risk, Percentage         27.00%            
U.S. Government Agency Securities [Member]                      
Significant Accounting Policies [Line Items]                      
Investment securities, available-for-sale 101,666,000       $ 101,666,000     259,276,000      
Aggregate related fair value of investments with unrealized losses 46,500,000       46,500,000            
Investment securities aggregate amount of unrealized loss 7,900       7,900            
Commercial Paper [Member]                      
Significant Accounting Policies [Line Items]                      
Investment securities, available-for-sale 66,453,000       66,453,000     124,370,000      
Aggregate related fair value of investments with unrealized losses 40,000,000.0       40,000,000.0            
Investment securities aggregate amount of unrealized loss 6,200       6,200            
Corporate Notes/Bonds [Member]                      
Significant Accounting Policies [Line Items]                      
Investment securities, available-for-sale 177,539,000       177,539,000     203,256,000      
Aggregate related fair value of investments with unrealized losses 78,800,000       78,800,000            
Investment securities aggregate amount of unrealized loss 39,400       39,400            
Significant Unobservable Inputs (Level 3) [Member]                      
Significant Accounting Policies [Line Items]                      
Assets measured using quoted prices 0       0     0      
Liabilities measured using quoted prices 0       0     0      
Contractual Maturity Dates More Than One Year and Less Than Two Years [Member]                      
Significant Accounting Policies [Line Items]                      
Investment securities, available-for-sale $ 54,900,000       $ 54,900,000     $ 188,500,000      
2018 Equity Incentive Plan [Member]                      
Significant Accounting Policies [Line Items]                      
Additional shares of common stock reserved for future equity grants | shares                 6,500,000   4,750,000
Inducement Award Plan [Member]                      
Significant Accounting Policies [Line Items]                      
Issuance of shares, Inducement Award Plan | shares             1,000,000        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares 314,138       314,138            
Performance Based Restricted Stock Units [Member]                      
Significant Accounting Policies [Line Items]                      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares   64,518   86,000              
Minimum [Member]                      
Significant Accounting Policies [Line Items]                      
Property and equipment, estimated useful life         3 months            
Minimum [Member] | Product [Member] | Bristol-Myers Squibb Company [Member]                      
Significant Accounting Policies [Line Items]                      
Royalty payment, percentage         5.00%            
Maximum [Member]                      
Significant Accounting Policies [Line Items]                      
Property and equipment, estimated useful life         5 years            
Maximum [Member] | Product [Member] | Bristol-Myers Squibb Company [Member]                      
Significant Accounting Policies [Line Items]                      
Royalty payment, percentage         9.00%            
Maximum [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                      
Significant Accounting Policies [Line Items]                      
Concentration Risk, Percentage         96.00% 96.00%          
Maximum [Member] | Inducement Award Plan [Member]                      
Significant Accounting Policies [Line Items]                      
Issuance of shares, Inducement Award Plan | shares             1,000,000        
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Schedule of Investment Securities (Detail) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 371,064,000 $ 596,921,000
Unrealized Gains 147,000 650,000
Unrealized (Losses) (53,000) (169,000)
Estimated Fair Value 371,157,974 597,402,126
U.S. Government Agency Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 101,673,000 259,304,000
Unrealized Gains 1,000 3,000
Unrealized (Losses) (8,000) (31,000)
Estimated Fair Value 101,666,000 259,276,000
Certificates of Deposit [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 25,500,000 10,500,000
Estimated Fair Value 25,500,000 10,500,000
Commercial Paper [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 66,454,000 124,368,000
Unrealized Gains 5,000 23,000
Unrealized (Losses) (6,000) (21,000)
Estimated Fair Value 66,453,000 124,370,000
Corporate Notes/Bonds [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 177,437,000 202,749,000
Unrealized Gains 141,000 624,000
Unrealized (Losses) (39,000) (117,000)
Estimated Fair Value $ 177,539,000 $ 203,256,000
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Fair Value, Measurements, Recurring [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities $ 466,407,000 $ 625,319,000
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 88,250,000 27,917,000
Fair Value, Measurements, Recurring [Member] | U.S. Government Agency Securities [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 101,666,000 259,276,000
Fair Value, Measurements, Recurring [Member] | Certificates of Deposit [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 25,500,000 10,500,000
Fair Value, Measurements, Recurring [Member] | Commercial Paper [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 73,452,000 124,370,000
Fair Value, Measurements, Recurring [Member] | Corporate Notes/Bonds [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 177,539,000 203,256,000
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 88,250,000 27,917,000
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 88,250,000 27,917,000
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 378,157,000 597,402,000
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | U.S. Government Agency Securities [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 101,666,000 259,276,000
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Certificates of Deposit [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 25,500,000 10,500,000
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Commercial Paper [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 73,452,000 124,370,000
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Corporate Notes/Bonds [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 177,539,000 203,256,000
Significant Unobservable Inputs (Level 3) [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 0 $ 0
Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities $ 0  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) - shares
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Stock options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Number of anti-dilutive securities excluded from computation of earnings per share 5,952,252 5,964,135
RSUs [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Number of anti-dilutive securities excluded from computation of earnings per share 1,601,273 1,702,538
Total Shareholder Return Restricted Stock Units [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Number of anti-dilutive securities excluded from computation of earnings per share 68,598 43,022
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Inventory - Schedule of Inventory, Current (Detail) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Raw materials $ 2,182,261 $ 2,483,801
Work in process 3,444,013 1,781,101
Finished goods 2,540,661 2,791,483
Total inventories $ 8,166,935 $ 7,056,385
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment - Property and Equipment (Detail) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross $ 6,359,391 $ 6,034,895
Less accumulated depreciation (4,423,083) (4,036,549)
Property Plant and Equipment Net 1,936,308 1,998,346
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross 408,751 243,532
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross 423,097 423,097
Scientific Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross 4,287,228 4,127,951
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross $ 1,240,315 $ 1,240,315
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Property, Plant and Equipment [Abstract]        
Depreciation $ 133,945 $ 121,044 $ 386,534 $ 402,146
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
AccruedLiabilitiesAndOtherLiabilities [Line Items]    
Total accrued expenses and other current liabilities $ 16,928,669 $ 10,902,117
Accrued expenses    
AccruedLiabilitiesAndOtherLiabilities [Line Items]    
Total accrued expenses and other current liabilities 12,144,235 7,896,942
Medicaid rebates    
AccruedLiabilitiesAndOtherLiabilities [Line Items]    
Total accrued expenses and other current liabilities 3,226,394 1,998,953
Other revenue related accruals    
AccruedLiabilitiesAndOtherLiabilities [Line Items]    
Total accrued expenses and other current liabilities $ 1,558,040 $ 1,006,222
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Right of Use Assets and Lease Liabilities - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2019
Dec. 31, 2020
Feb. 28, 2019
Jan. 01, 2019
Sep. 30, 2018
Right of use assets, net $ 21,710,677   $ 21,710,677     $ 24,324,762      
Net lease liabilities 26,400,000   26,400,000            
Operating lease expense 800,000 $ 800,000 2,500,000 $ 2,500,000          
Right of use assets obtained in exchange for operating lease liability     8,917,935 7,750,959 $ 200,000        
Operating Lease, Cost $ 583,142   $ 1,800,000            
Vehicle Fleet Lease [Member]                  
Operating lease discount rate 1.71%   1.71%     1.74%      
Right of use assets, net $ 5,679,974   $ 5,679,974     $ 7,295,515      
Net lease liabilities $ 5,679,974   $ 5,679,974     $ 7,295,515      
Term of long term lease 12 years   12 years            
Weighted average remaining lease term 1 year 3 months 18 days   1 year 3 months 18 days     2 years      
Operating lease cash outflows     $ 1,800,000 $ 585,490          
Restricted Cash $ 1,400,000   $ 1,400,000            
Percentage Of Minimum Net Proceeds Of Capitalized Costs In First Twelve Months     20.00%            
Percentage Of Minimum Net Proceeds Of Capitalized Costs Later Than Twelve Months     30.00%            
Vehicle Fleet Lease [Member] | Financial Standby Letter of Credit [Member]                  
Guarantee Obligations $ 1,400,000   $ 1,400,000            
Accounting Standards Update 2016-02 [Member]                  
Right of use assets, net               $ 20,200,000  
Net lease liabilities               23,400,000  
Eliminated deferred rent               $ 3,200,000  
NEW YORK                  
Term of long term lease                 14 years 3 months 18 days
NEW YORK | Accounting Standards Update 2016-02 [Member]                  
Operating lease discount rate               7.20%  
Weighted average remaining lease term               3 years 2 months 12 days  
MARYLAND                  
Term of long term lease             3 years 2 months 12 days    
MARYLAND | Accounting Standards Update 2016-02 [Member]                  
Operating lease discount rate               9.10%  
Weighted average remaining lease term               14 years 3 months 18 days  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Total Lease liability $ 26,400,000  
Less: Current portion (6,082,054) $ (5,541,802)
Long-term lease liabilities 20,323,918 $ 23,600,347
Real Estates Leases [Member]    
Three months ending December 31, 2021 871,321  
Year ending December 31, 2022 3,491,166  
Year ending December 31, 2023 3,566,466  
Year ending December 31, 2024 3,675,196  
Year ending December 31, 2025 3,787,248  
Thereafter 13,839,791  
Total 29,231,188  
Less: Present value discount (8,505,190)  
Total Lease liability 20,725,998  
Less: Current portion (3,322,657)  
Long-term lease liabilities $ 17,403,341  
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Lessee, Lease, Description [Line Items]    
Right of use assets, net $ 21,710,677 $ 24,324,762
Lease liabilities, short-term 6,082,054 5,541,802
Lease liabilities 20,323,918 23,600,347
Total Lease liability 26,400,000  
Vehicle Fleet Lease [Member]    
Lessee, Lease, Description [Line Items]    
Right of use assets, net 5,679,974 7,295,515
Lease liabilities, short-term 2,759,397 2,257,262
Lease liabilities 2,920,577 5,038,253
Total Lease liability $ 5,679,974 $ 7,295,515
Weighted average remaining lease term 1 year 3 months 18 days 2 years
Weighted average discount rate 1.71% 1.74%
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Lessee, Lease, Description [Line Items]    
Total Lease liability $ 26,400,000  
Less: Current portion (6,082,054) $ (5,541,802)
Long-term lease liabilities 20,323,918 23,600,347
Vehicle Fleet Lease [Member]    
Lessee, Lease, Description [Line Items]    
Three months ending December 31, 2021 596,241  
Year ending December 31, 2022 3,480,355  
Year ending December 31, 2023 1,691,462  
Thereafter 0  
Total 5,768,058  
Less: Present value discount (88,084)  
Total Lease liability 5,679,974 7,295,515
Less: Current portion (2,759,397) (2,257,262)
Long-term lease liabilities $ 2,920,577 $ 5,038,253
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 23, 2019
May 31, 2005
Dec. 31, 2014
Dec. 31, 2013
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Jan. 31, 2019
Purchase Commitment [Member]                    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]                    
Commitments         $ 32,100,000   $ 32,100,000      
Siegfried campaign [Member] | Purchase Commitment [Member]                    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]                    
Cash paid         5,200,000   5,200,000      
Lonza Campaign [Member] | Purchase Commitment [Member]                    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]                    
Cash paid         4,300,000   4,300,000      
Product [Member] | Bristol-Myers Squibb Company [Member]                    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]                    
Company made an upfront payment   $ 1,000,000.0                
Company made milestone payment     $ 1,500,000 $ 1,250,000            
Obliged to make milestone payments         14,750,000   $ 14,750,000     $ 2,000,000.0
License expiration period             through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product      
Cost of product sales         $ 1,100,000 $ 400,000 $ 2,800,000 $ 500,000    
Product [Member] | Bristol-Myers Squibb Company [Member] | Minimum [Member]                    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]                    
Royalty payment, percentage             5.00%      
Product [Member] | Bristol-Myers Squibb Company [Member] | Maximum [Member]                    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]                    
Royalty payment, percentage             9.00%      
Product [Member] | Bristol-Myers Squibb Company [Member] | National Democratic Alliance [Member]                    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]                    
Company remaining milestone payment $ 5,000,000.0                  
Product [Member] | Bristol-Myers Squibb Company [Member] | ITCI National Democratic Alliance Member [Member]                    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]                    
Payment of milestone amount                 $ 5,000,000.0  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares of common stock reserved for issuance         17,787,390  
Expected dividend yield     0.00% 0.00%    
Risk free interest rate     0.86% 1.31%    
2018 Equity Incentive Plan [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares of common stock reserved for issuance         7,459,117  
Additional Stock- based awards, grant     6,500,000      
Time Based Restricted Stock Units [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Unrecognized compensation costs related to unvested RSUs $ 29.5   $ 29.5      
Non-cash stock-based compensation expense recognized 4.4 $ 3.2 12.3 $ 8.9    
RSUs [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Non-cash stock-based compensation expense recognized $ 4.3 $ 3.4 $ 12.6 $ 9.2    
Stock Options [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Options, maximum term     10 years      
Stock Options [Member] | Minimum [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Options, vesting term     1 year      
Stock Options [Member] | Maximum [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Options, vesting term     3 years      
Inducement Award Plan [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Issuance of shares, Inducement Award Plan           1,000,000
Awards granted 314,138   314,138      
Inducement Award Plan [Member] | Maximum [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Issuance of shares, Inducement Award Plan           1,000,000
Total Shareholder Return Restricted Stock Units [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Options, vesting term     3 years      
Weighted average grant date fair value of stock options granted     $ 51.18   $ 32.56  
Unrecognized compensation costs related to unvested RSUs $ 1.3   $ 1.3      
Expected dividend yield     0.00%   0.00%  
Risk free interest rate     0.20%   1.40%  
Expected volatility     95.80%   91.30%  
Terms of award     Total shareholder return will be determined by dividing the average share value of the Company’s common stock over the 30 trading days preceding the settlement date by the average share value of the Company’s common stock over the 30 trading days beginning on January 1, 2020 and 2021, accordingly, with a deemed reinvestment of any dividends declared during the performance period      
Milestone And Total Shareholder Return Restricted Stock Units [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Unrecognized compensation costs related to unvested RSUs $ 2.1   $ 2.1      
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total share-based compensation expense $ 9,530,269 $ 6,900,719 $ 24,925,410 $ 19,352,150
Inventoriable costs [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total share-based compensation expense 413,103 345,460 1,212,943 996,802
Research and Development [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total share-based compensation expense 2,769,561 2,402,865 7,153,803 6,792,498
General and Administrative [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total share-based compensation expense $ 6,347,605 $ 4,152,394 $ 16,558,664 $ 11,562,850
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail)
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]    
Dividend yield 0.00% 0.00%
Expected volatility, minimum 94.50% 91.60%
Expected volatility, maximum 94.90% 92.70%
Weighted-average risk-free interest rate 0.86% 1.31%
Expected term (in years) 5 years 10 months 24 days 6 years
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail) - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding at beginning of period, Number of Shares 5,477,894  
Options granted, Number of Shares 670,250  
Options exercised, Number of Shares (202,124)  
Outstanding at end of period, Number of Shares 5,916,871 5,477,894
Vested and expected to vest at end of period, Number of Shares 5,916,871  
Exercisable at end of period, Number of Shares 4,212,172  
Outstanding at beginning of period, Weighted-Average Exercise Price $ 18.43  
Options granted, exercise price 30.39  
Options exercised, Weighted-Average Exercise Price 17.28  
Outstanding at end of period, Weighted-Average Exercise Price 20.70 $ 18.43
Vested and expected to vest at end of period, Weighted-Average Exercise Price 20.70  
Exercisable at end of period, Weighted-Average Exercise Price $ 18.66  
Options granted, Weighted-Average Contractual Life 9 years 6 months  
Outstanding at end of period, Weighted-Average Contractual Life 6 years 2 months 12 days 6 years 7 months 6 days
Options exercised, Weighted-Average Contractual Life 6 years 2 months 12 days  
Exercisable at end of period, Weighted-Average Contractual Life 5 years 3 months 18 days  
Inducement Award Plan [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding at beginning of period, Number of Shares 39,728  
Options granted, Number of Shares 0  
Options exercised, Number of Shares (4,347)  
Outstanding at end of period, Number of Shares 35,381 39,728
Vested and expected to vest at end of period, Number of Shares 35,381  
Exercisable at end of period, Number of Shares 4,658  
Outstanding at beginning of period, Weighted-Average Exercise Price $ 17.18  
Options granted, exercise price 0  
Options exercised, Weighted-Average Exercise Price 19.98  
Outstanding at end of period, Weighted-Average Exercise Price 16.83 $ 17.18
Vested and expected to vest at end of period, Weighted-Average Exercise Price 16.83  
Exercisable at end of period, Weighted-Average Exercise Price $ 19.70  
Options granted, Weighted-Average Contractual Life 9 years 2 months 12 days  
Outstanding at end of period, Weighted-Average Contractual Life 9 years 2 months 12 days  
Options exercised, Weighted-Average Contractual Life 9 years 2 months 12 days  
Exercisable at end of period, Weighted-Average Contractual Life 9 years 2 months 12 days  
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail) - Inducement Award Plan [Member] - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding at beginning of year, Number of Shares 251,867  
Time based RSU's vested, Number of Shares (82,355)  
Time based RSU's cancelled, Number of Shares (16,023)  
Outstanding at end of year, Number of Shares 153,489 251,867
Vested and expected to vest, Number of Shares 153,489  
Exercisable, Number of Shares 0  
Outstanding at beginning of year, Weighted-Average Grant Date Fair Value $ 16.03  
Time based RSU's vested, Weighted-Average Grant Date Fair Value 16.03  
Time based RSU's cancelled, Weighted-Average Grant Date Fair Value 15.81  
Outstanding at end of year, Weighted-Average Grant Date Fair Value 16.05 $ 16.03
Vested and expected to vest, Weighted- Average Exercise Price 16.05  
Exercisable, Weighted- Average Exercise Price $ 0  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms 2 years 2 years 2 months 12 days
Share Based Compensation by Share Based Payment Arrangement Other Than Options Vested Weighted Average Contractual Term of Instruments 2 years  
Share Based Compensation By Share Based Payment Arrangement Other Than Options Weighted Average Contractual Term Of Instruments Forefeited 2 years  
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation - Stock Options Activity (Detail) - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]    
Outstanding at beginning of period, Number of Shares 5,477,894  
Options granted, Number of Shares 670,250  
Options exercised, Number of Shares (202,124)  
Options canceled or expired, Number of Shares (29,149)  
Outstanding at end of period, Number of Shares 5,916,871 5,477,894
Vested or expected to vest at end of period, Number of Shares 5,916,871  
Exercisable at end of period, Number of Shares 4,212,172  
Outstanding at beginning of period, Weighted-Average Exercise Price $ 18.43  
Options granted, Weighted-Average Exercise Price 30.39  
Options exercised, Weighted-Average Exercise Price 17.28  
Options canceled or expired, Weighted-Average Exercise Price 18.66  
Outstanding at end of period, Weighted-Average Exercise Price 20.70 $ 18.43
Vested or expected to vest at end of period, Weighted-Average Exercise Price 20.70  
Exercisable at end of period, Weighted-Average Exercise Price $ 18.66  
Options granted, Weighted-Average Contractual Life 9 years 6 months  
Options exercised, Weighted-Average Contractual Life 6 years 2 months 12 days  
Options canceled or expired, Weighted-Average Contractual Life 8 years  
Outstanding at end of period, Weighted-Average Contractual Life 6 years 2 months 12 days 6 years 7 months 6 days
Exercisable at end of period, Weighted-Average Contractual Life 5 years 3 months 18 days  
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) - RSUs [Member] - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding at beginning of year, Number of Shares 1,311,877  
Time based RSU's granted, Number of Shares 710,318  
Time based RSU's vested, Number of Shares (614,838)  
Time based RSU's cancelled, Number of Shares (28,171)  
Outstanding at end of year, Number of Shares 1,379,186 1,311,877
Outstanding at beginning of year, Weighted-Average Grant Date Fair Value $ 18.77  
Time based RSU's granted, Weighted-Average Grant Date Fair Value 35.69  
Time based RSU's vested, Weighted-Average Grant Date Fair Value 16.58  
Time based RSU's cancelled, Weighted-Average Grant Date Fair Value 29.90  
Outstanding at end of year, Weighted-Average Grant Date Fair Value $ 27.80 $ 18.77
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms 1 year 8 months 12 days 1 year 8 months 12 days
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Average Remaining Contractual Terms 2 years 4 months 24 days  
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms 1 year  
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Average Remaining Contractual Terms 2 years  
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail) - Milestone and Total Shareholder Return Restricted Stock Units [Member] - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding at beginning of year, Number of Shares 72,678  
Milestone RSUs and TSR RSUs granted, Number of Shares 64,518  
Time based RSU's vested, Number of Shares 0  
Outstanding at end of year, Number of Shares 137,196 72,678
Outstanding at beginning of year, Weighted-Average Grant Date Fair Value $ 28.25  
Milestone RSUs and TSR RSUs granted, Weighted- Average Grant Date Fair Value 44.04  
Time based RSU's vested, Weighted-Average Grant Date Fair Value 0  
Outstanding at end of year, Weighted-Average Grant Date Fair Value $ 35.67 $ 28.25
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms 5 years 2 months 12 days 2 years 1 month 6 days
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms 0 years  
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Remaining Contractual Terms 2 years 4 months 24 days  
EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 58 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 220 329 1 false 60 0 false 7 false false R1.htm 1001 - Document - Cover Page Sheet http://www.intracellulartherapies.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 1007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 1008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Statements 8 false false R9.htm 1009 - Disclosure - Organization Sheet http://www.intracellulartherapies.com/role/Organization Organization Notes 9 false false R10.htm 1010 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 1011 - Disclosure - Inventory Sheet http://www.intracellulartherapies.com/role/Inventory Inventory Notes 11 false false R12.htm 1012 - Disclosure - Property and Equipment Sheet http://www.intracellulartherapies.com/role/PropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 1013 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 13 false false R14.htm 1014 - Disclosure - Right of Use Assets and Lease Liabilities Sheet http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities Right of Use Assets and Lease Liabilities Notes 14 false false R15.htm 1015 - Disclosure - Commitments and Contingencies Sheet http://www.intracellulartherapies.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 1016 - Disclosure - Share-Based Compensation Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensation Share-Based Compensation Notes 16 false false R17.htm 1017 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 1018 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 1019 - Disclosure - Inventory (Tables) Sheet http://www.intracellulartherapies.com/role/InventoryTables Inventory (Tables) Tables http://www.intracellulartherapies.com/role/Inventory 19 false false R20.htm 1020 - Disclosure - Property and Equipment (Tables) Sheet http://www.intracellulartherapies.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.intracellulartherapies.com/role/PropertyAndEquipment 20 false false R21.htm 1021 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilities 21 false false R22.htm 1022 - Disclosure - Right of Use Assets and Lease Liabilities (Tables) Sheet http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables Right of Use Assets and Lease Liabilities (Tables) Tables http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities 22 false false R23.htm 1023 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.intracellulartherapies.com/role/ShareBasedCompensation 23 false false R24.htm 1024 - Disclosure - Organization - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail Organization - Additional Information (Detail) Details 24 false false R25.htm 1025 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 25 false false R26.htm 1026 - Disclosure - Summary of Significant Accounting Policies - Schedule of Investment Securities (Detail) Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail Summary of Significant Accounting Policies - Schedule of Investment Securities (Detail) Details 26 false false R27.htm 1027 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail) Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail) Details 27 false false R28.htm 1028 - Disclosure - Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) Details 28 false false R29.htm 1029 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) Sheet http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail Inventory - Schedule of Inventory, Current (Detail) Details 29 false false R30.htm 1030 - Disclosure - Property and Equipment - Property and Equipment (Detail) Sheet http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail Property and Equipment - Property and Equipment (Detail) Details 30 false false R31.htm 1031 - Disclosure - Property and Equipment - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/PropertyAndEquipmentAdditionalInformationDetail Property and Equipment - Additional Information (Detail) Details 31 false false R32.htm 1032 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) Sheet http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) Details 32 false false R33.htm 1033 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail Right of Use Assets and Lease Liabilities - Additional Information (Detail) Details 33 false false R34.htm 1034 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) Sheet http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) Details 34 false false R35.htm 1035 - Disclosure - Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) Sheet http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) Details 35 false false R36.htm 1036 - Disclosure - Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail) Sheet http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail) Details 36 false false R37.htm 1037 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 37 false false R38.htm 1038 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 38 false false R39.htm 1039 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) Details 39 false false R40.htm 1040 - Disclosure - Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail) Details 40 false false R41.htm 1041 - Disclosure - Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail) Details 41 false false R42.htm 1042 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail) Details 42 false false R43.htm 1043 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail Share-Based Compensation - Stock Options Activity (Detail) Details 43 false false R44.htm 1044 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) Details 44 false false R45.htm 1045 - Disclosure - Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail) Details 45 false false All Reports Book All Reports d132524d10q.htm d132524dex311.htm d132524dex312.htm d132524dex32.htm itci-20210930.xsd itci-20210930_cal.xml itci-20210930_def.xml itci-20210930_lab.xml itci-20210930_pre.xml http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 http://xbrl.sec.gov/stpr/2021 true true JSON 62 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d132524d10q.htm": { "axisCustom": 2, "axisStandard": 24, "contextCount": 220, "dts": { "calculationLink": { "local": [ "itci-20210930_cal.xml" ] }, "definitionLink": { "local": [ "itci-20210930_def.xml" ] }, "inline": { "local": [ "d132524d10q.htm" ] }, "labelLink": { "local": [ "itci-20210930_lab.xml" ] }, "presentationLink": { "local": [ "itci-20210930_pre.xml" ] }, "schema": { "local": [ "itci-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 448, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 2, "http://xbrl.sec.gov/dei/2021": 5, "total": 7 }, "keyCustom": 31, "keyStandard": 298, "memberCustom": 23, "memberStandard": 34, "nsprefix": "itci", "nsuri": "http://www.intracellulartherapies.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://www.intracellulartherapies.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Inventory", "role": "http://www.intracellulartherapies.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Property and Equipment", "role": "http://www.intracellulartherapies.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Accrued Expenses and Other Current Liabilities", "role": "http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Right of Use Assets and Lease Liabilities", "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities", "shortName": "Right of Use Assets and Lease Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Commitments and Contingencies", "role": "http://www.intracellulartherapies.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Share-Based Compensation", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Inventory (Tables)", "role": "http://www.intracellulartherapies.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Property and Equipment (Tables)", "role": "http://www.intracellulartherapies.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "itci:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "role": "http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "itci:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Right of Use Assets and Lease Liabilities (Tables)", "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables", "shortName": "Right of Use Assets and Lease Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P09_15_2020To09_15_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Organization - Additional Information (Detail)", "role": "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "shortName": "Organization - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P09_15_2020To09_15_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Segment", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:AvailableForSaleSecuritiesTextBlock", "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Summary of Significant Accounting Policies - Schedule of Investment Securities (Detail)", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail", "shortName": "Summary of Significant Accounting Policies - Schedule of Investment Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:AvailableForSaleSecuritiesTextBlock", "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail)", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "shortName": "Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail", "shortName": "Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Inventory - Schedule of Inventory, Current (Detail)", "role": "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail", "shortName": "Inventory - Schedule of Inventory, Current (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Property and Equipment - Property and Equipment (Detail)", "role": "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail", "shortName": "Property and Equipment - Property and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Property and Equipment - Additional Information (Detail)", "role": "http://www.intracellulartherapies.com/role/PropertyAndEquipmentAdditionalInformationDetail", "shortName": "Property and Equipment - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "role": "http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "itci:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021_AccruedLiabilitiesMemberusgaapBalanceSheetLocationAxis", "decimals": "0", "lang": null, "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Detail)", "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "shortName": "Right of Use Assets and Lease Liabilities - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)", "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "shortName": "Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis", "decimals": "0", "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)", "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail", "shortName": "Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail)", "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "shortName": "Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis", "decimals": "0", "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021_PurchaseCommitmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommitmentsAndContingencies", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P05_31_2005To05_31_2005_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis", "decimals": "INF", "lang": null, "name": "itci:CollaborativeAgreementUpfrontPayments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Share-Based Compensation - Additional Information (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "shortName": "Share-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail", "shortName": "Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail", "shortName": "Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1041 - Disclosure - Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail", "shortName": "Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021_InducementAwardPlanMemberusgaapAwardTypeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail", "shortName": "Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021_InducementAwardPlanMemberusgaapAwardTypeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1043 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "shortName": "Share-Based Compensation - Stock Options Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1044 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "shortName": "Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1045 - Disclosure - Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "shortName": "Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "0", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "0", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Organization", "role": "http://www.intracellulartherapies.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d132524d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 60, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "itci_AccruedliabilitiesandotherliabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AccruedLiabilitiesAndOtherLiabilities.", "label": "AccruedLiabilitiesAndOtherLiabilities [Line Items]" } } }, "localname": "AccruedliabilitiesandotherliabilitiesLineItems", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "itci_AccruedliabilitiesandotherliabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AccruedLiabilitiesAndOtherLiabilities", "label": "AccruedLiabilitiesAndOtherLiabilities [Table]" } } }, "localname": "AccruedliabilitiesandotherliabilitiesTable", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "itci_AmtTaxCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AMT tax credit.", "label": "AMT Tax Credit [Member]" } } }, "localname": "AmtTaxCreditMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_AvailableForSaleSecuritiesMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available For Sale Securities Maturity Period", "label": "Available For Sale Securities Maturity Period", "terseLabel": "Maturity of certificates of deposit, commercial paper, corporate notes and corporate bonds" } } }, "localname": "AvailableForSaleSecuritiesMaturityPeriod", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_BristolMyersSquibbCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bristol Myers Squibb company.", "label": "Bristol Myers Squibb Company [Member]", "terseLabel": "Bristol-Myers Squibb Company [Member]" } } }, "localname": "BristolMyersSquibbCompanyMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_CaplytaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Caplyta [Member]", "terseLabel": "CAPLYTA [Member]" } } }, "localname": "CaplytaMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_CashAndCashEquivalentMaximumMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash And Cash Equivalent Maximum Maturity Period", "label": "Cash And Cash Equivalent Maximum Maturity Period", "terseLabel": "Maturity of highly liquid investments" } } }, "localname": "CashAndCashEquivalentMaximumMaturityPeriod", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "itci_CollaborativeAgreementUpfrontPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement Upfront Payments", "label": "Collaborative Agreement Upfront Payments", "terseLabel": "Company made an upfront payment" } } }, "localname": "CollaborativeAgreementUpfrontPayments", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_CollaborativeArrangementAmountPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement amount payable.", "label": "Collaborative Arrangement Amount Payable", "terseLabel": "Obliged to make milestone payments" } } }, "localname": "CollaborativeArrangementAmountPayable", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_CollaborativeArrangementLicenseExpirationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement license expiration description.", "label": "Collaborative Arrangement License Expiration Description", "terseLabel": "License expiration period" } } }, "localname": "CollaborativeArrangementLicenseExpirationDescription", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_CollaborativeArrangementMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement Milestone Payments", "label": "Collaborative Arrangement Milestone Payments", "terseLabel": "Company made milestone payment" } } }, "localname": "CollaborativeArrangementMilestonePayments", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_CollaborativeArrangementRemainingPotentialMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement remaining potential milestone payments.", "label": "Collaborative Arrangement Remaining Potential Milestone Payments", "terseLabel": "Company remaining milestone payment" } } }, "localname": "CollaborativeArrangementRemainingPotentialMilestonePayments", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual Maturity More Than One Year And Less Than Two Years [Member]", "label": "Contractual Maturity More Than One Year And Less Than Two Years [Member]", "terseLabel": "Contractual Maturity Dates More Than One Year and Less Than Two Years [Member]" } } }, "localname": "ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_CostOfProductSales": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of product sales.", "label": "Cost Of Product Sales", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfProductSales", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "itci_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer one.", "label": "Customer One [Member]", "terseLabel": "Customer one [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer three.", "label": "Customer Three [Member]", "terseLabel": "Customer three [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer two.", "label": "Customer Two [Member]", "terseLabel": "Customer two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]", "label": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]", "terseLabel": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]" } } }, "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "itci_ITCINationalDemocraticAllianceMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ITCI national democratic alliance [member].", "label": "ITCI National Democratic Alliance Member [Member]", "terseLabel": "ITCI National Democratic Alliance Member [Member]" } } }, "localname": "ITCINationalDemocraticAllianceMemberMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease liabilitites, current.", "label": "Increase Decrease In Operating Lease Liabilitites Current", "terseLabel": "Lease liabilities, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilititesCurrent", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "itci_InducementAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inducement Award Plan [Member]", "terseLabel": "Inducement Award Plan [Member]" } } }, "localname": "InducementAwardPlanMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_InventoriableCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "InventoriableCostsMember.", "label": "Inventoriable costs [Member]", "terseLabel": "Inventoriable costs [Member]" } } }, "localname": "InventoriableCostsMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "itci_InventoryCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory costs.", "label": "Inventory Costs", "terseLabel": "Inventory Costs" } } }, "localname": "InventoryCosts", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_Investment1Axis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment1 [Axis]", "terseLabel": "Investment [Axis]" } } }, "localname": "Investment1Axis", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_Investment1Domain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment1 [Domain]", "terseLabel": "Investment [Domain]" } } }, "localname": "Investment1Domain", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_JanuaryTwoThousandAndTwentyInitialPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "January 2020 initial public offering.", "label": "January Two Thousand And Twenty Initial Public Offering [Member]", "terseLabel": "January 2020 [Member]" } } }, "localname": "JanuaryTwoThousandAndTwentyInitialPublicOfferingMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after Year four.", "label": "Lessee Operating Lease Liability Payments Due after Year Four", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "itci_LonzaCampaignMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lonza Campaign [Member].", "label": "Lonza Campaign [Member]", "terseLabel": "Lonza Campaign [Member]" } } }, "localname": "LonzaCampaignMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_MedicaidRebatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicaid rebates.", "label": "Medicaid rebates [Member]", "terseLabel": "Medicaid rebates" } } }, "localname": "MedicaidRebatesMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone and total shareholder return restricted stock units.", "label": "Milestone And Total Shareholder Return Restricted Stock Units [Member]", "terseLabel": "Milestone and Total Shareholder Return Restricted Stock Units [Member]", "verboseLabel": "Milestone And Total Shareholder Return Restricted Stock Units [Member]" } } }, "localname": "MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "domainItemType" }, "itci_NationalDemocraticAllianceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "National Democratic Alliance.", "label": "National Democratic Alliance [Member]", "terseLabel": "National Democratic Alliance [Member]" } } }, "localname": "NationalDemocraticAllianceMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_OtherRevenueRelatedAccrualsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other revenue related accruals.", "label": "Other Revenue Related Accruals [Member]", "terseLabel": "Other revenue related accruals" } } }, "localname": "OtherRevenueRelatedAccrualsMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "itci_PaymentOfMilestoneAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment of milestone amount.", "label": "Payment Of Milestone Amount", "terseLabel": "Payment of milestone amount" } } }, "localname": "PaymentOfMilestoneAmount", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of minimum net proceeds of capitalized costs in first twelve months.", "label": "Percentage Of Minimum Net Proceeds Of Capitalized Costs In First Twelve Months", "terseLabel": "Percentage Of Minimum Net Proceeds Of Capitalized Costs In First Twelve Months" } } }, "localname": "PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of minimum net proceeds of capitalized costs later than twelve months.", "label": "Percentage Of Minimum Net Proceeds Of Capitalized Costs Later Than Twelve Months", "terseLabel": "Percentage Of Minimum Net Proceeds Of Capitalized Costs Later Than Twelve Months" } } }, "localname": "PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "itci_PerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Based Restricted Stock Units [member]", "label": "Performance Based Restricted Stock Units [Member]", "terseLabel": "Performance Based Restricted Stock Units [Member]" } } }, "localname": "PerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_RealEstatesLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real estates lease.", "label": "Real Estates Lease [Member]", "terseLabel": "Real Estates Leases [Member]" } } }, "localname": "RealEstatesLeaseMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "domainItemType" }, "itci_ReasearchAndOtherCommitmentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reasearch and Other Commitment [Axis]" } } }, "localname": "ReasearchAndOtherCommitmentAxis", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_ReasearchAndOtherCommitmentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reasearch and Other Commitment [Domain]" } } }, "localname": "ReasearchAndOtherCommitmentDomain", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_RoyaltyPaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Payment Percentage", "label": "Royalty Payment Percentage", "terseLabel": "Royalty payment, percentage" } } }, "localname": "RoyaltyPaymentPercentage", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "itci_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Accrued Liabilities And Other Current Liabilities.", "label": "Schedule Of Accrued Liabilities And Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative information about operating leases.", "label": "Schedule Of Quantitative Information About Operating Leases [Table Text Block]", "terseLabel": "Schedule Of Quantitative Information About Operating Leases" } } }, "localname": "ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "itci_SecuritiesAuthorizedAmountForIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Securities Authorized Amount For Issuance", "label": "Securities Authorized Amount For Issuance", "terseLabel": "Universal shelf registration statement, effective date value" } } }, "localname": "SecuritiesAuthorizedAmountForIssuance", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options forfeited average remaining contractual terms.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Average Remaining Contractual Terms", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Average Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options granted average remaining contractual terms.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Average Remaining Contractual Terms", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Average Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants in period remaining contractual terms.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Remaining Contractual Terms", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and expected to vest, outstanding, number.", "label": "Share based Compensation Arrangement by Share based Payment Award Equity Instruments Other than Options Vested and Expected to Vest Outstanding Number", "terseLabel": "Vested and expected to vest, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested average remaining contractual terms.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Remaining Contractual Term", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Remaining Contractual Term", "terseLabel": "Options canceled or expired, Weighted-Average Contractual Life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award options grants in period weighted average remaining contractual term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term 2", "terseLabel": "Options granted, Weighted-Average Contractual Life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangements by share-based payment award options exercises in period weighted average remaining contractual term.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term", "terseLabel": "Options exercised, Weighted-Average Contractual Life" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsVestedWeightedAverageContractualTermOfInstruments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation By Share Based Payment Arrangement Other Than Options Vested Weighted Average Contractual Term Of Instruments.", "label": "Share Based Compensation By Share Based Payment Arrangement Other Than Options Vested Weighted Average Contractual Term Of Instruments", "terseLabel": "Share Based Compensation by Share Based Payment Arrangement Other Than Options Vested Weighted Average Contractual Term of Instruments" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsVestedWeightedAverageContractualTermOfInstruments", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation by share based payment arrangement other than options weighted average contractual term of instruments forfeited.", "label": "Share Based Compensation By Share Based Payment Arrangement Other Than Options Weighted Average Contractual Term Of Instruments Forefeited", "terseLabel": "Share Based Compensation By Share Based Payment Arrangement Other Than Options Weighted Average Contractual Term Of Instruments Forefeited" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "durationItemType" }, "itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable Number.", "label": "Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Exercisable Number", "terseLabel": "Exercisable, Number of Shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable Weighted Average Exercise Price.", "label": "Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Exercisable Weighted Average Exercise Price", "terseLabel": "Exercisable, Weighted- Average Exercise Price" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding Weighted Average Exercise Price.", "label": "Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Vested and Expected to Vest Outstanding Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest, Weighted- Average Exercise Price" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "itci_SiegfriedCampaignMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Siegfried campaign [Member].", "label": "Siegfried campaign [Member]", "terseLabel": "Siegfried campaign [Member]" } } }, "localname": "SiegfriedCampaignMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_TimeBasedRestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Time based restricted stock units.", "label": "Time Based Restricted Stock Units R S U [Member]", "terseLabel": "Time Based Restricted Stock Units [Member]" } } }, "localname": "TimeBasedRestrictedStockUnitsRSUMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "domainItemType" }, "itci_TotalShareholderReturnRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total shareholder return restricted stock units.", "label": "Total Shareholder Return Restricted Stock Units [Member]", "terseLabel": "Total Shareholder Return Restricted Stock Units [Member]", "verboseLabel": "Total Shareholder Return Restricted Stock Units [Member]" } } }, "localname": "TotalShareholderReturnRestrictedStockUnitsMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "domainItemType" }, "itci_TwoThousandEighteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Eighteen Equity Incentive Plan [Member]", "label": "Two Thousand Eighteen Equity Incentive Plan [Member]", "terseLabel": "2018 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandEighteenEquityIncentivePlanMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_VehicleFleetLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vehicle fleet lease.", "label": "Vehicle Fleet Lease [Member]", "terseLabel": "Vehicle Fleet Lease [Member]" } } }, "localname": "VehicleFleetLeaseMember", "nsuri": "http://www.intracellulartherapies.com/20210930", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r103", "r223", "r227", "r232", "r338", "r339", "r344", "r345", "r412", "r516" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r103", "r223", "r227", "r232", "r338", "r339", "r344", "r345", "r412", "r516" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r53", "r55", "r101", "r102", "r235", "r242" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r164", "r248", "r250", "r470" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r234", "r241", "r261", "r263", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r468", "r471", "r518", "r519" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r234", "r241", "r261", "r263", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r468", "r471", "r518", "r519" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r164", "r248", "r250", "r470" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r162", "r248", "r249", "r430", "r467", "r469" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r162", "r248", "r249", "r430", "r467", "r469" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r234", "r241", "r252", "r261", "r263", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r468", "r471", "r518", "r519" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r234", "r241", "r252", "r261", "r263", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r468", "r471", "r518", "r519" ], "lang": { "en-us": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r517" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r517" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r54", "r55", "r101", "r102", "r235", "r242" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r115", "r119", "r262" ], "lang": { "en-us": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r115", "r119", "r214", "r262", "r417" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r165", "r411" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "stpr_MD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MARYLAND" } } }, "localname": "MD", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "stpr_NY": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK" } } }, "localname": "NY", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r42", "r415" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r9", "r22", "r166", "r167" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r88" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premiums and discounts on investment securities, net" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r12", "r13", "r45" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued employee benefits" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued and other current liabilities", "verboseLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities [Abstract]" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r40", "r204" ], "calculation": { "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r25", "r57", "r58", "r59", "r456", "r479", "r483" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r59", "r67", "r68", "r69", "r105", "r106", "r107", "r343", "r474", "r475", "r532" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "verboseLabel": "Accumulated Comprehensive (Loss) Income [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r23" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r105", "r106", "r107", "r305", "r306", "r307", "r359" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r108", "r109", "r110", "r111", "r119", "r173", "r174", "r184", "r185", "r186", "r187", "r188", "r189", "r222", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r328", "r329", "r330", "r331", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r410", "r432", "r433", "r434", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r528", "r529", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r245", "r246", "r327" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature", "terseLabel": "Common shares issued receivable collected" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r264", "r266", "r311", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Expense" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising costs" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r266", "r297", "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Non-cash stock-based compensation expense recognized" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Number of anti-dilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r97", "r151", "r154", "r160", "r183", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r338", "r344", "r375", "r413", "r415", "r438", "r453" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r11", "r52", "r97", "r183", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r338", "r344", "r375", "r413", "r415" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets measured using quoted prices", "verboseLabel": "Available-for-sale investment securities" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r175" ], "calculation": { "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized (Losses)" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r179" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale in a continuous loss position.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss", "terseLabel": "Investment securities aggregate amount of unrealized loss" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value", "terseLabel": "Aggregate related fair value of investments with unrealized losses" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "Investment securities, held in continuous unrealized loss position for less than 12 months" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.", "label": "Available-for-sale Securities, Current", "terseLabel": "Estimated Fair Value", "verboseLabel": "Investment securities, available-for-sale" } } }, "localname": "AvailableForSaleSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Schedule of Investment Securities" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r267", "r299" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r37", "r415", "r486", "r487" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash paid" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r37", "r89" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r15", "r90" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r15", "r90", "r437" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r84", "r89", "r91" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r84", "r384" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of Deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingEstimateByTypeAxis": { "auth_ref": [ "r115", "r129" ], "lang": { "en-us": { "role": { "documentation": "Information by type of change in accounting estimate.", "label": "Change in Accounting Estimate by Type [Axis]" } } }, "localname": "ChangeInAccountingEstimateByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingEstimateTypeDomain": { "auth_ref": [ "r115", "r129" ], "lang": { "en-us": { "role": { "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.", "label": "Change in Accounting Estimate, Type [Domain]" } } }, "localname": "ChangeInAccountingEstimateTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r96", "r97", "r120", "r121", "r122", "r124", "r126", "r132", "r133", "r134", "r183", "r223", "r227", "r228", "r229", "r232", "r233", "r239", "r240", "r243", "r244", "r375", "r526" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Commercial Paper, at Carrying Value", "verboseLabel": "Commercial Paper, at Carrying Value" } } }, "localname": "CommercialPaperAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r47", "r213", "r441", "r460" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r210", "r211", "r212", "r215", "r504" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Additional shares of common stock reserved for future equity grants" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r105", "r106", "r359" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r245" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21", "r415" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.0001 par value: 175,000,000 and 100,000,000 shares authorized at September 30, 2021 and December 31, 2020, respectively; 81,377,406 and 80,463,089 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r62", "r64", "r65", "r74", "r445", "r463" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r141", "r142", "r164", "r373", "r374", "r503" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r141", "r142", "r164", "r373", "r374", "r485", "r503" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r141", "r142", "r164", "r373", "r374", "r485", "r503" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r137", "r452" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r141", "r142", "r164", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r141", "r142", "r164", "r373", "r374", "r503" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r253", "r260", "r484" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Notes/Bonds [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r76", "r97", "r183", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Product Sales" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r140", "r164" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.", "label": "Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance", "terseLabel": "Shares of common stock reserved for issuance" } } }, "localname": "DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredRentCredit": { "auth_ref": [ "r393", "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of rental payment required by lease over rental income recognized.", "label": "Deferred Rent Credit", "terseLabel": "Eliminated deferred rent" } } }, "localname": "DeferredRentCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r323" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Deferred Tax Assets, Gross" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r87", "r202" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/PropertyAndEquipmentAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic & Diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r127", "r128" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r98", "r320", "r333" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "US statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r298" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options", "terseLabel": "Unrecognized compensation costs related to unvested RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options [Member]", "verboseLabel": "Stock options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Scientific Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r67", "r68", "r69", "r105", "r106", "r107", "r109", "r116", "r118", "r131", "r187", "r245", "r246", "r305", "r306", "r307", "r330", "r331", "r359", "r385", "r386", "r387", "r388", "r389", "r391", "r474", "r475", "r476", "r532" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r362", "r363", "r364", "r369" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities" } } }, "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r236", "r237", "r238", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r363", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r362", "r363", "r366", "r367", "r370" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r236", "r253", "r254", "r259", "r260", "r363", "r418" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r236", "r237", "r238", "r253", "r254", "r259", "r260", "r363", "r419" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r236", "r237", "r238", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r363", "r420" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3) [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r236", "r237", "r238", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r368", "r370" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialStandbyLetterOfCreditMember": { "auth_ref": [ "r216", "r220" ], "lang": { "en-us": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation if defined events occur or fail to occur.", "label": "Financial Standby Letter of Credit [Member]", "terseLabel": "Financial Standby Letter of Credit [Member]" } } }, "localname": "FinancialStandbyLetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r194", "r196", "r198", "r200", "r431", "r435" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r194", "r197" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant [Member]", "terseLabel": "Grant revenue [Member]" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_GuaranteeObligationsByNatureAxis": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Information by nature of guarantee.", "label": "Guarantor Obligations, Nature [Axis]" } } }, "localname": "GuaranteeObligationsByNatureAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GuaranteeObligationsCurrentCarryingValue": { "auth_ref": [ "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.", "label": "Guarantor Obligations, Current Carrying Value", "terseLabel": "Guarantee Obligations" } } }, "localname": "GuaranteeObligationsCurrentCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteeObligationsNatureDomain": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees.", "label": "Guarantor Obligations, Nature [Domain]" } } }, "localname": "GuaranteeObligationsNatureDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r87", "r201", "r206" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use", "terseLabel": "Impairment losses recognized" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r71", "r151", "r153", "r156", "r159", "r161", "r436", "r442", "r446", "r465" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r207", "r209" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r99", "r117", "r118", "r150", "r319", "r332", "r334", "r466" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax (expense) benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r66", "r317", "r318", "r321", "r322", "r324", "r326" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r86" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r86" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r86" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued liabilities and other" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r86" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Long term deferred tax asset, net" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r86" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r86" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r195", "r199" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r195", "r199" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r29", "r192" ], "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r8", "r50", "r415" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r14", "r51", "r93", "r130", "r190", "r191", "r193", "r428" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r31", "r192" ], "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r30", "r192" ], "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r78", "r149" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r182", "r464" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investment Securities" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r87" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Stock issued for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Right of Use Assets and Lease Liabilities" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule Of Maturity Analysis Under Lease Agreements" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r407" ], "calculation": { "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Total", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three", "terseLabel": "Year ending December\u00a031, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two", "terseLabel": "Year ending December\u00a031, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "verboseLabel": "Year ending December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "verboseLabel": "Year ending December 31, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "verboseLabel": "Year ending December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "verboseLabel": "Year ending December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Three months ending December 31, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r407" ], "calculation": { "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of long term lease" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r44", "r97", "r155", "r183", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r339", "r344", "r345", "r375", "r413", "r414" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r28", "r97", "r183", "r375", "r415", "r440", "r458" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r46", "r97", "r183", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r339", "r344", "r345", "r375", "r413", "r414", "r415" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities measured using quoted prices" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ManufacturingCosts": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred in the production of goods for sale.", "label": "Manufacturing Costs" } } }, "localname": "ManufacturingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Carrying value of cash held in money market funds" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used) in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r84", "r85", "r88" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r60", "r63", "r69", "r72", "r88", "r97", "r108", "r112", "r113", "r114", "r115", "r117", "r118", "r123", "r151", "r153", "r156", "r159", "r161", "r183", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r361", "r375", "r443", "r461" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r151", "r153", "r156", "r159", "r161" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r402", "r408" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities, Payments Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r397" ], "calculation": { "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Net lease liabilities", "verboseLabel": "Total Lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r397" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedTerseLabel": "Less: Current portion", "verboseLabel": "Lease liabilities, short-term" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r397" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Long-term lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePaymentsUse": { "auth_ref": [ "r399", "r403" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments, Use", "verboseLabel": "Operating lease cash outflows" } } }, "localname": "OperatingLeasePaymentsUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r396" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "definitionGuidance": "Right of use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right of use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r406", "r408" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating lease discount rate", "verboseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r405", "r408" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r6", "r348" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r336", "r337", "r342" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized (loss) gain on investment securities" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r61", "r64", "r67", "r68", "r70", "r73", "r245", "r385", "r390", "r391", "r444", "r462" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Other comprehensive gain (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "verboseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r81" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r80" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r267", "r299" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r10", "r35", "r36" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Initial public offering, Net proceeds" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r82" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds of public offering, net", "verboseLabel": "Net proceeds from the sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r79" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r82", "r300" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product [Member]", "verboseLabel": "Product sales, net [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r5", "r60", "r63", "r69", "r83", "r97", "r108", "r117", "r118", "r151", "r153", "r156", "r159", "r161", "r183", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r336", "r340", "r341", "r346", "r347", "r361", "r375", "r446" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r40", "r205" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r208", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r39", "r203" ], "calculation": { "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r16", "r17", "r205", "r415", "r450", "r459" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property Plant and Equipment Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r38", "r205", "r505", "r506" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r16", "r205" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r16", "r203" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment, estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "auth_ref": [ "r18", "r439", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.", "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "auth_ref": [ "r18", "r439", "r454" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.", "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentMember": { "auth_ref": [ "r18", "r439", "r454" ], "lang": { "en-us": { "role": { "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments.", "label": "Purchase Commitment [Member]" } } }, "localname": "PurchaseCommitmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r168", "r170", "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivables, Policy [Policy Text Block]", "terseLabel": "Accounts Receivable, net" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RegulatoryAgencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of regulatory agency.", "label": "Regulatory Agency [Axis]" } } }, "localname": "RegulatoryAgencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RegulatoryAgencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization that establishes and ensures compliance with rules or regulations.", "label": "Regulatory Agency [Domain]" } } }, "localname": "RegulatoryAgencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r316", "r429", "r520" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development, including Clinical trial expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r91", "r437", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r7", "r15", "r91" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r246", "r308", "r415", "r457", "r478", "r483" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r105", "r106", "r107", "r109", "r116", "r118", "r187", "r305", "r306", "r307", "r330", "r331", "r359", "r474", "r476" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r147", "r148", "r152", "r157", "r158", "r162", "r163", "r164", "r247", "r248", "r430" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]", "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]" } } }, "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]" } } }, "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r404", "r408" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right of use assets obtained in exchange for operating lease liability", "verboseLabel": "Right of use assets under operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Initial public offering, Gross proceeds" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r176", "r177", "r178", "r179", "r180", "r181", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r266", "r296", "r310" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r266", "r296", "r310" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Total Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r14", "r32", "r33", "r34" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory, Current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r40", "r205" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r267", "r299" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r274", "r286", "r288" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Assumptions Used for Calculating Value of Options Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of Information Regarding RSU Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "General and Administrative [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r86" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Share-based compensation", "verboseLabel": "Total share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Options, vesting term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Time based RSU's cancelled, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Time based RSU's cancelled, Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "definitionGuidance": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Time based RSU's granted, Number of Shares", "verboseLabel": "Milestone RSUs and TSR RSUs granted, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "definitionGuidance": "Milestone RSUs and TSR RSUs granted, Weighted- Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Time based RSU's granted, Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at end of year, Number of Shares", "periodStartLabel": "Outstanding at beginning of year, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding at end of year, Weighted-Average Grant Date Fair Value", "periodStartLabel": "Outstanding at beginning of year, Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Time based RSU's vested, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Time based RSU's vested, Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "positiveLabel": "Expected dividend yield", "terseLabel": "Assumed expected dividend rate", "verboseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate", "verboseLabel": "Weighted-average risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Issuance of shares, Inducement Award Plan", "verboseLabel": "Issuance of shares, Inducement Award Plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Awards granted", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Options canceled or expired, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options canceled or expired, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Options granted, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Additional Stock- based awards, grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of stock options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r276", "r299" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period, Number of Shares", "periodStartLabel": "Outstanding at beginning of period, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period, Weighted-Average Exercise Price", "periodStartLabel": "Outstanding at beginning of period, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested or expected to vest at end of period, Number of Shares", "verboseLabel": "Vested and expected to vest at end of period, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested or expected to vest at end of period, Weighted-Average Exercise Price", "verboseLabel": "Vested and expected to vest at end of period, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award", "terseLabel": "Terms of award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r265", "r272" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted, exercise price", "verboseLabel": "Options granted, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r267", "r273" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Initial public offering, Price per share" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Options, maximum term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r291", "r309" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable at end of period, Weighted-Average Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at end of period, Weighted-Average Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r92", "r104" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r19", "r20", "r21", "r96", "r97", "r120", "r121", "r122", "r124", "r126", "r132", "r133", "r134", "r183", "r223", "r227", "r228", "r229", "r232", "r233", "r239", "r240", "r243", "r244", "r245", "r375", "r526" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r49", "r67", "r68", "r69", "r105", "r106", "r107", "r109", "r116", "r118", "r131", "r187", "r245", "r246", "r305", "r306", "r307", "r330", "r331", "r359", "r385", "r386", "r387", "r388", "r389", "r391", "r474", "r475", "r476", "r532" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r105", "r106", "r107", "r131", "r430" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock issued for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r20", "r21", "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Common shares issued, shares", "verboseLabel": "Initial public offering, Number of shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r20", "r21", "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Exercise of stock options and issuances of restricted stock (Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r20", "r21", "r245", "r246", "r279" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised, Number of Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Stock issued for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r20", "r21", "r245", "r246" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Common shares issued" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r245", "r246" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Exercise of stock options and issuances of restricted stock (Value)" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r26", "r27", "r97", "r169", "r183", "r375", "r415" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r392", "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r392", "r416" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r108", "r109", "r110", "r111", "r119", "r173", "r174", "r184", "r185", "r186", "r187", "r188", "r189", "r222", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r328", "r329", "r330", "r331", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r410", "r432", "r433", "r434", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r528", "r529", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r100", "r253", "r447" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government Agency Securities [Member]" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r135", "r136", "r138", "r139", "r143", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic & Diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted average number of common shares:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e777-108305" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123389529&loc=d3e10037-110241" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e12803-110250" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e34017-109320" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r348": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707" }, "r394": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r521": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r522": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r523": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r524": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r525": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r526": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r527": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 63 0001193125-21-323812-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-323812-xbrl.zip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

H%RN)#Q2!,- M<^MR@XOA-^"@0=^9Q?"Q^BO[JG#>%WR&S,C53&*/4M' C+L//5<]Z):LP^X/ M&F 2M_ZA#AP)&"$EJ2D;$N#\YHUF5))-B4L-VNW>DK5:"]9:LHL57[W0/&9S M=]>#!1#)+I1;0;KG#T:N+@CBD7+!<3<$FO--JDLQU9&T86?TS;G+DD8EC;\I M.VOP9N"_$?T7R:8T_-0'9OP7G&#R9NI\5["0=&P8@F$(AB$Z%L M/FV9V)^W"?9ED;$K ZW&%#-,T3#%HV.*>4\MK&B,,N7'SBKBF'[)72Y+UD@A M8W&!7+!2M MQT 2T7C6YWB2-7W$> CG!X8\QA6K&^^]D= XP$Z:'ZCXD^K2J")75?=/5E>J M'BDUV=4:UU-G.M@\%BP"Q.$'& !2"E\>U3":W3I#(DJ!"=+ELIQ,"L!AOCH- M;K P '878IFXT? ,3S8\^? :'IBV3J28H^*E>6L"Z8+'O!Y*;16%827&R6X8 M@6$$SX81B#A/\C!.;D/DALB?&Y%K75MY@@#/]UJ8(F0LH36 ^_/C*5C&.#+L MTK#+DV&7CQM'Q@(RU&ZH_7E0.Y9M8PVR+^X<7W4J"\=$/VS M(GH>(%WJE6JIC$-C#VT VL\J>PK;PJMNJXO:),FD3JZBB9R'/%= 59O1"%YQ MC[U5>0YA=,P,:A[MMOH[JAU6*O2N*[?Z-9MH;:76+]Q6?_L8'>=SKY.J =Q<89U M?A$4KZF_,IQ.FQ(Y3'D()=9E4B]5KO[3FK+444$VGY>B0M6V.ZIG-Y-7I7>* M3B-9H2O^%'MAG6UMVK_8.312 _^RCCD\UQWO>@QZ242Z5\XBGLH>N)M_W1SM MK$=-@:-Q@_486SJ,)I13[XP3V1%*YZ99*;C4]:@YK^KGG[63XGF'OE^+7GDR M?K&)E&R__Z>H2./](XEV6PB81TLX^1 9L4Y#ZO-.8XEC%C;A2"@*J1M$7*Y6 MKJ]\]V8AM8XH]B2H+TCGTH;:OLQJGVXIS:8LYG 3=1.3]Y$)M&BRN6I#H5\/ MH3FGI]C6D@)9#=_JKBI4(\T*'?S^2!V0CE$L;U+.%^U<6C$^(7#0;+F]E=2Q"1FXVZGLPQ_.LBFRBL&8 MUE=KG6E/K:_ZIO75:;>^>D[8.&@V[7:SR95^<=9",)Q.L84[W,8W.6&26^TN M8S9.H/.I;JME#SOM1Q;..C>W70(S5# S.FZ*=I0#GPP)^_W/P6 MLQ'0LIO-OGW9?.R=^0C-_ 6X"BW2;[;M0>"S;=JO7MCO]?@8B?%//'@Z' M_!(<_!(Z$:@%)"WX>YS,,O'D')!_I"!ZLK5EGQJIMF5F>$WG3_B4WD"B4[Y< MBENTC+A++L\96:YHV2L)^OQI5G=8X?2(=(LJS]GWS"C.2RRX.ZK45577 M8[NF,XK-X]@%S3S':<%*P<0_$^=[AA3UIO#%ZNW><[>%]8K,2FZG';]>+8A> M@/S3- I>X@ ^=MXD^]A9#CSJ=1^V#^ITU];3OBY[OGNM'T@36.09OZSQC/-- M%7^VRM\K./#/9FEV;%1FKURC&5!9NU)-+G"M@L62?>L=5H1WY#;_H+NL, /GJ0)M,*=7:S M<:OTI8W:/T@F_)68\*_DAOSI-OKQ;^\7,-YB+_6MW(NYWIU?[T=T,A_R=L^= MP;3/%0-13SM)GG'.-]8T-W9B-V9H[-1N;'70K=/C=?C5#N Z->;G:W?;O3&VP,Y'T)%4- CVRZV[-;P[8A MH/T14*MIM]K]K5+0T=OC1N%8L<.%/I#^&>L:FQ#N8?EEK_G4&, Y,LLM2?_: M9>KP@*9GMM\<=+.&_G:Y\Y8]O'QJ3.<<*7!]_*V[WW:GO1>%1[NZE^=EGQL%9-52 MR?IF>D8'.4+>V>[;3>/?/(1_L]WO&CWD6=%2=VAW!J8::^\*?/]^,U"L<1,LE^$ZRU@6&2^V:2;?NROUTF:6CIT+34&K;M8:=CB&G? MVGM[8#=;VU7?34W("22YGLDQ#5X8O#!X8?#"X(7!BU.H"7G.\9WG43G"(Q#1 M12,.F9)Y*N;-8&'PPN"%P0N#%P8O3L%%8YPOAW"^_!+&L36.PJD:H1P& MQO%RO,;BJW[?[K0O3]18?'VZUN*K;M<>=C;O2OUZ?U+6T-,*]-0:#NW>P!#4 M_@FJU1O:@^'F"6>O]Z2?/.<0TO$E[U[C"$ 1)Y87C,*I2=0]1N;9&9K$POW7 M5&[78VVHZ-!4U++;)MM][W34L;O#EJD(.C>E G4)*W&^JR03Z]6M",382UX; M#>,(>6/;*!A[E_9FELP1X<*!O2.GFI5RRGZ1S?7[E3PB)B7EB&)L9W),@Q<& M+PQ>&+PP>&'PXA124IYSR.?4&[=_%(GEA_'S3U8YR:GIK_H]>]@\5;?V@>F8XI*:PMMKIYEBLII4E%K.+ [PU-MOGBB9-3J]>Q.<_,6T,8-LZI>V0&] MT@W36U\\;_WY:,YI,,-@AL$,@QD&,PQF[,0= _]U8&/%$XY\X42@*R:3-U/G MN]HAGNM%MNIVG DZ+%N#!<#PH]ULM^A' M]=\UK:HWY;&+>=R]IE]&;_6[V"]TN0G-EVQ\,;J7'@%#P8-W^4-),]\97/8U MHH$A 2M%5C(1\'\*X0)XPIHBPL666(II#R*"G\QF4?C=FSJ)\.?6RW:[T>;' MX!B^!]B,:[[L#AJMPL>V%8EX)D;8IMF?V]:(T!]>EH36RW[CLF:-5K/T<7&- M#8[2;!!"% 9FU9^NU>C5G:Y7.G3Y=)M V8D+P"GM:"&HEH%[)Z#"30+_@E\" M_^+/X8^W5Y___H#3T GNX;G;.6WBP[LK"S;^3HRTU[7I=:TA M;>Y6C)PI[//>\7R4.PB'ATD(KX#71+'E!=:O-'"$-_@5%O6"422<&/_ 6>7E M#<,VW)362>AA+_& /_A.&L JX6B41A'0$?XX!U,!.O2^$G?%K2:E=\\ [J/( MFU'EI17#5[B< QLB9MZPKN'*7-=+Y"4167+%IF/= 9BB $>G6'>1 __-P)\G<>O"2B;Q- "#(",*C.$E=3R NT'7CMS%B&E].W+!V(237T5CVK8/PY,#/ MDEANB%C.64[6SE*L(\-VHUDG&!K=79%A2636LX%F8["C]P-)UL-F!'S.BQ/X M(4@#N$JX)/VA*)P[/M#C6* :AOQM(AR77HV3&P#++=>+8(?<,;"1X6(,2KM. MIRMO5,V'@'WD>X,=N5%ZEVV+6#)>*_#K>P_X%SS-WPG>W&@"6,FPCA:,M\J2 MSN'@"->0)!M+.S@6"\-?_OWUJF']'01:&@LZR$B"L; ?W(IZ)2);4%T'>F6NZV3=W$78+8/(CHDG9YV[VOLO31[ZT( MUX+&L!XX='I^(E%:'NLU.>F5)*+:WWWHIR#GRMM_3. Q*QV4V?8B?T:= ,I7 MV(:7HBR'I MF)+"^="-1M,:9]B.*VH/2Y13_9X&KB?) RL? S[2LF%L!<@"S M8OP'9QYKWII)%LQZ\-QD@CMO@H!7OJ<.[EA+G&EU.[:E_O/ZS8L?%V)0J]-H M#_#7A:TV>OV:W'(M<.+!1QP(B&?_UQ7\EX>A%K4;2I-C;5U+WD*1A M%?@\_NE'9T4D*OGQ)"0&C:X'**0_CXDWV>XCWJ>3)F$I,X<^6I8MM*$.=72( M^R\!VK>/+8"#Q O8ZIHX(*> EMJ!-8+2#2'8D?'^&7IG@[J\O MFB_HWW)A^G=!SM(+)*/G^ U_(AD!R<<'_U.L?\DR#XB/*!M3DD/Q& M:H54.W)H?$.5Y(D)M>;&M!M#C<[ SF#[>=S8UK'=E*WMO-_R?JSL]]_A\4!- ML'K&A6BGV\>DU;=[_>&)5M&<;BN3MCW8\@AD0TJ')J5.Q^YV3[5=\@F3$O9* MWKS[^)X4$*-:;+$)LE$MCID?#NU.US0IW#<[[-N7O77,,:-9'#\EM;OVH'.J MI>ZG2TKMEMT=[$>SV&FM^_'7)1Y+]Z0S.>;)U*L>"\#.Y)@&+PQ>&+PP>&&: M#9IF@RMG4E)U^*/)DJ87X5$:EGV[:0S+?;90:S7M=M]$?IX-!76'=F=PJK,@ M3I*"NBW[<@NM/(U7YG2Z*)W+.4_&SCH:B)W+.0UF&,PPF&$PXQB],Z?I=SF^ ME)9?4JQSGHDH#(1):SE:BZ]U:?>[36/Q[3D8?VEW3%[+,R.E3MNX'P] 2IVF M?=ELGTK&[',._AR?$O)KUJX%&V,8+>1866?+'K:-VWG?G+-E5)!G1D<=>S!\ M:A6PH:,G:R#V97>[05#CWSAZU>(F"4??0)O#?FW8KU,$L8-]28U^<91\L34P MQ3O[+PON7PZ,AO&L*&E@=WI]0TE[+X/K#X:GHF$8%\<^]9!/R41$V*WV/V(D MFZ2K7OI&%3E"!MJW6WVCBNS?1&LVMUO[:"CIT)34ZMK-H?$:[IN4AO:@LUVM MWB2L'G5=U)D<\V12SXX%8&=R3(,7!B\,7AB\,(FJID#8% B?='FC*1 V!<*& M@DR!\"E1D"D0/KM2IW,YY\E84$<#L7,YI\$,@QD&,PQF;.AW@?_B%,_B"4<^ MF.Z@(2:3-U/GN]JAG"LJ5UWD,-EP<&QAQ*D.T=* V]KYK&IP.TV%?]GN-YI\ M8-B([X5!<7YK86SK8U-;X\+ ^9>M9J.SE:7AOY&8H:\$QSW?P='RZ?/AF FGEEY>-=G6M<'&ZC2T'2-,,7H"6CD5U2OGZ4P*^7E^TVH-+NP9-M_:"=BM; M'P^WDW=T.C(#!@%Y%SE3O % JSL&;]RPK@,+!VMA0K5-P(S$U(&+@T=T[' 2 MN,7;-%'CM?4K](+BQ6_])$$87"ALDL=AG$*X3:N59W@J?AJ4=%>A"]\!K@Q@\F$!5[WP=/A9=]BXK#]P90KUFNRLVVITM['R>MRLNP5F MUJWCPX8![8$!L4 (NRM)TWH-NB"UJ?X6G%S0A1_%=-N=5H'E"Y BX M8J!^ MVWK &?.@D'HS^'YQ0(7A5H&[NC:$0T9!TQ"T4H9F!5BC,'#3$1$N7'/(!.Q: M@!I! -#[/,$%.OH%%FXV9C@39856F"[:#LV]!\X"(+=B.$8$"\SA9' S_X(# M1_!_?AS"8G^DGF10R*P A_(V 8EJ?7AWQ9AX7Y%< %$X(B%V( 1R M1KR'$LJGL;#1YPAWQ]P'L&F?)P$<([2+TCN\!KQD1B+] SAGAFQ(6O"C61C' M'JH-2L^ L^BPB"O8BX<',H(]X..Q=2OF@%16/)IX?X8S4(T#SSDD 0*"C=(( MMI$ RD^<>Y%AH)(6-@%"GI=8B'8^U+.P+5#TF'S@AT#/ 1P)?_K@ M@0"''\>%N\PE9 R\QO=UX8CT^_G=>T6V^4%@:[8U"1\0;B3NPPAY*R_.K A> MZ&P?P;>^H#S^Q>W\0OY9L)MOG=A#*1<7SH9W?QN%C@N7$X.JX[A2*O)#"J2H MV0BXSX)HD])*>XQ!>BM$0)PY9KK$=T1B[,,3A#1L6)("#_+L7B(?*$NQO-[_ M_J]!NXW^FT&[U7Y3B?C0WYF#82/ :^MYB>-[H^KC!;7VG8:L[VL"_PW:>NO- M 7G"H;(DEG$/P ]@#L '!/Z/$Y%\E@\ ;<#H5T0C$ MCO7WZ72LX"FE:0PL_"-+;N4%4.!2*%Z!P\'N@9N";-(9)Q-8#)POSE6%6P$@@ 59LDV=.7R"E_Y-:(14 M/,"=")#_$ZLET4S/C$/?#Q_H'HN^M HI$ ;T5DWTJ2.F?(4M./O0S4>,8@3\ M7 [>_NN+Y@OZMUR8_BVWP&Y*>H&2C%2/]L92 \*;S3+EK4<7TA$*J_K.+(:/ MU5_95X7SOBA%75?.[?I^YTEI]=YI2;921(RJ.^G^I+*4?\H.%=9@ (1OK)J0GF$ZAND8IG-Z3&)(.PC=,(!@8$D!:H&54L\7T(Z+D3B\F/68V!F+9$XK &N!1T?S@MOV:W\^(V>]&Q1UC-LU+$FD1C_]<5_)>'HQ=^^DIP! M@GD+SP(*Q#_]Z*R(*B76)L\[:'11:%<9G=QCQ+MQTB0L%?_01R^,]#/2[YE* MO\4J=ZYA7Y4T[(_OKL"T'R?D9M3=#X[OEX6C494-LS#,8MO, AMWQACR1L]8 MB08Y0+X3_Y^*-$L\!UR8R9"7U&Z+.63PE^=[H @#SY!_H_//2:0)CK]PV.XN MA5#@UY%P/2 $8CA7GZ^E+Q%X2SP1I5@Y!NCX;^'28VCJ[FS M45(9.QF++=>5GS&F-X]^_O6S\2X:[F6XUS-0=18S3>28.3>C1)I2TE#L87B2 M.0H&0BGSQ'42QXK3&29=J!3&HNW/;L4 >1!F\$B&-8)O/9<"GA,GYH0#CGS* MP&B97Q&?>JMVE+&H-YQO:!0LPZ(,BWH.+ KY4"3N/5B8,H]4EJ-4K\#PPAQ1 MS%O"3.RYEEXB\RHH5PS0RF$'2N9QK$NV:.R6<^PI7XCR3M(1)K>,4[^Y)+!7&[DYL'FEA@)O+B3 L'[JQ58*3#NB/%7\ M0$OU<3"IYQ9L9MA6Y,7?.!L1-H79A;?(R_AGG-,8S)=L_\'S:"1FB2>K=.Z=:,Z5//!B6"Z1";5T5Z,P]3%?#-YI SN9>@D"!)ZZ M1R34P)Q#(I(_ O1)?4KV]9U;X5L/3H050W&6(X]9SY@QCRE;<59P<0_?2+0@ M++*5XX:N@A/ ]/=J:6,8PX3#8497]>",=WA%>#,/PN(,28QZ^IZXEUH/:3F, MU[$USCE_VI5.,1*")71KTDHS4"7N$$E*MZ(.8!T!W#Z-"*?4%GJ:Y<_LV4VIWS;*Z8NWAW7EG4&YKE/)/&>:5?O!1RNB4+^NTC2O M?9,XI;Z,I4.DF$=OZQHF81&9F[%4-AB%$FQ]B)^\;)4IQ"X7,PXO6_P Z$II MS'5 H%$X8$Z4BR19UT<;*U?4N+0Q UEI\=[PLKAXP[IQ?">B)-G;,$ACJ8NJ MY6Z!0,:>7DR(HHM?R>JX.OP8# Y61@OW;]']QX_=/"R%EX::5 Q"/<5W%_?> M:?] CUUV?L"46_:1 5! UY4&2@%?SI9&?UZ!I3'EMOKE2OFG<>N:/A@+*W)K M";5$E^U:NJRCQA@GR5U4)\D1LVB7]F#7E?W6T4AW6*01V\)"6U++^)<9'*L_ M[G0[Y1\K&Y_[,+A O%P.&:<1.E9M5.S'@D+?<&UCH6QX)G3UKJ<1ZA+YMFMZ M[?:97KME>E7D^IBZJY5:I*T@E[FTR'DRW2=;,'5[$%%VRI5=GN2*MO;U]!,>O^! M64FG:=+[3R^]?U>B[NC0\U_,-D=)KM(_:NTL:%B%C2FJK:/^X'B/;&*3_U"W M%*03#3:2\_9<)^(XNS3&P6I!09EW%@L18[@-9I;ZX#O L">$45>??_GWUZO< MM(:7)Y0+<.O-0A 2EDN&$$JIQ[CHYCDGZP1YCG%RS"_>'ZGG>C*;[:TSPYB1 M]25KEG3.T9^ODRA,[R:+] #J%H>1>H^:D*6!FVL>X0Q)B!MRS653,W)CL[^Z MQI[)NOK=2@41\Q.=>*(WC)/[F:6WOHQJPI?W6,@8CLO)=)"@G!?7;QZ%-O9MP!>[35#8)J]V'\2@J MN$_&6>8'$5G" Z6U9$R,N_#!/3XXD4OI.VYH"&(&S)U@EK=I-AGYVPML4^!]0\G !DRY\MJY7XLD;4HLJSP;2CXF09^M189;#)Q8)3Z\17,MF-N< M$G 7A;%LJ"3<6)5-R6?8.!J6C2E"[T D^<^J5-ZNX*BJL@(>(CM!$@$]()7" M/]!=AFV> ''QB%S&)9M J;/D1M*A,>H:KC8%,RJ[3H)PNU.^L0)W8H:!EWC\ M#>R#_ZOOPB] M,=&QLBXH/"R17W::#>!(,U2))LKX<.Y &[E#=:K$_CD_HNSD S&S+\?ST1]R 4AV@5IHX9(\:GK$'6QS[9QY&5CI'FFZ>&Z[+L1Q.2S'&;%] MXP2LZPM4P$'U=FY542:Z*SWN3XP&=B3=D?HCI##GQHO>GK83H5SBE$FUN=WX]8E.MN3)+1DKOE%MVKV48FH\C\C[](;K MLL>X=&WR E7WIE[ZM73MJF/SS:-3#60F/![_@CJCY\2MY@+4+J*ESU>*(G1Q ML*LI&V\42^#:#T#A-+N 8NL![:H):[.Y#:[TL$A^K3%P>2UU-[X$EER"JWSH MN70Y)+>1PG0,UP4'*%J$K0*5A197 J4S.4>KY+7(B4HK2.)&#WKR[7(9(HF6 M11W61%%Q#V70HI8/R #0C0L_<=Q[++"#7Q3P5FU"&UZA4*XR)(ODEEVH)\IP MPB[+D)SF)9:7 B$E%I'[3'7,R-=O6)\R2JE_(F-GU.-:ACP*55^[L+O/9AI. MP_H?-1)A)V.%WG[ZY_6[B]90;0(.*J9@3&)U78!F(L?S/;#/1LD*:A:AW"TW M2]%[L1/#E<-?T!LO9[\ I\_PO::"L;*>')RBRQ2T&VLJVS(13EV@EM<2RM0, M>-5#&'T##!X)E=P1<1M5_$XUU;=U2K 7L V=A"BG!0&*:K+4[LG'[^1#7BBJ M&*L&KDK!\E7<"E[C8T+P'3D'T)1/ S5X;>I\$Q(*PO4TAB_K< %R=]BZ@7-5 M0#7"$1.CB1/!52'2R$,C2OHJR++DB3A$E9%Z 8 &V!+UEM#G/KS]>)-__B9_18TFMQ/.W&SV57?X M4.IA='&(<$AZ;]8!P,[D!PI!I4PJS'2EUB%T&&DS=_:IX!8FD>CRJKR^^LM(KD]%0P9!RVIL(0M_CU$C+2E%-<9)D80?P7AMP%4V<.!Q.)G< MN>-+3NJT3.[<:>?.[00;]68-:NQ9-J/-#V.9WHSJ_IP;&X"M.:)GL(6'SLG$ M=_416<,MM(8GH.,]B#PX"+)ZZ^P]G5V 9ATDJ@N#8-D&FJP'FE9" QDY64:W M 9T\.4:EPK!NE#4-R_-HR#L,3TIX$)#8QY79IFA85S'[_0M;H6>RAI4L+@OCP&9I%*>B M.)RR3J'3Y*(^FE&94HO=:W(JH"P?*!E.6=*D[D(5$F 9O+A94"H;L; :GL=# M]#Q/"@=AJN?MPDQ/.23TH-,C8R&^T:D:,.O("EWD>5Z/QB!-&P+SA MRW\XXA-0M)70*,0N1>&#=*7CL^A_=E6"'+XOZ_R42'>9Q_V9Z"(XSB?;H>99 M7^C[=>[#B*U2H&: Z&^ >#ZAH).W!2P0L,PMJPG)/HY^&TU?RX(*=?^^*VZ3PC>3,($WXBG M8R4REU%=0IGE^!H3HQ%B2?Y0<5-'EP(LHHM2W2,.CR?H37 M Z!5FFFA>0^)RX23-"2W_/_;N[:F-I(L_;X1^Q\J_(0C!&UN=MOL3(0,-DI2@6HL52FJ5&#VU^^Y9F9=)"1 2+(K8G<:2Z6LO)X\E^]\AZ^_ MU+@+T$'1#_A*+%;X-2[N#X>E$>6@(=H8\W.%*N.%1C$>\*"!/6.#DWA'G-^W> M1UY: S)>?^B#D$?EH%O"'C4#/&>@ AK68)@ (@M+F<\_'L3P:7-F M6=1XR9M9 *96HA++B,/\$DS/0 _X'"V*0?SQUR4'2BQB_A^%*.+%593P[J0[ M(/NE!$'69A:-Z"Q)29#$*P[$ZGZG.S<';7_O+)6H&1$9U; #0"-:F9ZA:H;# M?J>7:3?H^;ER>=D8%=B0$\D>4RI@>%E$_)A!W[%,*A0*5 &>JU T7EZC2&-Q M:I<,1%6S.:_9@2K8OY MHI:3R:M1!"5QBZ;>,64#@I+"H&?ASZ4?H)4UH(#2T9E=!R 6Y)5@UO.GH! MNQ6PV?A&*4_]*/4E;YP)0F&9^JYY1_VC;5?P'9B F$+#V.VO9JBUV!@#:,^. MF0P,489I8-31G/V6NU9-4-<983] % B9PB,\CDR2[T)Z&EXWFU"JDQ[@2=P0 M) C8I1-$,>!,Z&M-9)L47-BR,G)U$Q6MN"JW4J-R"AI3;6DVAGEL2LI,RC>- MF^'=ZA*2+DG\5I%O?.6D"$TSEOM=C)8\+%\^Y&LIH.5'#;V6V$N&9J^)ADKI M\WZ(Q0"1\-?$Y'>\IE&(D);#"=>@K .QYQ,>=-D(!NRT9:[F(9';*^0-C2,0 M:N,\M, GYFT2XF:\I"#:BP^_RR)[#E@/=4A\9\#IN%_VM[FX3L*DR]I0<6]5 M.B'9KIN&(U# 1E0<)I\N-W3)6V:5.*]MX4JGI+S["%9F$(XM@EJ]4@J-I?,] $L/XX)Z+?3#(5)O-!PG,$KK M$6T71ETQ3,17WY)Z7E'10/>5WAB\-4 E]_E^I4N4?19*HN-T &1'[NPSQ[G> M40WI B5.\?FEU=IQWKQ71!1NBT=.0'_*.)?L[*Z^@@].02:O"] MY*?BDB-$+O0-^_"-(<4EO&_*APK=2IRF@OG+$=X[[9O*5>;0KJZQDQAL)I32 MTK:1)OQ!)761N[./VDT(%PQ!@%"-NU7U*3&\FWG_H/4<@MRD0BGTL.,V=)L1 M71;SXXBO/$@-HH4Q)LAU#]L;]@-<,W?^,!-R,9SR+]7+01S?)-$:.! M5Y8)EIC@2%SIJ^0:#NR)E"A/6M!5"$S&6E!!B5A]*D_;*93+>P!5'NQM41^K M8/V7J>\:71FUB4_>UNY;MHQ<*GV<42SL11.F!NUKE@AHE%$J9E-6H3(*R&.\ M>^ _HYA5AVK/M0LMH9L+;_W28[D+;0G)317@S=GXDJV]N1<,&Z*D-PK2FD,2 M+\&Y4[&4U>MSA*_?VI7#)V&B>LR+:H* M'BMOI,-\0[HXMVG[QQ5.5$X!1D-Y2QEC^F'3H&J*EH4'4S\,44DFY#\%:9SI M83L8(R;%R!0.CDRK>]*A:&;N0XU._X2:$(*\R3 AH"K71Y'Z78.@]XW!59KG M"188V-FB64_Y>)31>I% ;7C7.YV=$M=&/@R'"CL%!2<:C1O'*9Y!)]HV]L>( M@^[%R3BF2")(:#7+;;)#;ZQ#$M9'O M$[2Q4BC8)R>TFTE-"HEOLZ/(UB)7/*&&_!$%Z!H.'Q4Z/#4-^\;;?=_X<+CO MI2@1 P2GD8V=@8Z&ZR!VER9MQ>C#0FL3O!,%UL/_.:V%BZ-Y'#,* M/13 /83S\.\X^6;_PLVW^WX'UU:O$%6H4NY2Y9#+0#BPRGJ];/Q@"J?=A7=@ MMF8C,Q'<1Y?+V%0DSC&LXE2BVBKJ3Y""L&>W ,V8<#.D@BZ"'DIRBG9J(-]Q MMAQEB6"%SB!!!T5/@@ \V^1+3ITG_B\@=[!^CUDZH!LD?5O[L]FY?GDE&;;6 M^^UW>TY5*%%)*!TY2[!:%Z?EN^0-P_Z"X MPW);J0O6?$3JP'EO$MN()N$:?E40%GF=K$-'O;'\]ALINQ;&68IW8T^,2WH! MN\YE@[FG@F")IK7=@YU]"9D$)NGDJT^1[X\T(5^";H)1/ L2>N1X8K?V&[OO M9X\?7G,5WZ?H,/T*K0^)=M?,R5B,IS $$,JE$31A;PYQ#'L4-H8! M26,?&E/'<1> "$$E;HC]S8F:GC"/D .84X)&,8@(_0W;OGHP@]%X&#\$$M"J M;%=$4RIC6!@P%2$KNCO0.3/PQO M'EP:"%0^>>-JBHTD(MWZ$7V#3Y@Q<7AN,F4(M$_0J&6,1$TK.37T@-8+NDV: M5N1<@(YK> 1;*2?\K0G#))EYVF=73)H^4X@RQFVL'RGBAL\&Q@ 3Q\.A)],2]HV#<+ M:PQ8(*.Q%+XFR:TII^2OVX%U(K-4XS84%0^1ILA$E3$%TPR CPD_07>JVW[B M1)6@90^^HCM3ASAKGJFH %6Q8(/G A0=K]UN>&T8M??!D-JO<5E%FO S,,"] M/?4K9Y&?]4.NC#/W^EI<8S!,@WNR*5=3 M])F+W%=6D 78@'Y"WQ->I%(NQ12X $WK 0ZL'@.[;\R14^HH.L?XF,.&A+5: M79J:JFVG]ZY=9LFF[5=IKN[RPJ+VPC'>HL*500H: C&L\R)7G9I0&>0"^ZW9 MO&#-H2 36?!4'@]3QQGFW+\U%@,E?5M)591^'/#C,!^SU!BD$FOQ:1J(O':) ML7P#)+",-X')24@'5(.9)K[;/8)9Q M%Z,J?3 QNC&[F6A_#.-44 L,*[@EGYWMO#3X)R]^_J:@U CC_J+>)2$A^\5+ MC/96C'YM-@>*,^GPZ+*C+B'8$U,2&5VJ%R:];(39%#T+>9J^1C!NAD M@EW19C2SJ[XF<11G8GJLB=KZ)T6G0V@G@O]W9#$E+OE)7R)-8B()J&/,[F0G M $#^;88Q1(10DA+@?C\VJ91DA!'<0!MG?S7>$SNH? CT4"90X>"5?2I(#A.D MQ[HW.7A.]065!H&I2SU]P3KZ/J=>]0^EEKE1W)>8#FO?!E+H*PK9]A%]+- * MO#./[&#CK4 M:@3?'2L8#(. .!L<*\09Y=N<$T^-$P[/SNZ'HU0A2>,D)H2WDD-^"Z3]P,U[ M1907>[;%F5TEGI9[Q/YP"%A@]5.^0$1T%*?("AB5%6ABB.$P"OQ(TKGQGQ>2 MQ-JQ".=3^ ^3S<+P2(5L]L@'N_OQXZ$JG3DYSA ]ANNS(L5_)V'Z#:X9F^RK M7BMA(QGAY%%^J6QFMICP&NOYF:C8?DZ1:Z">3SL@8MR,T"X)-%!4>[:EAP^. M,D=:'T%O%8U6;B\M-0B7/,)D45A1?^&>-94.ID\[7>-3OM-KCR/$Z0=1'6W??'@O7&M#2? M@:3T-YCRL$3"#YIIK19*D;V#+YN77DF6VE!8NKH/U,<:ZK.&4)_] M&NJSV5"?'VDWVA0*SCT0PJ)*?M9'Z5F/IEP:1A$-1UUH/]#&4,:6N*Z4OR9S M\SOBI-RX/YD@7";_E)(#.BY4]\ZI' "YL"=A&DSK?^[2JP91PQ\3D;T%=:%T M+SCM@VV#B7(W&6KPL^76.6@A62H,<4$V;9G1Q44Z70*-HDDYB>+[AA(U8S:FHW0YKD")9YG#U MV3A_QN@YU70OL:!!(VJHK:S,"H:HL_B-6EZES\G>*7Y:T;2DZA8_QI6*^J6' M05\J?B;^WM*CRLY;?B'1-L_9CV'X#%SY%'W7I,TQN*'[8J_HP'50_RMF[ M^C%1B]'Z,#V5YHR#$HI\P5+(HA<80KXB RMJ=TZDEW#MG(EL,$PYQ+XC&^"D M]&E+/\PT[+$BXO3OR9ZWY\&XFR0FF3>);>_06!?;&AM(+>>T[T49 0I1N* W M)9]];*-QG*O+7I.\QX2]:13Y,L)0,H=2S$U7+M&B](/BTT%* M0A-0AELLYHUFN >/0I& MB=L./YF + NX]@OJ*+DT..=[SF>EV/I1]7L49Y7C5C0NU8;YT;TS#LG*$N A MP1-> M2.X:&F[P'71#%_TH.ICC2E.&/PX_]Q@"C%<&,U5,3;(R-SQ35.5X-3 M16 RNX:3D? 51H;#]L%N>LJ;C+MID,A[2O4Z6+-\0$#-@Q0RT?D\(CED@@M^ MCRE+70\G)Q#P@&B<2;%*VD4(FY3U<%%E99# )J7\3,&O$ M)!XB-2TK]"S4^#T+5.$BG+E;7$5K55CNX%D%?(YF6FEN[KZ5R)0(#E\070-F M"= ETZ?P#N:'HW.92KFC.]56K#J:ZO>$,Q40^ X>&(528F&LFIW/(801M M!!\J2+BBC@/S,)AA;;O3G6=W,C'X=0XBZ@E*DH7U8@G^!=J"G0 M*!_[0DTI=HY3S*&0]B\T2%.K-4BYJ-8381R,5T046-3= A!J\1I$6^+B$ MSQTP!;Z7@.<,O7E-9+0!H*1>-F:XR$*]+Q.VR7C08D*-"[-C"1XI$2"5+WQM MIH+'<&GL5DP%.$37H\6M.DB\QC1SHR$'0:XJ1!6R624&X3P6C<;7]=E7AR)I M))*D UFS<2\3/*3)0">#PG#O>".:*SS2F.27['@=E^3'IPQJT@Z0I3LFD<&5 M@6"/D5/3GO39LZ-:!$@>'UEUT8RL@/.N#%;_9V"L3#X^I V8TKEB8A)>SL8^S S+D)!-J;4S 04)@SL/(VOPI\)(=@[X)S9FO:%_2\/T;^E#EPKMT M4M%+@"($W3F3I&0$,?L,VW<3C%#[6O\Q7 MN?&^X3&8 )<3#@NI6,$GS[^+P[X^"*O>!_'^?7=_[W#OX']W[=#, *#_Q#X& MVHH&BV!2CXZW, A[%&3A3A[5-NGKP*2Q.?L^-9#&@;$7 MPB!.V]D>CFM; Y 1RHSAIN 2_[ANGEVUKYI7[7^UO.;9B0QOS:](:@K\,,3 9' M(_^[SIF(AU6!&LMR"?\V*_DLUFBG/0S<@/U8/@X:ZKED1!^<=#+!'G*' VNV MP+TTJUC\P.]/P8LI'5VA@G9#43T$'5$.4H2$Y(FZ#S[\6JC4SM53&,JBI5>$ MF4<2I;P!+"U6U2W J!VVG2E)4?3K= #Z!Z>84X;4%2;69'"'Y=B$D/ZF(6 X M>N'V;>(3O6"!]2<7*F6^(,VW8D*#F'SW:"B)+>-$Y-SR<>B7YYF@X$!RQVA' MCO*5()7UQW)RN15;J)V$+0@TL\!HS*3-_1'N%LE8R_+HH% ]JAR8)F!BA-X'-8BRH8I:G4W1<)\O<#O1$DK5 M&.-;VT8/9$[JV(6FI8')BV\C MIO1 KG,XE4/ZURV&F,N2XUV1X5\/R-R)K^PS]D4[G?.E!]4OQ0R'UU-SAUAKQ0KML2A#7_F.1]=G7I7] MTW K:L%SA1>HUSB7,\[<_51(CGAXB:*Y;R[I0L[R.:+OXC0EPNTR4V)HN9R5 MY$FYNA6>Q72))6IT?KGZ1R2"KG4%J$Q( 9U%]>)3R;;7' J'JK_VK6R0;V5W MTWPK![5O9=4YG^=G5Y?GIQWRJUQA;V0MY"-B6!,L@1@-QUB40S]7OKR9#OP3*^ MH1)QT@G)?S-UAB*G7H=#5])SNS8V7?.VB-3M1H-9+V[O76+9)4E0W?>W=P^W M@K=.(OW+1WH.^[F7V BID[O:^L[VM4U9W3_(4QB*!><^^-8)8Y%^<.,0RE"% MB41!?'!?+SG15V/!I,W V@I' KHP&I9TB/PL@=FMC7DWQ3UBY6Q-,L1%N$PS MEF"9*P,CBV1DRTJYN#RG' $C>#A?F^8I,^X-#3"K!P8#S4XNG%W#W,*%*?D' M$F5B[5$*;D,(T,1IX' $.>G-%/U6*B I\V$COYW6L<'D4MDP3S(91^+"# FL ME8TRA@2INR^+PIYBA,CUY$#>\^4(JL[_(^>>Z9LX5).:=3M2EMXHH#,PVK\.DF@W!U$![W4/-.?]T@?[KLT<%S& M;AYW&+>1\^\Z'.E?5X[\W<3IBG*XE[ M!YM- G+1O+SRVNU/WOG5[ZU+KWWVY?SR:_.J?7[V&+N'^^J]YUN%>[55^#)6 MX?ZF686[M56X8B%PVOJM>9KL[9M+ZM:^N/61N@<;)W6;M=A=-;4E0I:^-(^OSB]_((D[)R4UV?0Y MN+T+KB8:0MBBG@M2GTI*N#Y,XXT2 #Y?T=HX)X[CT2B4W.+%R0OK"V#M+H## M3;L ]FKYOV+Y?WUVV?JMW;EJ7;9.O$[SM-7QSK]XK3^NVU?_1@?C]67[JMWB M6,UUIX5?BH[^*M?%"ZW< KKY6BY2E 2W8CJ4#1O?>"V.SSO2?1YOR0]B MW)S%$R6>@SU64Y@_6N*7 )C>19; Y9_6&PBMXW[8%\[_L4P+9TX))2G/C@/I M=3S34D)TON(DM0:U,1K4^TW3H.I4H55+UI/6E^;UZ57'N[XX/P.5Z:Q]?NEJ M3J^M)6VX7%[L8J]%Z-J)T ^;)D)K1."J1>C7]ED+C,\O+; YW>3*6G36HO-G M$IV_;IKH/*Q%YXI%YWR0F5IHOJC0K-/\5I+F=UBG^6U>FM]/?ZE_W+1+_7U] MJ:_X4F_]]7O[<_OJ]0R@S8?0+^]J3JC.L8*4<,+ MN<#(9[W@\-=%YG!62WM+Z^J:=T^OVO6?2%WSC>GI^Z?TE&5K^:C.HT:37O^X MAC#E(M6QB_3@?VX["N:[AH?_][;XB)YV1RK)-_2F3QY5[D6B\#(FS;VYC2[X M>GI'Z_L@[(:3W$W737YYQ1Z<44V*!74>72JYFJRR3K8W;!6,[OA*D0L4,%.;Q#TLSRYY,^D/]0[Z*D["/0A>(Y7]P1NF'H' MU=)]L1W4:1U[J%7_4@OVE]1);H5BI=#PJA/]$]!H<1 MAA+][8TE)JF;7==FG^.(Y C%DSV1&-*K]!;F+X7]W9W=^2^&A2\4[(43X^YS M2+4??-_?W=T93$9O_GZ,O[B1VF)*=79)R5)8.=/08UT8PJJ6(;(Z%R([*H?N M1U1*J,/\19K'L:=-=ORDZT=!NGW^?1@\*!_;WKMW>X@8\1?P!#SU5JV\_/Y: M_GN?Z8BO>S/7D:ZE?MWL)DG]O=5(_;VG2OTOAK:MEOH_@YQ=K][44K]N=O.E M_FID_C21/TNC9UKK)\C^C^_>U[)_TZ7M>O6FEOUULQLO^W??+=_-I2'8/O6CVPP6]^TG;RM\BVD=?7@:FH&_*"A"/.Z?_2'1W'<& M08#5E&>5Q/2VLLC/^EA6Z"U=E-4D^.:YB]W1TTQM!WU9J#-813H)!CC%H"")73K;J&9PF*E7^#X+6.&\*^M.UVYLWC"!(Q3.F8U-J>+3J=V:N5K7=6= M]>I-K7S5S?X RM?!TI6O8RIN<0$CX?(A/E?4.?$G/F$$O"VKP8!ZX6HP7%4F MFOA:FTGAT: TUI)Z?67C>O5F*0F-=9[^2O+TW]=Y^IN7IT^-YC+7]VQV[1*+ M%TT%UN68XCE!=B.2MSOMW\Z:5U/YJXJKN_P292N:APO'R<[%\ZAPF[$WYZIU MR#]4OX\WP"J0V?#!Z_D9USJFXGKD^N'*?2GL42XJ&,)KNL' ']YPL<. Z_/) M UCA.,@B^!&U!Z=@$%,MOCEIL^9.E9]K']?UIXKC+4_:0LGSTN^#%TM57GHB M?>G\OY0.]S+=V]^>L@%U[QHMSH-KWUVO/.BJ'.^G%[> M:_.3M+MJ^5),\'FW\^%P7,W25)\PE]W;G\!OS^([)[[QD<,;+Y5K999B,6$] MI9DE*1'+[72]#1_9AI\?/CUUNSTU&T_WTXR$O$57?ZE=J7?0S!WT2_J+UQGX M"5C&7T&FI0WO8K!SLHB.4*O"/V,GZH/UF+^O/E3K$J;:E'-E?E$?K9E'ZWC@ MA]"#"(Y5$N"6CR84;CX>A,%-&?==V[OKT^ZJY5UM:-3V;FWO;NPVK.W=VMY] MOKU[ZM\3/YSWCQWO=_@8OZIU\UHWKW7SYY^O^FS59ZL^6TMR*051&"?>O\"H M=2S?^$828P+'""XE-S^E6(A'X%K/0==.ARYM,"SJN2CA!?J\$MSPBD"8KX0J M_C #50Q2YY=NW'^ +P>3T?#O_P]02P,$% @ JCYI4P:4#1]"!P ^A@ M !$ !D,3,R-3(T9&5X,S$Q+FAT;R7<:EV"Y/E0UA?OV>6[;!3>@\>F8SVQ_2N%R/<^^Y]]Q; M,+A>?ID-!]>3R_&P7ALLI\O99#CY3_M=K],;=/-'C'>+"6QP-1__QJX^C^:S M^>*B\>OU=#EI#%F]ADDC$:="#P?CZ5=VM_QM-KEH;*27!OU_=#[(N,%X*%?Q M12,4?MJP>]V6TR*N5S)NIRKIGR;I.2N>'96F*LJ'?!6G;2/_$/W>_MGGD0RW M_:6,A&$W8L,6*N(XZ7(V_7QST=!R%>"HP=5P\A!(1Z:,S&*#[M5PT+TENXXA MZ)W]A1!?IJ/+Y71^<\?^?3.>+-C=9$2/[-WI&2- QSWRE^ 9 M3EOL+N!:Q?7:%YX*TV*W06?<:3%7Z%3Z6Y8&/.T_ >/C=U"DXB%MR]B#H?WW M/[\25:_#IBS@:\&T6$NQ$1YP2,-^S[B&W\(MQA.E4Z9B]DGIB T^S6^6N^@* M9"K:)N&NZ,=JHWF"'4_;_QIT:=:0*;]>F\:IYNV1",,LY)HM X%IDNR?QF[G M_$?\_JN$/AK40K-[PPUU-8%:N4N=B+RYCQ>,LRF)() M9E+P%^%PV,QC[BE:<2^\C8#3,/>\*I%>M:($12C"?P"?%)/(?ACJ]ZK?"5 M.3@;0>%)VKE%WLQ"3 !+"JZTYQD+R.4F8'ZH-J:D4(N5-,@&G,1I, <.F*T* M$Z9$\PCNWT#&^PXE; 7X+S_UWG\\-X6W"^FBT%*^+_%X8IK6J"GC6MA0@SND M$PHRDPF0YH32!+2"ID5(+4HO>O:D<4-E,JRCI-,JS/V8:.4*#\.F7CN!WSP! M(G+G3![<@,D=;_<^G(AF*5)TQO.K/GCYJF^62:HM<1X0 M!)A1$E7B).>-C'L6.&A](7+_AY#[>^3$Q&$X8B>J F]>?WBS7O.$05\"QU@A M>SX,6B2R+L_,RY>0V#F"[4[*Y5-E&AL@[=;2V&3&+!';?:@8[W6[JB5:A-Q2 M6NCGWHNM0F?HI80D (M1H?1X:H$Z1GJ2:UOZ)/@FA;;R%M-6F2'IM6EEK$[; MW%=& %$*K:%5"6JR=*F,0K-@ET6QEW"LR M"M9#ADR-H(E0%ZX7W]A77:;)O M**[77IPWCZA^><:]F'%$R5IZ1"0W*N:D5=P@"*C0$KM<>Z6CP;WDC@QENB5- M/W8LQ9WEQ+H[#QEJ@XX5KEP3'PJ+DDPGX-O8*N2Z2GL6@:W9*Q&CMH2@'6]$ M0@%%4]"0Y-0B\&0"%7E[9C;(R7#A^ZB8<@W$QEC3TZ,5Y 5)FS\> M+X:62BQ$PIF\Y#HJ2X\BL(,OD16^FRVHH?"?[X^84[8J-CH+3P#/.6U.][:W M9<-KEH8^=AAUL$75L6^.D?**]"*!5*Z;:?+*7HRH9SK<-5(FQ5*ZBF$OXV*C MXG[!3H[C\,$NPOY@<@$;C96PK3=UY7&V@]7,007<[)2;$L9&@_"LE%AO%&F^ M17]]+\*B#3^8WWJ-@ZK9O?/0>5Z>WS@ /OQXPV9O@;OH:>U#FS*M2N$^RNLU MT/ *,7]4,DMT'%4S5=KLY-,.8,<(=ZE4B,<==+G24=!G>NU)P+-[G(!H9*TA M5<#_5+I+ 1>_9Q+H;2!FL6N;]6;_J;[Z?]3UV'L&E28)%J@#H^;0E0(N*X1O MUWQL!+\G)@&*%N/I /WL-*(739\C[6B%&(% M?(^"USN]G(TO?E\T3AMV.?;R_&X M?/YU.EY>7S3>G_[<8%?SQ7BRL,,%A'RD/9K/9I>W=Y-^^>%)YQ\R15]&UFL6 MTF)8?!B7!_=.3Z:?KY>PYF/5EK>R MXX"MJ_ER.?\"? _,7E#83Z?V7V/8-=WB6TI6_9+R;1'G$=L8_M\ &05<0JQP M7;A%GRA);_)0@'#E'T:!%'[^"JKS0CN/I5VQ?_":1YVR7?KS H/W-X[]02P,$% @ MJCYI4YHHAE9H!P !L !$ !D,3,R-3(T9&5X,S$R+FAT;>59:V_B1A?^ MCL1_&%&U"A+7[$4M(4@)L!LJ&E)"MV\_#O8QC&)[J,>&T%_?YXP-&,)NPK9- M*[V1DC#CF3//N3WGC&G?3'X:=MHW_:M>IUAH3P:38;_3_U_U3;-VWJZG0\S7 MLP6B?3WJ_2:N/W9'P]'XLO3KS6#2+W5$L8!%70ICBCKMWN"3N)_\-NQ?EE;* MC>>M[VOO5%@2TE>S\++DDQ>7K*R[S;) 1C,55F.]:#46\87(QE,=QSI(ISP= MQE6C_J!68XJGW=Z3_.U53% M@M42[?IUIUV_8[V.(6B>_XT0'&N34J?;'T\&'P;=J\E@='LO?KGM],6^5OP= 85,92KB$*'Q(^U8N%&A>3CMR( M?P9&3(]Q584N-&V]_?9$6,V:&(BY7)*(:*EH12YP*"-^3V0$P_EKS"]T% L= MB@\Z"D3[P^AVL@VON8JI:A;2H5:H5Y%<0&*C^G.[SJLZ0GMB$,:1K';)]Q-? M1L7"9$Y8ILA4\,BI77R-X?^2QNRI J%#-(Y-#0+W'BT6,EN9@[,1%*YBR16V9N)C ;RD84I[GK& '&GFPO/URFQ< M&-%,&:0#3I(\F0('S$K.$V:#Y@GF;)5:B!D1#;48 XU]8G5% 2G37UEYKR#EP5(+4XO'KO*.+XV"?9QTD7: M3^VXB+1#+J9-L7 &N[D$1Z3&Z3\Z)#_#/\],;66V^.Z/RAJ3X MC.=WO7/377O;%!>7, T(!BPXB7)QDOJ-E7L6.-SZ0N3>5R'W=LC9$X?A"$E< M!5Z]_LARL>"206,"PU@B>SX,*DRRCDS,R[''>/''URS/NQ1Y'E"R5RXZ41H>2N4H:! $7 M6O:NC-R-H>%[):?*5_&:.?W8L1QWUB?6W&G(:*]8.%:X4DY\S#1:)-$"_C:V M"CF.CER+P-;L&86H+3[TX(#B)6A(4M:B8:@G$QEC5XZ,5Y 5)FPZ/%T/K2FQ$PIFTY$YU$A]%8"=?0BMRNYJXH?"> M[X_$=-.JV.C,+ $\%RR<+VZOZPVWO%'TJ<&X@\VJCGURS"DGI!<3I':<)&*K M[,B(>Z9#J8$V,;;R70RRC -!V?U"G!W'X<&["/N#Q1EL-%9D6V_NRL-D"ZN< M@II+LV5N3A@;#>1:*K'6R-)\C?[Z@?RL#3]87SG%0/GLWEKH(BW/KQP [[Z^ M8;.WP&WT5':AS9F6=^$NRHL%N.$$,G]2,C?H)*IFK".SI4\[ 8D![E(QT=,. M>K-SJL'/_-A5@&=EG,'1R%K#K(#_7+HW!$Z_)PKH;2 FH6.;]7+K2WWU/]3U MV'L&ER8%+W 'QLVAHP@FRXAOVWRL2#XPDZ65P7*9+6KVJKFY@& M.%N/I(-TL=/0-AL^Y[6L%&(';(^"54GIU(!+31+ :K"'52:CH*.WLUVBO.K5 M9EJVC.A%"+4*+$(V06!3>V?.C%])*46%2^TOB7DEE+/L[A]E.47!PM=KPM/5 M7*=9)/=<"U=\GG)/:(9JAVR2TY=-=/ 6[XG!2IWOPJE97%@I_++QZGK8%]W^ M<'A_=]4=W'Z\+#5*=GQWU>MMQK\.>I.;R]+;QKJW=%P M>'5WWV]M/GS1^(>>XK>1Q8*%-.YD'WJ;@YL-G-QIUR<]_C/.+=U@6, EU2D" M^0'!@":;6G*IE2M.Q) =^RE[!]ZZ'DTFHY^ [U'8"XKXIF%_2OG@$OOA)(YF M8#;%KY1;S5JC0<%^5E8WDR>E9MW4\R]+Q>9=*0?NZQHOU?6_8I?_EDWR;/TO M&N6>0J6SU/R$CB;]=(>&7K'4=*B]]/\'RZK9&I2=]$-WKFAO 6@W'8[2)NG_ M/?#.LALFO\+>UJ6L@2SO&X?O/+:P6(WJO<$GS&??3*7$7>>OL#!IO_GZ$U!+ M P04 " "J/FE3P&&[V+\$ #B&0 $ &0Q,S(U,C1D97@S,BYH=&WM M66%OVD@0_8[$?QBY2D4D# :2-'' $F GX42 @I->/R[V@E!L-5N&9F=H?H;.97?8'XY;RJ>KGFTI!A0+:-2E :>QT31[MS"Q/_>MEK)B M+O?TT\HQ"Q0@/IL'+<6G,ZY(7Z/<;$'B.0M4'D:Z%O%SR,;3D/-PD4[-PH"K M"?M&]=K#>$86S%_K-EO0! 9T!>-P0?"D=K]W.6@I,9M[>%2S8UCW'ILR#HTZ M-*L=HUD=B:R>.K]6_Q<#<&1%%*-KC>W>1:_;MGO#P01N!J8UAHG5%4,XTT[@ M[P3$Z3U76>#B&?K1P!":9H-T#3W66L<:V5P/!)A(=+5 MDP;Z*A8XXSY-9VJG9;@)&*'S_;O: MT8?S;KB(2+ 6@]-S/-4-,0)T0Z=KP%,XFZW+LDY+&8T\6AB?G"?P)0A7/G7G M%"T\PO6?(7GR*X#$?.'CDL187G\-8XH) HG.L+440%M,U27(3Q IH7PX&]^01[B(N:1,2A.N:*M56,FJ9^S*K5K IC(P.I6,AJ M";.EC^$X./(1"U@Q[LF(8OIUR6*ZP%PE>I.4)QD/&L@GP-AKQR7W<,-%ZBQC MQH4;ZQZ9%,QI3LC:6>,($4;N"4,68-Z+%%X':T:8X H+Y.*S28G4LS PO3RO M&6&BKE%,$Q%R6;@COH\P8ET9\8L%7(DPB:0LCYFQ@ 0.+H@(7"9C$?&AU=)/ M4PXCFG(PR3/,BE:1Y-EJBUM$$$U@ITM^QR3%2..77D0K;W?Z%G2M?G\R:G=[ M@\N6HBER/&J;9C[^U#/MJY92T[0#!3K#,;8F.9_%D,ZHV._[[='$TO.+G])R ME\.BW6/#%S&-C>S"S$\^^G" /;IJFP\KMUG_3'-[B#$WW''PW/[M3?_LI)-\ M'O^,MY+*JQ61.56G,25?\ .=,)?JY"YD+KRP6CO!(>+*-B_@,1/@R:Z238F[ MK5ZK:!I=/.XT:C[YHG9C(N]='0;AW58G.4L;B>#==M%V4D'ZG MQP?G<"<>-3O$5^5[$EW60TA&W&'\4$B*2[-WB_/9VY=4K53%:QJ>Y9[^C@ ML&=0U_0LYL[/>KZ<];_O_?3CG__TPU_Z_9^I2SF1U#*F:^/\\NJ3\'Q\/K!ESA6?[$AB( ]-S!O#^<\#0&!\? M',)7^'1XTO_D/5!G2GG_S>&;(^/?A\>G;]_#?_\Q_CN\^5^_CU((V[=N$RP5(O&0T8(QT#T^.<8@V14DO/>ZY]B'UHY.3DX%Z&S<%0JR$- MQ2[>W9-PAW?C= M('B92%%"]Y?KE!"^Z,\)6<;-9T1,5=/PA5)<__"H?WP4=3$]'_2\S@HBJ'DP M]QX&X4O5+>[@91H+ M9A8WA1>9AJ GN5Y24:A!]:9 A4(NN88\O-G0Q))3$V>U%M*3 >$F]VP*O$W9 MIZNE35PB/;Z^A.\Q3R[S,L+#(O&XU TJ?E70S9)\HUM&4G@]P-?8\Q![PB#1 M9Q#7]21!]Z.^+9?,G7GX$2?+*8YK KT,_' _OJHZX94^/H+'XK=D#G.(@?Z2 MKS%YBX+[8XKY$0DI$F982TC(!8!TF9JF\).%7H*1G(5Q6?;"<-6,=-P#*^ MS=#^:P?>!@ZQ1L5H-EIB&(?AV+U+?(M)#'FT"&[KJ8'Q;348$^J&-S,2^L:W M,8<.S#)(/GH.C'P!;=@#O?9$;4Q+"&B@?=<$V@P; _ET$%>$^$YZYF\+S[9@ MTW3QN\_DNB[&910T(+]O G*:SS=&P*F#N>I,)F)Q:7N/]6=POJ,&U.\:S5P@ M;RCZ'92-H:P:+]6AH@'Y^_V!W(55">@C/BDUJ_/.=QS"U[ VL;G+9F!>KAR:*KW#W/DMF*D)[0-%5VQ;#,'1X28$ M(3FU8"4$C82B$9%\S0!=N0\P*(^O PR2KQHU'VVJ.>[QFK5XRSW8T\CUT+4P M'%JBPPT46OA&H]LWF[J-.AO$M8RX^VM6-,Q>[E/K8K7$M4Z 5D?8ZJ/*_LIK M1J;,AB%$+J5Z!0M=/E S0C(*804P0Z9*+!U'"954 BZAG 15T/J)BMQ M60,-$N\VD4C14 ADJ+QF[=\M(-C^0-2.P$$GDHHU->\T.G^?"WFP>U_U-]($ M7K6Z*T6532+1;1'I=\TC4MB1A9]>]6:L&@X3,K7K(1?VT.#V_2ZX!:1?-6KQ MCB -S.9#C>YS&^FX7Z=:S3XCK>62]\4*?Y/;-A?O.3KMU]E\I"&IVTF#4V[? M76\CTN%7;4>21JYZ>OP. MGN[;G)Y"$(T=[I*=R=HA"FTHJ8VTV/%Y>TIR%>W%LO?!E_51^LZ4=S1E3#9[ MKKJ7E-+VQOZW>,O?X56<)"MZE@:M9I]BY(ZK)M/T6;8.OD+XMNYZC!UI:$PCEUZL MGO/MG,INB-\0B3LG6 .(O19,W+L6Y9,%5>V&\I0=M( M F@0B&#X*(,!6C)LU9[$8G2V4LU6DB7A'SYLI!BJX(&F)MUPZODR_*&:.U?= MZUK.+CPT=I3+HP9V-*ID1_&: \W3$F5\C9+)B(4*"'5FU= %C6;@*?!0B;CK MNTN;4IGIL=[1%U4DKS&F7":VCC'EG1(X,_1(H3C?"&.& H4>RHY$ZBRI_ +F MUK"E85^-#>2RH*77-KL0I?YY]?9#M]K=-%CFDX:ZD^T.QOK7#CQ);)51S;T* M]VW;,:U,0P-P+C%8 K#B%:2 BQJ$_#K ]?-6"-]9XBYG_S5C+C$]ZXOEL&S'HCQ3X\P5+E&8)6H0B= MC6AM1$VO4%U#$V)I"' PVV_YIMJ.W=JD@JNO045C![FT98D=!*="$<81O^ X M(>)H(,L.=SWNT1%A:NT5+K:#H0G\:K/+7_*#>,7(*S#4_1F5(C4[IA-A72EK3"E_5W0'4XIE458T5^R5#4WNQNE'7XDIX3]81W9,9X:J$GN*I3+/ M>H(Y2QM+P*IG"TYG9SVL>]N/"MK^"D,Z6#EVU 0IEQ1_5::WJ860<40BK"9: M7L46B*@#=K#I021\SQCL84"@\;H#RH+TLH9CDVG=X4 7:K^\D8!IUQW)QFS8 M\W@&J6*Q@VP961B,QZ7A%I:@UM59#JI77WNF(E/2!;_UHWY]?-0_>M,_/CI8 M"2N4K88 R:CJ"1#UJRE <>'HBJRC#LCS715NI06EBYB*2,3"G@-J2Q$]Z2>T M*@^\N%!UJ2!%7:(O2H3ZS+,UKZMQ3_>)OS7CGZJ-78EWW%Y]:L8S76.[$M.D M0_"Q&=ND7G7OM7)LZZF^BY0,X1_,4$+@ M4;.0H]DM]RS?E/@[%=$S@BA/_=&)4P?V51*V7U>2.K@-Z1ED*G"[*L]Z,V*K M/V>A&D+@Q3QKHKI:?E#[N6>XS%8_@SGK2>Z'M?4Q5/RUB*_P@323ZN^+_,P] M?QD)P8!YQ&<:5 L')G3*9.&8_DY<'T2>/'J3A><+V KBYO01&JRO,/8G]JT_ MM9DYFLU :-C,JK]5$HT[_ML$IY;G$.86C3P83*.!-Q5NBW(*U'#EFAPO9IS3 MX/]7;O8>4GS90U(17D)M!_M&@NW+.'(7A=-W0L;3Z.+;2] 2SM(6U])G^F"F39-;F6UZDFTW.L/)$ZAH2]2-Q@P'Q>4 M_QY3Z7-W#.\Y,U5=8]#6/;@JT>IH=Q.QODJ23'D!V?'=?:N#KRI,DT4B.G\; M/A)NX1EQ[Y?<37JLN3I @3BIC^E5T^LN&OF*A[BRU%>2N0&BV3\.^ZA+Q<> M9W]0:^A@NN?2XU="^$&R<.>8*L@?RK(%L)HD]8(HB,XL712UM?1>"R9018A= M9L4MY2J &5HG6^KSK*.0$V6@JA P=%PQ=J8PSF.>K0L6 %=_$.36K12Q,Z5 M\EM;P7)\Z^L>KV"C)#ZQHUOW-QZX]@5Q1R[]%R5<_51 "'P">T=\TJ[M[21A M@_ KV1]?X$\6*'6#/T(#FT=H!=%]ZZ%*/9$:K"9E[JS-I;6J(/6'N%G2)5FV M(INZ5:)6'>0N>\;JLC28SD0L\%I-IJ;-#5DQQW?*1AJ)O?=L6PUYFBT<0>D+ M3\B6\H>;//>5'AI[:V*#,LA:79^$" $#R3G-^YAE\&[? ],+T, ,?=@Q.Y2# M@VYWKTW]Y#6H MJ&:-W$]XQ1 O+,!Z#SL#3*MJ)>SUM)]3>4;&^I_T\*!&*?4\^7_*3*7Z)9YG$/N%Z:22@/O2 M4D@1HZ?HXI&:D>VH0,]];XENC!L(-Q?Q+<*X*E1+I[];)=CE-+B$>*NGPQ7D M:')22.&#[!/F=/8=:>N$4PH=]ZT M<_[Y7&-[ A3$%E$O5K#S9X+6E?:% /%TPVMQ1D370D!C?O#G;=#SJZLRP2@^ MPYI.\8:3[6G.*?' RCF*CVI!L8SW$LC[Q^)YS[7_RH3T/!C5$O/0XG5&F?HO_I>#0 M<'CM[TJ .S+WN?JY9))%_$+#X]9&^Y*BY;!([1:9G]6+M3K,EX1-X)"_6DRV M#N\E81'._J]_IM08Z$O")YM%^FK1J3S,*M@,@KHG/_X?4$L#!!0 ( *H^ M:5,D'-$6P H Z/ 5 :71C:2TR,#(Q,#DS,%]C86PN>&UL[5UM;^.X M$?Y>H/_!]7UV["37ZR6XW,%Y6QC(QH:3O3V@*!:,1,7L2J*/I!R[1?][AY(= M6[9$4GX)J>P"0>+(''*&SW"&' ZI7WZ;1F%C@ADG-+YH'A]UF@T<>]0G\?-% M,Q%!Z^?F;[_^]2^__*W5^H!CS)# ?N-IUKB^[=TW_K@=>!?^-0Y:]W3 M"8Z>,&N==$Z.&__LG)[_^!/\_*OQW^['_[5:DHN0Q%^?$,<-X#KF%\V5=J9/ M+#RB[+E]TNF",4I_1STDTG[4\M4H+2'_:RV*M>2CUO%)Z_3X:,K]INP#1D,\ MQ$$C;?YHE"*_##"6/!F0];^:=C+B4!BP9"'PS )$1,C4((QP1F6LGC;I-[V 5A_ M$/!;:ASO!_VQU$VI8Y]BE/@$OMZC,-J6#BW>%8W&#(^@#)G@.\H/+J6JP8,+ MB_CH-J0OAQ>RH*&W%VZ &'PUPH)X*'PS2==:W5'LAR2*$)OU@P?R'), ZHQ% MU_-H$@OP) -@R0.&I9GUDQ#W@UX\P5Q(YAZPES BX-MK+!#9L@/VV?Z.72&K MC@5ELWQKZ:.KA,E>WT72"M7O*,B 43!U8M:-_9L_$S*6O57T;!=IJK:QHTA# M\CP2_> 3QUW.P2]!$W<8_.P=04\D3+7@(Q)2'Z!U%,XX@0'C8_8XPFFY[C/# MV9#:1>C]44R+* M\KC(9CFTFTY\ L2?TME/PEO/"(W;$K V#@5?/$DA;'6.YY.@'^:/OV2=MZ@Z M1$\X3!O\LEZ@;8>S^6C4,OA:;AW%+LNSC)BWJ P^;D"8GT?.2[2YM(RRMA98 M_6A!'S :%7?6O$&JY#3AT#0=RVJE\Z ,M!-6#\W&"Y:ZG7Y\\UZ7/@Z&DOPC M[<8$A7*(=,458FP&7N!W%"98@88AO0,HK6G6.EB&@A2#>&(7Q.X$#!IZ"O$M M90_ ^-(]&PPG/:W[X!D(40S.'5I-O2 E91W'Z(2QHM!^;ME8YBM8/@0>QC,.!B%>RP, M[*"2S'V(U/P7(_637:1>EV# J0*9?#'WD$]C3VN_2LH[#$H)Q\5HG%E&(XM?Q\]I+&$M M%J%"14WG,CIJSDL6LYU-F-IK(99O,>JR$J0"Z_,@J/=U1$/H,BXMD9@I-$A/ M^N:#884E,\8M*[II[Z\/@9P$)0IO.7R3'Z4+AF=F'D-/ZPIL9D:J4(02W"Q' M;%9DTR]-B@J[CDP1SR506([!+!9. S23JR;SE>(Z@2N0&"X4U]DO0<=RB 6X M90GV\R8\G3F:>2%#^OI@9R)-"93V S.2^9MH'-(9QI-HED9V/_&GRL1]2;:98/ MK=N5.F3+5D>O@6X4;GH=LD.N'(GQ[P;R?G(?Z0SX=MEFJ_5X%#^_,JJZP-+UR$,HU"R^@%6VI=RMH8U MZ]'=Z[:;)50-=_/,?&/QM3:YY=:9BW+!Y+3P4#JS5O>WIC-KXG\_IO->(*]^ M@.?-O;KYZ>+Z9-A;X7*(7C["V&8$A5D@$R9XF$V4"1XFQ%9'1A$&I4<&%$(X MN31Y9?PS95][\8!1#_/JV*FHZP.>2@HG'=(KY[KHJ:CK@YY* M"G=]3\6[(-[/02,GI$@GH=O(,2>T.CI,L#$^2#47R$DGE=L&'S/LD;1[X'.( MTUZ/_?DD-7U>*J/9KO..3=1.)?8GNM9'MJR9V;W?/O/F!PY@2H)Q23+C ,TR MWI1[!^95O/UQ"A5K 3A:8P5^S=3.3<#?4S4)RZVJ\]NTF1%A#=.;&PGLY,6 MOT2*ZMG*-<>T5"IWMTBVNDJR3OD,;[O 6S1^"[H%/0JZD( Z+/LPBYEFY1[1 M%/.;*> #^D!BQ&8]Z/7T<#90 CK X',/3 ##RHV>@[9J=3P6XKZYHCR@^&Z; M6Z-!45C:'D+6'9%?"A7 ?[D0PR"BGK M!.LATU+6 S2M&/N]1VSS!EOYY(OKWJ%)=WNZ5*V MG;SW:P@C-T[PPM?".+5/9,JF-UA%E)-_:;+&\)YR\N^Q5\KF]FA]UURX9"RCJLMPK8%U[ MD9F]8P(:!5E[-/H!F]^-5-=3V8K>DN6JE227TST;?6JX*C0L;=M=^8 M3\GT>%.FXN Q=*XB73&=B&Y5E6U#7W$$Y&;>6PGL9+!G=0=7,=CSQ6H*7;$P M3MX3_S!"#%^BU&%'V3 <$22 MB"]7=KI;[+:IL.:ZL*W8VJB7E<#]YBQA\\Y^]1+9@+SFB)L)J0UP.8+O_,TF MUSC ,.DK?L-))<3-*GQW.F FMC84YHA6+,18B0]64H)"^G>'>:&4YB$U-PS[ M_([=K:SZ*^V[@W9#0O.7"5B'M>3ZW>5ZW^A6XMVK?H]*4:D#W+R/?U.NQ?FB MJ@J1HWMW:.>DTU_1;\6L@\ !$9IDMM5"-4=I510WK^HOD3%;^^VX45%8R?>- MBDK=Y>8K!!9Y\H^TZT$'R8UYDYB+FLS%L:X8!QMC72F<_OT!M@RRA[&?IEW( M_*;EB2O_BH8A*+%,OEB]-4ECN:O75G?8MY'9S?<2;&CP-LH5A"-]_:L,KX\_Y"3\SDK+V!;'MFNGL;#@T"+ M(8N=%.GBXK3JX?WWB462M<1*1O"&E DTNIPV@[SGGEAOW.7?_N-]&G]Z0UD> MI(S_]W\__;_>[?__\H5($4?)M^<@1Y^PU$G^V^>5[[P_9_$O:?;RM7UPT/FZ M>/ S>_+7]SQ:>_I[9_%LZ^M_W]X\C"9H&GR)YE"6K.U:IZ>G7^E?\:-Y M]&M.V]^DHZ"@>E3*]4GX!/G7E\5C7\BOOK3:7SJM7][S<"D7?B8LEI]9?<'1 M5_;'ST1=61JC 1I_HI+^6LQ>T6^?\VCZ&A.$]'>3#(U_^QP5HXAJ_>"T>!M=K M^*.DR((1BN,R#K)B@EN]1HAU!/+XUVI?^NH8WD.1CKY-TCC$'?7RSS(J9JYA M2K]8$^X@>ID4_?%3CGIYCHJ\EX0W"'>OFRAXCN*HP)(^!L\QRJMA,WA]32 / MDR!#9P%5X_05ZY-VC#JRR]]84]Q^]A(DT5_TE;T0ZU;$O"FNJ\SU*\HRAFF$0BQBOA MC/>[.@HQ_49-2%C768G"RW>R@"'2/?M$J/,RR_!'5I;ACXZNW:2.&IJ0R_W6 MR/K25O>;[B'?!@69PW!?#>)9'N&=-]Z6/DX0?:[WDB$V,3I6@J$4[M7RT4W_ MJ\137(2W[]$;6F&H]YR6Q?S DKS0YJZ55$NFYGM2?XP))%OM()D]7,4(%6LM M9@UW*5UQ:I\WI].([@Z(4/@(2*A B9.-<]5O.3F:V3\6F'_&S9DS+8*8[F6V M_C1?N^RCU/^F$\CTR_U7:HKIC? L@\<'.76$Y8A.Q/=QX(!:DZ^Z@;W8W*YT MK0%Z"3)B(\6SQV,T98T&>;D0D R\28"'W7+-;DSPOIVQEP7O&\"K-EB:(Y(5:@7TT)#$)J 8@T2;_JQ-Y$Y$:_.^B%[GY-9Q.9'><_0!#\3O2%B^G<.4O)!%V#/@ICXESQ,$"KR M^X"8M">HP--=95N/X4><@W*%HPE;I3.K8VWAR>UB4J39K)J(*\UM"5)G/=IZ MB2VAUN_"Z:_F%T=U]K &KV]^]GWD,T!J3-ZC#]"0079:(%K M_N/J=Y<>A/CC7\-H^G7^S-<@CC\K%2'P95RX(A(GQB.J'_JV.N+@G\E:G29? M0C0.RKBP*!SGW99$3:=!E+B1=/[J6H+2=WR94M];FU*NO[>.B!,L338JG]&7 M)72+@G+?7D?<)"UZ5L?-XH54*-P[HX1:RF[PJ]8^@MX+A.?R*&P?Y,T5@N#U*YE)OZ*XR!>_H7/KEX/6W/GY M7^>_'B[EP?C1-?XQ7WPF#IY13#\^%#\\/.X>'K4[;CH^*4-,;2:W,[ER!M5A5ECL&EK\R*_?D3 M;H:RWSZWP+H:1C#?)IRA!#.D[B9;+;!&=Y!B/@P^/6T0>A;>HDQ>K6',;S(\ M/MHQ@B0X^ Q!S-5WJ/B8+22TK#TW/#[=*2ZVA><3< A P-)C38L&SM/#X\.= M(D,$@4_)$0 E _2&DA(MUDZ\DRS^'A63\S(OL, 9\^3& (@=#/\OQ+.PA+(* M;QL>=W:*TJH0^90? U"^A$R-"3K[;/H@TTO;"5DK)@D+% GD9B>P7\E&#Q^J M+F/Z"#[%H1=VP[?X>YQBVG[[7&0E$M%V4I^V/"M6*,/_VJ0+_VIXGZ5A.2KZ MV0/*WJ(1ZKU'O!E3]"B#[F8_+SF_2RC<8&2-/B4*/A?=9KD@QKFY6:,XZM/8< P2R)]<;"_PUB8]!0 :$=8%ZHBFI6'F*@N@<[!H1/ 0" M&B"L".=I3C$MKX*><[K'E' B:L(4L5L')B46 540Y@26.R4F@3M-WP"-2 5Y$K-20!;T86A6UW!_(;*G-_/%]A228$ MWN 0/,D6U5T:'BH@ D5;L $8#Y#+($OP^%VF3]#8'8B:,&7LUCV#$HN *@LF M@MI4G05Y-"*CF27!,&!LH^7PV(T-3I,T)0=ZU/% "=BS8$8P9N_OB'B HK#W MAI?,%W17$J7TQU3TO%\6)*<F%_RR98+'U _CAL;>T99,O-YK/#T]V9&_G" M^^.X5=5EI.O&M\?4742B^&UY+;J)0-A0EXC89I&,^#2A< M'2>2KMK_1PC%'V>L#1&%?@O2YX6[S5>W716V&737-OI;>"D3 O;T<'GD]N6>1F^V^:[X M5/J2&YD]!"Y(_QDD)1;]\7OZ.$G+/$A"DG+V.YY19M=$G7@#5#['T:@_'J., MI*@5+6)WG)0HO2M)GV"4<,URSWY.J27-/?!51VB\:M@Y 70G-632$YI''FE3\ M._2=_JDRM9-&(>IF0#<'W( OI_1_NFF,4 M%656G6.==P]/?>:@) %'_"0N3./\]>*+;L978#)G"H4%9$ MSS&Z0,\L,PG]%;$97"%2*:VNPZ+.)X@O7N?P8'=6>OO !1UG8?-JV,U8OYSW MKOD4'WNTT_$P ME1_E@S_.ZL#TQ[6W1@:EDR,WDV*%#$H2F@1R6W2-@]A7T=ZV2-I5!O$CRJ:* M6S91$Z82-^;AFIF5&%."T:= XX_K+T]4Y?V,N!%%Z"JM@O85FU+_^K1MP/+' M5=@-<;Y(KE?-6[AQMO9HIP+=8"?[^Q#IFN9=QPXXT5A&1BX_-^M2UNDKU#V$U^A8Y;=AM MZF+WY\!>U9AYU'5S9C"U9,J(XTB\X^&]M,,]XL\H#)=KSPV/' 6(UC%5'DEN MX[:%]R=B5["=S;(@>6%)>\YF_'GB U82WL=!0KQZU3[G#CZ'=0]M"N50+!C# MSO#[$V&\)UW*%R,M>-^R&A$M,"K>1C$^U*0)D> Q7>1.8C[D U24V>8QB!YZ MY";?.N_$N&%3C3N;)S@FR/J*LA!6+>@8CWB@4(P\$08/3_(NH-<:8X!UXFZ2 M;!.5V(B^%O!ZG83E""V!$.'E5 H;$.MW%SAS7),$JA6AB--N^!Z@G[T$2?07 M4\G2%VWE@F->FKYNCUK]SD?Z2?)1K-H,Y5AA

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end